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ABSTRACT 
Mechanisms governing the release of drugs from controlled delivery systems are mainly 
diffusion, osmosis and erosion. For poorly soluble drugs, the existing mechanisms are 
limited to osmosis and/or matrix erosion. These mechanisms are commonly employed to 
control drug release from single unit and multi-unit dosage forms. More recently, multi-
unit dosage forms have gained considerable popularity for controlled release technology 
due to their advantages over single unit dosage forms. However, the mechanism of 
polymer controlled surface erosion from a multi-unit dosage form has never been 
reported in the literature. This study describes the development, characterization and 
evaluation of a matrix pellet system which releases an insoluble drug via polymer 
controlled surface erosion mechanism. Extrusion/Spheronization method was used to 
formulate matrix pellets. The effect of various formulation and process parameters 
affecting the drug release were characterized by analytical techniques such as Differential 
Scanning Calorimetry, X-Ray Diffractometry, and Mercury Intrusion Porosimetry. 
Different insoluble drugs were used as model drugs to demonstrate universal applicability 
of this novel system. The effect of drug solubility was also investigated on the 
mechanism of drug release from this system. Solid dispersions of the model insoluble 
drug was formulated to increase its solubility. It was observed that when the drug 
properties were changed towards increasing solubility in water, the release mechanism 
and rate also changed from pure surface erosion to erosion/diffusion. Drug release of 
nifedipine pellets in vivo occurred for more than 24 hours following zero order kinetics in 
fasted dogs. Thus it was proved that the approach of controlling drug release by polymer 
controlled surface erosion mechanism from a multi-unit pellet system is possible and 
such a system may be beneficial than the current marketed dosage forms of insoluble 
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PREFACE 
This work has been prepared in accordance with the manuscript format option for 
dissertation preparation, as outlined in section 11-3 of The Graduate Manual of the 
University of Rhode Island. Contained within is a body of work divided in to three 
sections. 
Included within Section I is Introduction, which introduces the reader to the subject of 
this dissertation, a statement of the hypothesis tested herein, and the specific objectives of 
my research. 
Section II is comprised of five manuscripts, containing the findings of the research 
which comprises this dissertation. These five manuscripts are presented in the format 
required by the journal to which they will, or have been, submitted. 
Section ill contains appendices containing, ancillary data (information essential to, but 
not usually included in published manuscripts) and other details pertinent to the 
understanding of the concepts presented in Section II. This dissertation closes with a 
complete listing of all the works cited in this dissertation, arranged in alphabetic order by 
the author's last name. 
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Introduction. A general introduction fo llowed by compilation of the specific 
objectives of this research. 
A statement of the hypothesis tested in this dissertation. 
INTRODUCTION 
Release of poorly soluble drugs in a controlled fashion is a challenging task for the 
pharmaceutical scientist. The mechanisms that are utilized to control release of drugs are 
mainly diffusion, osmosis and erosion. Alza Corporation has developed the GITS 
(Gastro Intestinal Therapeutic Systems) system for the release of nifedipine, a sparingly 
soluble drug, over a period of 24 hours. This is an "Oros" tablet that delivers drug under 
osmotic pressure differences between the GI fluids and the drug formulation encapsulated 
in the semi-permeable membrane surrounding the tablet. The release of the drug occurs 
as a fine suspension from the laser drilled hole bored in the tablet (1, 2]. 
Other approaches used are matrix tablets which release the drug in a controlled fashion. 
Low to moderate viscosity grade hydrophilic polymers such as hydroxy propyl cellulose, 
hydroxy propyl methyl cellulose hydroxy ethyl cellulose, chitosans, alginates etc, have 
been used for this purpose. One of the drawback of these matrices is that they are single 
units and bioavailability from such matrices is dependent on gastric retention [3, 4] . 
Single unit dosage forms of poorly soluble drugs that release the drug by osmosis or 
erosion are commercially available. However in vivo drug release from such dosage 
forms may not be predictable and complete due to physiological variations in the gastric 
retention time and gastric emptying rates. Additionally, the frequency of bowel 
movements is also a factor that seriously influences bioavailability of drugs from such 
systems. 
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During the past 20 years there has been a growing interest in multi-unit solid dosage 
forms such as pellets for controlled drug delivery. Pellets offer significant therapeutic 
advantages over the traditional single unit dosage forms. Since pellets disperse freely in 
the GIT, they invariably maximize drug absorption, reduce peak plasma fluctuations, and 
minimize potential side effects without appreciably lowering the bioavailability of the 
drug. Pellets also reduce variations in gastric emptying rates and overall transit times. 
Thus, intra and inter subject variations of plasma concentrations of the drug, which are 
common for the single unit dosage forms, are minimized. Another advantage of pellets 
over single unit dosage forms is that the high local concentrations of therapeutic agents, 
which may inherently be irritant to the mucosa! membranes, can be avoided. Pellets, 
when formulated as modified release dosage forms are less susceptible to dose dumping 
than the reservoir-type single unit formulations [5] . 
During the early developmental phase of nifedipine GITS system, 20% of the population 
in the clinical trials taking nifedipine GITS tablet expelled the tablet intact through the 
GIT via fecal matter. The pellets on the other hand, due to their small size and large 
number are dispersed rapidly in the GIT and thus avoid dose dumping or loss of dosage 
form. Pellets also offer technological advantages over single units such as better flow 
properties and ease of further processing during tablet compaction or coating for 
controlled release. Table I shows a partial list of pellet products marketed in the US. 
Traditionally coated pellets have been used for controlled release applications . Most of 
the marketed controlled release pellets available today are coated. More recently, matrix 
pellets have gained popularity in controlled release technology. Controlled release via 
matrix pellets avoids the coating process and thus saves time and money. Pellets, 
manufactured by the pharmaceutical industry, are sized between 500 and 2000 µm. 
These can be produced in different ways such as spraying a solution or a suspension of a 
binder and a drug onto an inert core, building the pellet layer after layer, spraying a melt 
of fats and waxes from the top into a cold tower (spray congealing) forming pellets as the 
result of the hardening of molten droplets and spraying a binder solution into the whirling 
powder using fluidized bed [5]. The most popular method of producing pellets is the 
Extrusion-Spheronization technique. This process was first reported by Reynolds (1970) 
and by Conine and Hadley ( 1970) and involves four steps: preparation of the wet mass 
(granulation), shaping the wet mass into cylinders (Extrusion), breaking up the extrudate 
and rounding of the particles into spheres (Spheronization) and finally drying of the 
pellets. 
Traditionally, in the Extrusion-Spheronization technique, microcrystalline cellulose 
(MCC) has been the excipient of choice to prepare matrix pellets. Due to its excellent 
plasticity, it is widely used as a carrier or filler in the.Extrusion-Spheronization process. 
However, MCC forms a non-disintegrating matrix and thus incorporation of a swelling or 
disintegrating agent is necessary for drug release to occur from such a system. Drug 
release from such matrices has been studied extensively by O'Conner et al. [6] and it was 
concluded that drug release occurred by Higuchi' s square root of time equation and 
followed first order kinetics. Incorporation of a poorly soluble drug in such a matrix 
system would minimize drug release since the MCC matrix system is non-disintegrating. 
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Therefore, such a system would be inappropriate to formulate controlled release pellets of 
a poorly soluble drug. Additionally, since the drug is poorly soluble, diffusional release 
will be negligible. Thus, the only choice remains is that of an eroding pellet, which is a 
matrix pellet system that erodes from the surface as a function of time and releases the 
drug which is homogeneously dispersed in the pellet matrix. There is no such system 
reported in the literature. 
Hellar et al. [7] prepared discs of poly (ortho esters) and studied in vitro and in vivo drug 
release of the highly water insoluble levonorgestrel. Poly (ortho esters) are polymers that 
erode due to pendent group hydrolysis of the ester groups, however; it is not generally 
recognized as safe for pharmaceutical applications. Hellar et al. concluded from his 
study that levonorgestrel release from surface-eroding polymer discs bas three important 
consequences which are (1) The rate of drug release is directly proportional to drug 
loading, (2) The lifetime of the delivery device is directly proportional to device 
thickness, and (3) The rate of drug release is directly proportknal to the total surface 
area of the disc. 
The controlled release systems developed by Hellar et al. using poly (ortbo esters) 
showed zero order release for months. Drug released in vitro was analyzed by measuring 
the drug present in the device after periodic time intervals of dissolution and the polymer 
erosion was detennined by gravimetry. This study demonstrated that an indirect method 
such as measuring the drug left in the delivery device after dissolution may be employed 
to quantify drug released and also the use of gravimetry to determine polymer erosion 
profiles. 
Based on the information given above, the specific objectives of this research were, 
1. To search for a surface eroding "GRAS" (Generally Recognized As Safe) polymeric 
system suitable for Extrusion-Spheronization technique. 
2. To develop pellets of poorly soluble drugs for controlled release which releases the 
drug following zero order kinetics for 12-24 hours. 
3. To characterize and evaluate the release mechanisms by analytical techniques such as 
differential scanning calorimetery, x-ray diffractometry, mercury intrusion 
porosimetry, particle size distribution, microscopy and in vitro, in vivo analysis. 
4. To test the universal application of the system developed initially by using another 
poorly soluble drug. 
5. If circumstances allow, to test the bioavailability in vivo of one of the model drugs 
from the pellets tested in vitro. 
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Table I. Partial list of pellet products marketed in the U.S 
Product Company 
Sudafed S. A. Glaxo-Wellcome 
Theo-24 Searle Pharmaceuticals, Inc. 
Theodur S. R. Key Pharmaceuticals 
Nitrostat S. R. Parke-Davis 
Bontril SR Camrick Laboratories, Inc. 
Compazine Smith Kline & French 
Hispril Smith Kline & French 
Nicobid T.S. U.S. Vitamin 
Papaverine HCL, T.D. Lederle Laboratories 
Russ-Tuss Boots Pharmaceuticals 
Slow-bid Rorer 
Theobid S. R. Glaxo-Wellcome 
Inderal L.A. Ayerst Laboratories 
Indocrin S .R. Merck Sharp & Dohme 
Xenical Roche Pharmaceuticals 
Novafed L.A. Merrel-Dow 
Fas tin Beecham Laboratories 
Catazyme S Organon Pharmaceuticals 
Source: Sellasie, L G.,"Pharmaceutical Pellitization Technology", Marcell Dekkar, Inc., 
New York, 12-14, (1989). 
HYPOTHESIS TESTED HEREIN 
It should be possible to develop a multi-unit controlled release matrix pellet system by 
Extrusion/Spheronization technique without microcrystalline cellulose (MCC), which 
can release an insoluble drug by polymer controlled surface erosion mechanism 
following zero order kinetics for 12-24 hours. 
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MANUSCRIPT I 
DEVELOPMENT, CHARACTERIZATION AND EVALUATION OF A NOVEL 
MULTI-UNIT EROSION MATRIX FOR A POORLY SOLUBLE DRUG. 
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Abstract 
Mechanisms governing the release of drugs from controlled delivery systems are mainly 
diffusion, osmosis and erosion. For poorly soluble drugs, the existing mechanisms are 
limited to osmosis and/or matrix erosion, which are commonly employed via single unit 
matrix dosage forms. More recently, multi-unit dosage forms have gained considerable 
popularity for controlled release technology, because their rapid dispersion in the 
gastrointestinal tract maximizes drug absorption and provides reduced peak plasma 
fluctuations. Bioavailability from multi-unit dosage forms is affected the least by the 
presence of food and gastric emptying rate. This study reports the development of a 
novel multi-unit controlled release system for a model poorly soluble drug (thiazole 
based leukotriene D4 antagonist, solubility in physiological pH < 1.3 µg/mL) by a 
polymer controlled, surface erosion drug release mechanism. The drug, rate controlling 
and pellet forming agents (Eudragit~ 100 55 and Eudragit® S 100) and a binder 
(polyvinylpyrrolidone, Kollidon®K90F), were wet granulated, extruded and spheronized 
to form uniform matrix pellets. In vitro matrix erosion and drug release from the pellets 
were determined using USP Dissolution Apparatus I in pH 6.8 phosphate buffer by 
gravimetry and UV spectrophotometry, respectively. Results showed that matrix erosion 
and drug release from the pellets were well correlated. Pellets eroded with a consequent 
reduction in size without any change in the pellet shape for over 12 hours. Matrix 
erosion and drug release followed zero order kinetics. Data obtained strongly suggested a 
polymer controlled, surface erosion drug release mechanism. 
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KEYWORDS 
Extrusion/Spheronization, Eudragit® L I 00-55, Eudragit® S I 00, polymer controlled 
surface erosion, controlled release matrix pellets. 
14 
1.0 Introduction 
Release of poorly soluble drugs from controlled delivery systems is a challenging task for 
the pharmaceutical scientist. Alza Corporation has developed a gastrointestinal 
therapeutic system (GITS) for the release of nifedipine, a poorly soluble drug, over a 
period of 24 hours. The system is an "Oros" tablet which releases the drug under osmotic 
pressure differences between the GI fluids and drug concentration in the semi-permeable 
membrane surrounding the tablet. The release of drug occurs as a fine suspension from 
the laser drilled GITS device {l). Other approaches for the release of poorly soluble 
drugs from controlled release erosion matrix tablets employing hydrophilic cellulosic 
polymers are reported (2, 3). These matrices are generally single units and thus may be 
associated with drawbacks such as irregular bioavailability due to presence of food and 
dependence on gastric emptying time. Therefore, existing mechanisms for the release of 
poorly soluble drugs by controlled release are limited to osmosis and/or erosion. Due to 
their negligible aqueous solubility, diffusion has practically very little or no contribution 
in the release of such drugs from the controlled delivery system. 
More recently, multi-unit dosage forms have gained considerable popularity over 
conventional single units for controlled release technology. Due to their rapid dispersion 
in the gastrointestinal tract, they maximize drug absorption, reduce peak plasma 
fluctuations, minimize potential side effects without lowering drug bioavailability. They 
also reduce variations in gastric emptying rates and overall transit times. Thus, intra and 
inter-subject variability of plasma profiles, which are common with single-unit regimens, 
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are minimized. They are also less susceptible to dose dumping than the reservoir or 
matrix type, single-unit dosage forms (4) . 
Controlled release of poorly soluble drugs such as nifedipine, ampicillin and isosorbide 
dinitrate via pellets have been reported (5-9). All these studies primarily employed 
microcrystalline cellulose as a pellet forming agent. Due to its excellent pellet forming 
properties, microcrystalline cellulose offers potential advantage in pellet manufacturing 
by Extrusion/Spheronization technology. Release from such pellets was extensively 
studied by O'Connor et al (10). It was concluded that drug release follows first order 
kinetics as described by Higuchi's square root of time equation from such pellets. Since 
microcrystalline cellulose forms a non-disintegrating matrix when formulated as pellets, 
incorporation of a poorly soluble drug in such a matrix would only intensify the problems 
associated with its release. Such a matrix system would often provide no release of the 
poorly soluble drug at all. 
This paper reports the formulation of pellets which release a poor! y soluble drug as a 
result of surface erosion of the matrix pellet. It was postulated that for drug release to 
occur in zero order fashion, a matrix pellet must erode slowly as function of time from 
the pellet surface. This will allow the release of homogeneously dispersed drug in the 
matrix in constant increments as the erosion progresses in the pellets from the surface 
thus controlling drug release. A schematic representation of such a delivery system is 
shown in Figure I. 
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2.0 Materials And Methods 
The poorly soluble drug used as a model was a thiazole based leukotriene D4 antagonist 
with a solubility less than 1.3 µg/mL at pH 6.8 (Hoffmann-La Roche Inc., Nutley, NJ). 
Eudragit<!I L 100 55 and Eudragit<!I S LOO (Huls America, Inc., Somerset, NJ) were used 
as release rate controlling polymers and matrix forming agents . Kollidon<!I 90 F (BASF 
Inc., Parsipanny, NJ) was used as a binder. Avicel<!I PH 101 (FMC Corporation, 
Philadelphia, PA) was employed to prevent inter-pellet sticking during the spheronization 
stage. Triethyl citrate (Morflex, Inc., Greensboro, NC) was used as a plasticizer for the 
Eudragit® polymers. All other chemicals were used as received. 
2.1 Formulation of Pellets: 
Eudragit<!IL 100 55 and Eudragit<!IS LOO powders were mixed in a turbula mixer (Turbula 
Mixer, Impandex Inc., Maywood, NJ, USA) for 30 minutes. Trietbyl citrate was added to 
some formulations (Table- I) as a plasticizer and the resultant mixture was triturated in a 
mortar for 5 minutes. Drug and polyvinyl pyrrolidone (Kollidon®K90F) as a binder were 
added and mixed for 30 minutes in turbula mixer. This mixture was then granulated with 
deionized water in a mortar and later extruded (LCI Xtruder, Model DG-Ll, Fuji Pauda! 
Co., Lld., Japan) at 40 rpm screw speed. The extrudates were immediately transferred 
into a rotating plate in the spheronizer (G.B. Caleva Ltd, Model 120, Dorset, England, 
consisting of a stationary vertical cylinder with a friction plate (diameter 32 cm) of 2 mm 
cross hatched pattern and a rotation speed of 200-3000 rpm). 
17 
Spheronization was carried out for 20 minutes at 500-1000 rpm. During this period, 5% 
w/w of total batch size Avicel® PH 101 was sprinkled over the rotating extrudates to 
prevent the pellets from sticking. Pellets obtained were dried on trays at 50°C for 12 
hours . Dried pellets were later sieved to obtain different particle size fractions (Rotap 
Sieve Shaker, Model RX-29, W.S. Tyler, Inc., OH, fitted with sieve# 8, 10, 12, 14, 16, 
18 and 20). The pellets consisted of drug (10.0% w/w), Eudragit®L 100 55 and 
Eudragit® S 100 (88.0% w/w) and Kollidon®K90F (2.0% w/w). A flow chart of the 
manufacturing process is presented in Figure 2. The composition of formulations with 
different polymer ratios is given in Table I. 
2.2 Characterization of Pellets: 
2.2.1 Determination of Glass Transition Temperature (Tg) 
Polymer blends (Eudragit® L 100-55: Eudragit® S 100 in ratio of 1:3) with or without 
triethyl citrate as a plasticizer were weighed in a DSC aluminium pan. The DSC 
(Differential Scanning Calorimeter, Seiko Instruments Inc. , Japan, Model SSC5200) was 
programmed to perform a heat-cool-heat cycle from 0 - 200°C. Heating and cooling rates 
of 10°C/minute was used. 
2.2.2 Determination of Matrix Erosion 
To study the erosion process of the pellet matrix, three criteria's were monitored, namely; 
microscopic evaluation of pellets, matrix erosion after dissolution of pellets and volume 
reduction by erosion of the pellets at different dissolution time intervals. 
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Pellets were visually inspected, sized and photographed under an optical microscope 
(Optical Microscope, Nikon HFX,IIA, Japan) before and after matrix erosion and drug 
release studies. Ten pellets per time interval were evaluated. 
Matrix erosion was evaluated by using standard USP dissolution system (Distek, 
Dissolution System 2100A, USP Apparatus I ,Baskets). Matrix erosion was determined 
by removing the baskets with pellets at intervals of 2, 4, 6, 8, 10, 12 hours and drying 
them for 12 hours at 50°C to a constant weight. The difference between the initial and 
final weight was calculated as percent matrix erosion. 
Volume reduction due to erosion of pellets was calculated by using Equation 1. 
V, = .1/6 7t 0 3 Equation l 
Where, V, is volume (mm3) of a sphere and D is the diameter (mm) of a sphere. 
Cumulative percent erosion volume was calculated by dividing the change in volume at 
time 't' by original volume at time zero. The result of this was multiplied by 100 to 
obtain percentages. Rate of erosion volume (%/hr) was calculated by dividing 
cumulative percent erosion volume with the time interval. 
2.3 Dissolution Studies: 
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Since the drug is poorly soluble, drug release from the pellets was determined by an 
indirect procedure which involved determination of drug left in the pellets after 
dissolution by UV analysis. The difference between initial and final amount of drug 
present in the pellets after dissolution was calculated as percent drug release. 
3.0 Results And Discussion 
3.1 Pellet Processing by Extrusion/Spheronization: 
Extrusion with Eudragit®L 100 55 and Eudragit®S 100 as pellet forming agents was 
satisfactory and pellets of uniform shape and size were obtained (Figure 3). 
Spheronization occurs by rotation of the extrudates at high speeds on a friction plate 
within a vertical cylinder. During this stage each individual pellet rotates on its own axis 
due to centrifugal force. This action results in liquid migration from the interstices 
between particles to the surface of the sphere which may be accompanied by migration of 
ingredients in the formulation. lf the drug is soluble in the granulating liquid, then on 
drying may lead to non homogeneous distribution of ingredients in the pellets (11). 
The drug and the polymers used in this study were insoluble which prevented them from 
solubilizing or retaining moisture within the pellet matrix, resulting in the migration of 
moisture alone towards the pellet surface. This action created inter-pellet adherence 
during the spheronization process. Inter-pellet adherence was eliminated by sprinkling 
5% w/w of Avicel®PH I 0 I on the extrudates during the spheronization step. 
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3.2 Characterization of Pellets: 
Release profiles of the pellets ( 1.2 mm) prepared with and without Uiethyl citrate as 
plasticizer is shown in Figure 4. It was observed that 70 to 100 % drug release was 
obtained within six hours from these pellets. Pellets with 1: 1 and 1 :3 ratios of Eudragit® 
L 100 55: Eudragit® S 100 were formulated. Pellets within each of the two formulation 
ratios containing plasticizer showed enhanced drug release rates when compared to 
pellets without plasticizer. This effect was consistent when the polymer ratio of the 
pellets were increased. The increased drug release from the pellets containing plasticizer 
may be the result of increased dissolution rate of the polymers after plasticization. 
This effect was investigated by determining the effect of plasticizer on the glass transition 
temperature of the polymer (Figures SA thru D). Results obtained are tabulated in Table 
2. Polymer blends with plasticizer showed a significant reduction in glass transition 
temperature and enthalpy. Glass transition temperature of both the polymers were 
reduced by about 60% indicating that the polymer blend became more amorphous after 
plasticization, therefore its solubility was increased. 
3.3 Characterization of Matrix Erosion and Mechanism_ of Drug Release: 
Microscopic studies showed that the pellets during drug release were reduced in size as a 
function of time while maintaining a constant surface geometry (Figure 6A thru F). To 
extend the release period to more than six hours, 2.0 mm pellets were formulated. Figure 
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7 shows the extent of matrix erosion and drug release from the pellets . Matrix erosion 
and drug release occurred simultaneously (Figure 7). This correlation of matrix erosion 
with drug release holds true at stirring rates of 25, 50 and 100 rpm as demonstrated by 
Figure 8. These findings prove that drug release was a direct consequence of matrix 
erosion and was stirring rate independent. 
Figure 9, shows the correlation of drug released with percent volume reduction by 
erosion. It indicates a direct relationship between drug release and volume reduction by 
erosion. Volume reduction depends on the diameter of the pellets. As the pellet erodes 
with time the pellet diameter reduces due to which erosion volume increases to maintain 
a constant rate of drug release (Table 3). Table 3 shows the changes in pellet volume, 
cumulative % erosion volume and rate of erosion volume as a function of dissolution 
time. The rate of erosion volume from Table 3 was observed to be constant up to 10 
hours. This indicated that pellets eroded from the surface with consequent size reduction 
without affecting the erosion volume. Thus drug release following zero order kinetics 
was obtained. 
These discussions explain the zero order release and matrix erosion profiles achieved 
from pellets and provide strong evidence for a surface erosion mechanism and for 
negligible diffusional release of the drug. 
4.0 Conclusions 
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Unifonn matrix pellets were obtained by using Eudragit®L 100 55 and Eudragit® S 100 
as pellet forming agents. Pellets of satisfactory quality without microcrystalline cellulose 
in the matrix can be fonnulated. 
As hypothesized, multi-unit pellet system fonnulated for controlled release of a poorly 
soluble drug by polymer controlled surface erosion mechanism were developed and 
characterized. These pellets reduced in size as a result of polymer controlled surface 
erosion of the drug and provided zero order controlled release up to 12 hours. 
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Table 1: Fonnulation of 1.2 mm and 2.0 mm pellets with different polymer ratios. 
Eudragit® L 100 SS: Eudragit® S 100 Triethyl citrate 
ratio (% w/w of total Eudragits®) 
1.0 : 1.0 15.0 
1.0 : 1.0 -
1.0 : 3.0 15 .0 
t;: 1.0 : 3.0 -
'" 
°' 
Table 2: Effect of plasticizer (triethyl citrate) on Tg and t.H ofEudragit'" L JOO 55 and Eudragit'" S 100 polymers. 
Polymer blends T, (•C) t. H (mJ/°C mg) 
l•IEudragit'" L I 00 55 93.2 0.112 
Eudragit'" S 100 166.4 0.189 
WEudragi~ L I 00 55 54.5 0.050 
Eudragi t'" S I 00 109.4 0.083 
(a) Ratio of I :3 unplasticized polymer blend 
(b) Ratio of I :3 plasticized wi th 15% w/w oftriethy l ci trate . 
\ 
\ 
Table 3: Detennination of the rate of erosion volume reduction from 2.0 mm pellets (n = 10). 
Time Pellet Pellet 'Volume 'Cumulative Percent l'Rate of Erosion 
(hours) Diameter Volume Change Erosion Volume Volume 
(mm) (mm') (mm') (mm'} (%/hr) 
0.0 2.08 4.7118 0.8889 0.0000 0.0000 
2.0 1.94 3.8229 1.8573 18 .8654 9.4327 
4.0 1.76 2.8545 3.6645 39.4180 9.8545 
~ 6.0 1.26 1.0473 4.1392 77.7728 12.9621 
8.0 1.03 0.5721 4.6783 87.8581 10.9822 
10.0 0.40 0.0335 4.7077 99.2890 9.9289 
I : Original Volume - Volume at time 't'. 
2: Volume Change divided by 4.7118 (Volume at time zero). 
3 : Cumulative Percent Erosion Volume divided by the time interval. 
Schematic representation of a novel multi-ur.it erosion matrix for 
controlled release of a poorly soluble drug. 
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Flow chart of pellet manufacturing procedure . 
Polymer blend (Eud L 100-55 + Eud S 100) 
mixing in turbula mixer for 30 minutes 
Addition of plasticizer (Triethyl citrate) 
+ binder (PVP K90F) + Drug 
mixing in turbula mixer for 30 minutes 
granulation with deionized water 
Extrusion at 40 rpm 
Sprinkled with A vice! PH 101 to minimize inter-pellet sticking 
(5% w/w of total batch size) 
Spheronization at 500-1000 rpm 
Drying at SO C for 12 hours 
Pellet screening (Sieve fractions 
collected 10/12 and 14/16 mesh) 
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Photomicrographs of p.:llcts (2 .0 mm) viewed under an optical microscope. magnification 
sx. 
~7'· 
- ~ • .. "}:• · 
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Effect of plasticizer on matrix erosion from pellets (pellet size: 1.2 mm, drug load: 10% 
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DSC thermogram showing the glass transition temperarures ofEudragit® L!00-55 . 
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Figure 58 





































DSC thennogram showing the glass transition temperatures ofEudragit® Ll00-55 and 
Eudragit® S 100 mixed in ratio of l :3 and plasticized with 10% w/w triethyl citrate. 
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Microscopical ~valuation of matrix erosion and size reduction of pellets (magnification: 5X). 
A. Time: 0 hrs, Size: 2.0 mm B. Time: 2 hrs, Size: 1.75 mm C. Time: 4 hrs, Size: 1.6 mm 
D. Time: 6 hrs, Size: 1.4 mm E. Time: I 0 hrs, Size: 0.8 mm F. Time: 12 hrs, Size: 0.2 mm 
Correlation of matrix erosion(% w/w) with drug release(%) from pellets. 
(pellet size: 2.0 mm, drug load: 10% w/w), Eud LI00-55 : Eud S 100 ratio of I :3, n = 
5:tSE). 
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Correlation of matrix erosion(% w/w) with drug release (%) at different stirring speeds. 
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Correlation of drug release(%) with volume reduction by erosion(%) of pellets. (pellet 
size: 2.0 mm, drug load: 10% w/w), Eud Ll00-55: Eud S 100 ratio of l :3, n = 4:tSE for 
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EFFECT OF FORMULATION AND PROCESS VARIABLES ON MATRIX 
EROSION AND DRUG RELEASE FROM A MULTI-UNIT EROSION MATRIX 
OF A POORLY SOLUBLE DRUG. 
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ABSTRACT 
A novel multi-unit controlled delivery system for the release of a poorly soluble drug by a 
polymer controlled, surface erosion mechanism was reported earlier. The present study 
was undertaken to determine the effects of formulation variables (ratio of polymers used, 
drug loading) and processing variables (water required for granulation, pellet size and 
spheronization time) on matrix erosion and drug release. Powder mixtures containing 
drug, different ratios of Eudragit®L 100 55 and Eudragit®S 100 were blended with 
polyvinylpyrrolidone (PVP) and were extruded/spheronized to obtain homogeneous 
matrix pellets. Drug release was predicted by matrix erosion studies. Matrix erosion was 
determined using USP Dissolution Apparatus I in pH 6.8 phosphate buffer by gravimetry 
and UV spectrophotometry, respectively. Matrix erosion and drug release rates were 
found to be a function of polymer ratio. Drug loading at 5, IO, and 20% w/w levels 
demonstrated that drug release was predominantly matrix erosion controlled. At 30 and 
40% w/w drug levels, matrix erosion and drug release rates decreased. Pellet size had a 
profound effect on the total duration of matrix erosion and drug release from the pellets. 
Thus, by optimizing the formulation and process variables, pellets can be prepared which 
release a poorly soluble drug for 12-24 hours following zero order kinetics. 
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1.0 Introduction 
The design and evaluation of a novel multi-unit erosion matrix that releases a poorly 
soluble drug by matrix erosion for 12 hours was reported earlier [ l]. Several authors 
have reported factors such as polymer type, drug concentration, drug solubility, 
pelletization technique used, influencing drug release rate [2-9]. All these factors were 
evaluated for osmotically or diffusion controlled pellets employing microcrystalline 
cellµlose as the principal pellet forming agent and release rate governing polymer in the 
pellet. 
The pellets used in this study were manufactured by Extrusion/Spheronization technique, 
therefore any change in the formulation or process parameters may influence matrix 
erosion and drug release from the pellets [10]. The aim of this study was to investigate 
the influence of the most critical formulation variables (ratio of polymers used and drug 
loading) and process variables (water required for granulation, pellet size and 
spheronization time) on matrix erosion and drug release from the pellets. Previously, the 
linear relationship between matrix erosion and drug release at various dissolution stirring 
rates was described [I]. It was concluded that in such systems, matrix erosion and drug 
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release occurred simultaneously, thus matrix erosion can be monitored to predict drug 
release from the pellets. 
2.0 Materials and methods 
The poorly soluble drug used as a model was a thiazole based leukotriene 0 4 antagonist 
with aqueous solubility < 1.3 µg/ml (Hoffmann-La Roche Inc., Nutley, NJ) . Eudragit® L 
100 55, Eudragit® S 100 (Huls America, Inc., Somerset, NJ) were used as pellet fonning 
and release rate controlling polymers. Kollidon® 90 F (BASF Inc., Parsipanny, NJ) was 
used as a binder. Avicel® PH IOI (FMC Corporation, Philadelphia, PA) was used in the 
spheronization stage to prevent inter-pellet sticking. Triethyl citrate (Morflex, Inc., 
Greensboro, NC) was used as plasticizer for Eudragits®. All other chemicals were used 
as received. 
2.1 Formulation of Pellets: 
Eudragit® L 100 55 and Eudragit® S 100 were dry mixed in a turbula mixer (Impandex 
Inc., Maywood, NJ, USA) for 30 minutes. This dry mixture was triturated in a mortar for 
44 
__ ....-
5 minutes with triethyl citrate (plasticizer). Drug and polyvinylpyrrolidone (PVP) as a 
binder were added and mixed in a turbula mixer for 30 minutes. This mixture was then 
granulated with deionized water in a mortar and later extruded (LCI Xtruder, Model DG-
Ll, Fuji Paudal Co., Ltd., Japan) at 40 rpm screw speed. The extrudates obtained were 
immediately transferred into a rotating plate in the spheronizer (G.B. Caleva Ltd, Model 
120, Dorset, England). The spheronizer consisted of a stationary vertical cylinder with a 
base friction plate (diameter 32 cm) with a 2 mm cross hatched friction pattern and a 
rotational speed of 200-3000 rpm. Spheronization was carried out for either 2, 10 or 20 
minutes at 500-1000 rpm. During this period, 5% w/w Avicel® PH IOI was sprinkled 
over the rotating extrudates to prevent them from sticking. The pellets obtained were 
dried on trays as a monolayer at 50°C for 12 hours. Pellets were later subjected to sieve 
analysis to collect the desired particle size pellets in a Rotap Sieve Shaker, Model RX-29, 
W.S. Tyler, Inc., OH, USA, fitted with sieve# 8, 10, 12, 14, 16, 18 ,20 and 25. 
2.2 Composition of pellets prepared to evaluate formulation variables: 
Pellets of 2.0 mm size were formulated to determine the effects of polymer ratio and drug 
loading. Pellet compositions are tabulated in Table 1. 
2.3 Composition of pellets prepared to evaluate process variables: 
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Pellets of 2.0 mm size were formulated to determine the effects of granulation water 
level, pellet size and spheronization time. Pellet compositions for granulation water study 
are tabulated in Table 1 Pellets of 0.8, 1.2 and 2.0 mm size were each formulated at 
spheronization times of 2, 10 and 20 minutes (Table 2) to determine the effect of pellet 
size and the spheronization time on drug release and matrix erosion. The formulation 
parameters maintained constant for this study were drug loading (10% w/w), polymer 
ratio (Eudragit® L 100 55 : Eudragit® S 100 was 1 :3), Kollidon® K 90F 
(polyvinylpyrrolidone) as a binder (2% w/w), Triethyl citrate as plasticizer for Eudragits 
( 15% w/w of total Eudragit content), deionized water for granulation (70% w/w). 
2.4 In vitro release studies: 
Drug release was performed using a standard USP Dissolution Apparatus I (Distek, 
Dissolution System 2100A USP XXII). Pellets (100 mg) were immersed in 500 ml of pH 
6.8 phosphate buffer maintained at and 37 .0 ± 0.5°C and stirred at 50 rpm. The baskets 
were removed at intervals of2, 4, 6, 8, 10, 12 hours and were dried for 12 hours at 50° C 
to achieve constant weight. The difference between the initial and final weight of the 
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pellets was calculated to determine percent matrix erosion. The matrix erosion was 
determined to predict percent drug release [I]. 
3.0 Results and discussions 
Several studies report the influence of formulation and process variables on drug release 
from pellets formulated by Extrusion/Spheronization process [2-9]. However, the results 
of these studies are specific to the formulation and utilize either microcrystalline cellulose 
(MCC) or MCC with various hydrophilic or hydrophobic in combination. Drug release 
from such matrices is predominantly characterized by first order kinetics due to the 
presence of microcrystalline cellulose used as the matrix [11]. Tapia et. al. [2] studied the 
effect of chitosan on drug release from matrix pellets manufactured by 
Extrusion/Spheronization and concluded that drug delivery occurred by gel formation of 
chitosan through diffusion process. Gel formation was found to be a direct function of 
polymer ratio. 
The rate controlling polymers used in this study were Eudragit® L 100 55 and Eudragit® S 
100. These polymers dissolve above pH 5.5 and 7.0 respectively. Some of their popular 
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commercial uses include tablet and pellet coatings to achieve controlled or sustained 
release. 
The effect of increased Eudragit® S 100 content on drug release from 2.0 mm pellets is 
shown in Figure 1. It was observed that rate of drug relea3e decreased as the ratio of 
Eudragit® S 100 increased in the formulation without any significant change in the release 
kinetics. 
Figure 2 shows the effect of drug loading on drug release. Matrix erosion data was used 
to compare the effects of drug loading with that of placebo pellets. The same figure 
demonstrates that drug release from pellets with 5, 10 and 20% w/w drug loading was 
similar to that of placebo pellets which strongly indicated that the drug release 
mechanism was matrix erosion controlled up to 20% w/w drug loading. However, above 
20% w/w drug loading, the release rates were found to decrease as the drug load 
increased up to 40% w/w. The reason for this finding may be hydrophobicity of the drug 
incorporated into the matrix. 
The influence of the amount of granulation liquid on the drug release rate from pellets 
made by Extrusion/Spheronization has been the topic of many publications (Baert et al. 
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[4], Jerwanska et al. [5]). Baert et al and his co workers demonstrated that slower release 
rate was the result of increasing amounts of granulating liquid. They correlated the 
effects of granulation liquid with the differences in hardness, density and structure of the 
pellets, whereas Jerwanska et.al and his co-workers, through their study concluded that 
rate of drug release increased with increasing granulation liquid level due to an increase 
in porosity obtained after drying. They also correlated these results with differences in 
hardness of the pellets. 
The effect of the granulation water level on the matrix pellets prepared by employing 
Eudragit® L 100 55 and Eudragit® S 100 as the rate controlling and pellet fonning agents 
is shown in Figure-3. Increased granulation water levels had a direct effect on the drug 
release rates. These findings are similar to the findings of Jerwanska et al [5]. However, 
there seemed to be no significant difference in the release rates above 65% w/w 
granulation water level. This can be explained by the effect of moisture content on the 
degree of liquid saturation of the extrudates. Jerwanska et al [5], proposed that for a 
continuous extrusion process, adequate water is required to bridge the particles together 
until liquid saturation in the granulation is achieved. This is necessary to deform the 
granulation to form extrudates and consequently shape them in to spheres by 
spheronization. If the granulation water level is below the liquid saturation point the 
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spheres obtained will be hard and less porous leading to decreased drug release rates. 
Above the liquid saturation point the hardness and porosity of the pellets are not 
significantly affected. 
In order to investigate the most critical spheronization times which would have an effect 
on drug release, pellets were spheronized for 2, 5, 8, 10, 20 and 40 minutes. The 
hardness of pellets (n = IO) was measured (Chatillon Force Measurement System, Model 
TCD-200 attached with a 5 lb load cell, Greensboro, NC, USA). The results of pellet 
hardness test of IO pellets per spheronization time are tabulated in Table 3. From Table 3, 
the pellet hardness changes with spheronization time up to about IO minutes with 
maximum hardness recorded for pellets spheronized at 8 minutes, where after the 
hardness decreases up to 20 minutes. No significant difference in the pellet hardness 
from 20 to 40 minutes was observed. This may be explained by the densification process 
occurring during the spheronization step. As spheronization time progresses from zero to 
time 't', the extrudates are cut into uniform particles and shaped into spheres due to the 
centrifugal and frictional forces present in the spheronizer during operation. These forces 
act on each and every particle making them more dense and more spherical with time. 
However, after a critical period no further densification occurs with increase in 
spheronization time. Data from Table 3 indicates that the pellet densification process 
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talces about 10 minutes above which very minor changes in densification occur. Thus a 
spheroinzation time of 2, I 0 and 20 minutes was selected to study the effects of time on 
drug release. 
Figure 4 shows the effect of spheronization time on the drug release rate from 0.8, 1.2, 
and 2.0 mm pellets. Spheronization time appears to effect drug release rates at the 2 and 
10 minute processing times for l.2 and 2.0 mm pellets. This effect became less 
pronounced when the pellet size increased from 0.8 to 2.0 mm. However, there is no 
significant difference in the drug release profile of l.2 and 2.0 mm pellets above JO 
minute processing time. It was also observed that the duration of drug release increased 
as the pellet size increased without any change in release kinetics above 1.2 mm pellet 
size. 
4.0 Conclusions 
This study shows the effects of various formulation (ratio of polymers used and drug 
loading) and process (granulation water level, pellet size and spheronization time) 
parameters on drug release by surface erosion from multi-unit matrix pellets. Each 
parameter evaluated, demonstrated a change in drug release from the pellets. Increased 
5 I 
amounts of Eudragit® S 100 retarded the rate of matrix erosion and drug release from the 
pellets. The drug loading had no influence on drug release mechanism up to the 20% 
w/w level above which increasing levels of drug up to 40% w/w retarded matrix erosion. 
Granulation water level at 65% w/w had a significant effect on the rate of matrix erosion 
and drug release as compared to the formulation with 60% w/w granulation water level. 
Above 65% w/w, there was no significant effect on the rate of matrix erosion and drug 
release. 
Matrix erosion and drug release rates can be optimized by processing the pellets at 
different spheronization times. Thus, by optimizing the formulation and process 
variables pellets that can release a poorly soluble drug by polymer controlled, surface 
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Table I. Composition of pellets fonnulated with different polymer ratios, drug loadings and granulation water levels. 
Ingredients Pellet Compositions with Pellet Compositions with Different Drug Pellet Composition 
(% w/w) Different Polymer Ratios Loadings with different 
Granulation Water 
Drug 10.00 10.00 0.00 5.00 10.00 20.00 30.00 40.00 10.00 10.00 10.00 
Kollidon® 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 
90F 
Eudragit®L 35.20 22.00 22.00 22.00 22.00 22.00 22.00 22.00 22.00 22.00 22.00 
100-55 
Eudragit®S 52.18 66.00 66.00 66.00 66.00 66.00 66.00 66.00 66.00 66.00 66.00 
100 
• Plasticizer 15.00 15.00 15.00 15.00 15 .00 15.00 15.00 15.00 15.00 15.00 15.00 
Granulation 60.00 60.00 77.90 70.00 70.00 62.00 60.00 65.00 60.00 65.00 70.00 
Water 






Pellets of different size prepared at different spheronization times. 













Table 3. Effect of spheronization time on pellet hardness. 
Spheronization Time Pellet Hardness (grams) 
J..minute~ J..Mean+SDl 
2.00 1091±139.39 
5.00 1383 ± 177.14 
8.00 1511±157.12 
IO.OD I 259 ± 170.25 
20.00 1034 ± 177.40 
40.00 1110 ± 146.06 
Effect ofvaryi.ng polymer ratios on drug released(%) from pellets. 
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Effect of different drug loading(% wlw) on drug released(%) from pellets . 
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Effect of granulation water level (% wlw) on drug released(%) from pellets. 
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MANUSCRIPT Ill 
EFFECT OF FORMULATION AND PROCESS VARIABLES ON POROSITY 
PARAMETERS AND RELEASE RATES FROM A MULTI UNIT EROSION 
MA TRIX OF A POORLY SOLUBLE DRUG 
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ABSTRACT 
Controlled release erosion matrix pellets were prepared by a Extrusion/Spheronization 
technique. The effect of drug loading, water required for granulation and spheronization 
time- on porosity parameters (intrusion-extrusion isotherms, pore size distribution, total 
pore surface area, mean pore diameter, shape and morphology of pores) and drug release 
rates were investigated. Porosity parameters were detennined by using mercury intrusion 
porosimetry. In vitro release was performed in phosphate buffer pH 6.8 using USP XXIl 
Apparatus I (baskets, at 50 rpm) by UV spectrophotometery. The drug loading was found 
to have a profound effect on the porosity parameters. Pellets with low drug loading 
showed increased pore surface area, with small mean pore diameters and an increased 
number of total pores. Whereas pellets with high drug loading had decreased pore 
surface area with bigger mean pore diameters and a decrease in the total number of pores. 
With high drug loading, drug release rate was found to be decreased. Water required for 
granulation had a direct effect on the total porosity of the pellets. Dissolution studies 
showed that release rates were directly related to the water required for granulation. 
Spheronization time from 2 to 10 minutes had a pronounced effect on porosity parameters 
and release rates. No changes in porosity parameters and release rates were observed 
from lO to 20 minutes of spheronization time. It was shown that each porosity parameter 
investigated was well correlated with drug release rates and thus it is important to study 
the effect of porosity parameters in evaluating the In vitro performance of multi-unit 
erosion matrix for controlled release of a poorly soluble drug. 
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INTRODUCTION 
Porosity is a measure of void spaces in a material and can be generally calculated by 
using a number of techniques such as density, gas adsorption, water displacement and 
porosimetry (I). Determination of pore structures of solids can provide important 
information on disintegration, dissolution, adsorption and diffusion of drugs (2). Pore 
size measurements provide information on the actual pore structures, including pore 
diameter and volume, and can be determined by gas adsorption and mercury porosimetry. 
The gas adsorption method is limited to pore diameters smaller than 2000 Angstroms, 
whereas mercury porosimetry is capable of measuring larger pores and inter-particle 
spaces (3). Thus mercury porosimetry is a suitable technique to determine a broad range 
of pores of a sample. 
The method is based on intrusion of mercury into the pores of a solid sample and is 
quantified by the Washburn Equation (4). 
Pr= -2 yCos 0 
where P =pressure (psi), r =pore radius (µm), y =surface tension of mercury (dynes/cm) 
and 0 = the contact angle of mercury. This equation holds true only when the surface 
tension and contact angle of mercury are kept constant and shape of the pores is assumed 
to be circular. 
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By mercury penetration under pressure, one can determine the size and quantity of void 
spaces and pores in porous materials. In addition, mercury expelled from pores as a 
function of decreasing pressure provides information about the shape and structure of the 
pores (5). In porosimetry, voids are defined as spaces between particles or the several 
pieces constituting the specimen, whereas cracks, crevices, holes and fissures within the 
specimen, whether a single piece or a powder, are termed as pores (6). 
Mercury porosimetry has been extensively used in porosity determination of granules (7-
II) , tablets ( 12-17) and pharmaceutical powders ( 18, 19). The development, 
characterization and evaluation of a novel multi-unit erosion matrix for a poorly soluble 
drug was reported in our previous study (20). In which, matrix pellets of a model poorly 
soluble drug (thiazole based leukotriene antagonist, aqueous solubility < 1.23 µg/mL) was 
pelletized with Eudragit® L 100 55 and S 100 used as release rate controlling polymers. 
The pellets were prepared by Extrusion/Spheronization technique and the effect of 
formulation (drug load, water required for granulation) and process (spheronization time) 
variables on drug release were studied (21). In this paper we have used mercury intrusion 
porosimetry to understand the effect of formulation and process variables on drug release 
behavior relative to the changes in porosity parameters. 
MATERIALS AND METHODS 
A thiazole based leukotriene D4 antagonist (Hoffmann-La Roche Inc., Nutley, NJ) was 
used as a model poorly soluble drug. Eudragit® L 100 55, Eudragit® S 100 (Huls 
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America, Inc., Somerset, NJ) were employed as matrix forming and release rate 
governing polymers. Kollidon® 90 F (BASF, Inc., Parsipanny, NJ) was used as a binder 
in the formulation. Avicel® PH 101 (FMC Corporation, Philadelphia, PA) was used to 
prevent inter-pellet sticking during the spheronization stage. Triethyl citrate (Morflex, 
Inc. , Greensboro, NC) was used as a plasticizer for Eudragit® polymers. All other 
chemicals were used as received. 
Preparation of Matrix Pellets by Extrusion/Spheronization: 
Eudragit® L 100 55 and Eudragit® S 100 were dry mixed in a Turbula mixer (Impandex 
Inc., Maywood, NJ, USA) for 30 minutes. This dry mixture was triturated in a mortar for 
5 minutes with triethyl citrate used as a plasticizer. Drug and polyvinylpyrrolidone used 
as a binder were added to this mixture and were mixed in the Turbula mixer for 30 
minutes. The dry blend was transferred to a mortar and was granulated with deionized 
water for 10 minutes. The wet granulate was later extruded at 40 rpm screw speed (LC! 
Xtruder, Model DG-Ll, Fuji Pauda! Co., Ltd., Japan). The instrument used was a single 
screw extruder capable of extruding at speeds upto 100 rpm. The extrudates were 
spheronized in a G.B. Caleva Ltd, Model 120, Dorset, England, at 600-800 rpm 
spheronizer speed. The spheronizer consists of a stationary vertical cylinder which has at 
the base a friction plate with a 2 mm cross hatched friction pattern and a rotation speed of 
200-3000 rpm. Spheronization times used were 2, 10 and 20 minutes. Av1cel® PH 101 
5% w/w was sprinkled over the rotating extrudates to prevent pellets from sticking. The 
pellets obtained were dried at 50° C for 12 hours using a tray dryer and were later sieved 
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through Rotap Sieve Shaker (Model RX-29, W.S. Tyler, Inc., OH, USA), fitted with sieve 
number IO and 12 to obtain 2.0 mm size pellets. 
Drug Loading: 
Composition of pellets formulated to determine the effects of drug loading are given in 
Table I. 
Water required/or granulation: 
Composition of pellets formulated to study the effects of granulation water level are given 
in Table 2. 
Spheronization time: 
Pellets were processed at 2, IO and 20 minutes spheronization times. Formulation 
composition maintained constant for this study were the drug load ( IO % w/w), polymer 
ratio (I : 3) same as in Table 2, Kollidon® 90F as binder (2 % w/w), triethyl citrate as 
plasticizer (15 % w/w of total Eudragit®L 100 55 and Eudragit®S 100) and water for 
granulation (70 % w/w of the total batch size). 
Drug release studies: 
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It was shown in our previous study that pellets prepared with the model poorly soluble 
drug, released the drug as a direct function of matrix erosion (20). In vitro drug release 
was determined by using USP XXII Apparatus I with baskets at 50 rpm (Distek Inc., NJ, 
USA) in 500 mL of pH 6.8 phosphate buffer at 37 .0 ± 0.5° C. 
Mercury intrusion porosimetry: 
Porosity parameters such as intrusion-extrusion isotherms, pore size distribution, total 
pore surface area, mean pore diameters, shape and morphology of the pores were 
determined by using a Micromeritics PoreSizer 9320 (Micromeritics Inc., Norcross, GA, 
USA). Incremental intrusion volumes were plotted against pore diameters which 
represented pore size distributions. The moisture content of pellets were determined with 
an infra-red moisture analyzer at 105° C (Computrac, Model Max-50, Arizona Instrument 
Corp., USA) prior to porosimetry studies. The moisture content of all the pellet samples 
varied between 2.2-3.0 % w/w. The pore diameter was calculated by using Eq 2. 
D = _-_4~r_co_s_e 
p 
where D = pore diameter (µm) 
y =surface tension of mercury (485 dynes/cm). 
e = contact angle ( 130 degrees) 
P = pressure (psi) 
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The total pore surface area (S) was calculated by using Eq 3 
l Vtot 
S=-l-£JI f PdV ycos 0 
where; P =pressure (psi) 
V =the intruded volume of mercury (mllg) 
V,01 = total intruded volume of mercury (mllg) 





Pore morphology was characterized from the intrusion-extrusion profiles of mercury in 
the pellets as described by Orr et. al. (6). 
RESULTS AND DISCUSSION 
Effect of Drug Loading: 
7 1 
The intrusion volume of mercury is a function of •total porosity. In Figure 1 the 
cumulative intrusion volume was plotted against pore diameters showing the intrusion-
extrusion profile of pellets with different drug loading. The intrusion and extrusion 
curves form a hysteresis indicating that majority of the pores present in the pellets were 
ink-well type pores that had smal l openings with broad bases. Although no particular 
trend was observed in the intrusion profiles with respect to drug loading, the intrusion 
volume of mercury was significantly lower for 30 and 40% w/w than the 5, 10 and 20% 
w/w drug loading (Figure !). 
Figure 2 shows the incremental intrusion volume as a function of the pore diameter of the 
pellets with increasing drug loading. From Figures I and 2, the number of pores and 
mean pore diameters of the pellets can be characterized. The data indicates that as the 
drug loading increased from 0-10% w/w, the mean pore diameter increased with the total 
number of pores essentially remaining constant whereas, with 30 and 40% w/w drug 
loads the mean pore diameters increased and the total number of pores decreased. 
Figure 3 shows the effect of drug loading on the total pore surface area and mean pore 
diameter of pellets; they seem to have an inverse relationship as expected. 
Table 3 lists the calculated ranges of pore necks and pore bases as a function of increasing 
drug loading as characterized from Figures 1 and 2. The data from Table 3 indicates that 
pore bases were nearly twice the size of pore necks at all levels of drug loading; 
indicating that all pores have large bases with relatively small necks. This difference 
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becomes more apparent as drug loading increases above 30% w/w. This interpretation is 
supported by the relation of drug loading, total pore surface area and the mean pore 
diameters of the pellets as shown in Figure 3. The results indicate that with increasing 
drug concentration the pores became wider with larger necks and thus reduced in number. 
These changes are illustrated schematically in Figure 4. 
Figure 5 shows the dissolution profiles of the pellets with different drug loading. Drug 
release from these pellets occurred via surface erosion. Therefore theoretically, the nature 
of pores present at the surface of the pellet must influence the erosion rate rather than the 
total porosity of the pellet matrix during the dissolution process. In pellets with high drug 
loads, the total polymer content is relatively low. Since the weight fraction of drug per 
unit weight of the drug-polymer mixture is high, the drug particles associate to form drug 
agglomerates (22) and this agglomeration tendency of the drug at high drug loads will 
reduce the number of pores and thus total pore surface area is reduced. Such a system 
during dissolution will have a low contact surface area with the dissolution media. 
However, in pellets with low drug loads, the weight fraction of polymer per unit weight 
of the drug-polymer mixture is high, therefore chances of drug agglomeration are less 
resulting in more pores with smaller mean pore diameters and increased total pore surface 
area. Thus, the increase in mean pore diameter and decrease in total pore surface area of 
pellets with high drug loading were primarily due to agglomeration of the drug particles. 
As it is discussed above, because of the existence of larger pores, the surface area of 
contact between the dissolution medium and pellets with high drug load is reduced, which 
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reduces pellet hydration and consequently the erosion rates. This was confirmed by the 
dissolution profiles .given in Figure 5. 
Effect of Water Required for Granulation: 
The intrusion-extrusion profiles of mercury for the percent water added to the granulation 
are shown by plotting cumulative intrusion volume against pore diameter in Figure 6. 
The total intrusion volume was found to be a direct function of granulation water level. 
This indicated that total porosity of the pellets increased with the addition of water for 
granulation from 60-70% w/w. These findings are similar to the results obtained by other 
researchers (23-26). 
Figure 7 is a plot of incremental intrusion volume against pore diameter which shows the 
pore size distribution of pellets with different granulation water levels. All pores present 
are between 0.01-0.l µmin size. Table 4 summarizes the results of granulation water 
level on the range of pore necks and pore bases. The pore base being the average width 
of the ink-well type pores inside the pellet matrix. From Figure 7 and Table 4 it is 
evident that increasing the granulation water level from 60 to 65% w/w increased the total 
number of pores, but the pore necks and bases were not affected indicating that the water 
levels used in the study increases the porosity without affecting the morphology of pores. 
When the granulation water level was increased from 65 to 70% w/w, the pore neck and 
pore base ranges remain narrow but the number of pores increase, resulting in overall 
increase in the porosity of the pellets . 
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Figure 8 shows the effect of total pore surface area and mean pore diameters against 
granulation water levels. The data indicate that the total pore surface area increases 
without any significant change in the mean pore diameter as a function of increased 
granulation water levels. This finding also strongly supports the fact that with the 
addition of more granulation water, the number of pores increased without any change in 
the mean pore diameters. These changes are illustrated schematically in Figure 9. 
Fujiwara and Kato et al. reported similar findings with the increase in granulation water 
level on pore structure and porosity of sucrose and lactose granules prepared by wet 
granulation (9). 
The dissolution profile of pellets formulated at different granulation water levels are 
given in Figure 10. The dissolution rates increase with the increase in porosity and total 
pore surface area of the pellets with 60, 65 and 70% w/w water for granulation. This 
increase in the porosity and total pore surface area of the pellets increased the dissolution 
contact area of the medium with the pellet surface resulting in faster hydration and 
consequently caused higher erosion rates. 
Spheronization Time: 
The sphericity of a pellet is a function of spheronization time. The longer they are 
spheronized more spherical pellets are produced. The circular motion of the friction plate 
in the spheronizer, shape the sphagetti like extrudates into smal ler and uniform granules. 
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Eventually, the collision of these granules with the friction plate and the walls of the 
spheronizer change their shape into small spheres or pellets as a function of time. This 
transformation may be analogous to tablet compaction. "The term compactability is the 
abi lity of the bed of particles to cohere into or form a compact of a defined mechanical 
strength"(26). In compacting a tablet, the force applied by the upper punch has a direct 
relation with the compactability of the tablet. It is also generally observed that after a 
critical force no further increase can change the degree of compaction. Similarly, during 
spheronization, the pellet is compacted up to a critical strength above which no more 
compaction is observed. The change in porosity parameters of tablets as a function of 
compaction force are reported (12-17). However, for pellets no information showing the 
changes in porosity parameters as a function of spheronization time is reported. 
Therefore, it was important to elucidate this process with respect to the change in porosity 
parameters, particularly because the dissolution rates of the pellet were a function of 
spheronization time. 
To understand the changes occurring in porosity with spheronization, the pellets were 
processed at three different spheronization times, 2, 10 and 20 minutes. Figure 11 shows 
the total intrusion volume against pore diameters as a function of spheronization time. 
The data indicate that porosity was not significantly affected by spheronization at 2, l O 
and 20 minutes. 
Figure 12 shows the plot of incremental intrusion volume against pore diameters which 
demonstrates that the pores increased with 2 to 10 minute spheronization time. However, 
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after 10 minutes, no change in the pore size distribution was observed upto 20 minutes. 
Figure 13 confirms these findings by demonstrating no change in the total pore surface 
area and mean pore diameter from 10 to 20 minutes. 
In summary, following the argument given earlier, processing period from 2 to 10 
minutes increased the pores, total pore surface area and decreased pore diameters, beyond 
this time up to 20 minutes none of the porosity parameters changed. Figure 14 shows the 
effect of spheronization time on dissolution profiles of pellets which were processed for 
2, 10 and 20 minutes. The dissolution rates of pellets processed at 10 and 20 minutes 
were same. However, pellets processed at 2 minutes spheronization time showed faster 
dissolution rates. Figure 15 shows a schematic representation of the effect of 
spheronization time on the porosity of the pellets. 
CONCLUSIONS 
This study demonstrated that the changes in porosity parameters (intrusion-extrusion 
isotherms, pore size distribution, total pore surface area, mean pore diameter, pore shape 
and morphology) of pellets made with insoluble drug substance is affecting drug release 
rates with erosion controlled mechanism when the drug loading, granulation water level 
and spheronization time are modified. 
By increasing the granulation water level, the number of pores are increased without 
affecting the mean pore diameter. The total porosity of the pellets was increased with 
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higher granulation water level. This increases the erosion rate of pellets leading to faster 
dissolution of the drug. 
With spheronization time, the porosity parameters are affected depending on the time. 
Up to I 0 minutes of spheronization time, the number of pores increased with total 
increase in surface area and decrease in pore diameter. No significant increase in porosity 
parameters was observed when the spheronization time was further increased from I 0 to 
20 minutes. This difference is reflected by erosion rate and dissolution profiles. 
Thus, the study of porosity parameters is important in characterizing and predicting the !!! 
vitro performance of multi-unit matrix pellets. 
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Table I: Formulations prepared to determine the effects of drug loading. 
Drug Load Kollidon®90F Eudragit®L 100 Eudragit®S 100 *Plasticizer 
(% w/w) (% w/w) 55 (% w/w) (% w/w) (% w/w) 
0.00 2.00 24.50 73.50 15.00 
5.00 2.00 23 .25 69.75 15.00 
10.00 2.00 22.00 66.00 15.00 
20.00 2.00 19.50 58.50 15 .00 
30.00 2.00 17.00 51.00 15 .00 
40.00 2.00 14.50 43.50 15.00 




Table II: Fonnulations prepared lo detennine the effect of granulation water 
levels. 
Drug Load Kollidon®90F Eudragit®L 100 Eudragit®S 100 • Plasticizer Granulation Water 
(%w/w) (% w/w) SS(% w/w) (% w/w) (% w/w) Level (% w/w) 
10.00 2.00 22.00 66.00 15.00 60.00 
10.00 2.00 22.00 66.00 15.00 65.00 
10.00 2.00 22.00 66.00 15.00 70.00 





Effect of drug loading on the size of pore necks and pore bases as 
characterized from the intrusion-extrusion profiles . 
Drug Load (% w/w) Pore Necks (nm) Pore Bases (nm) 
0.00 15 - 90 50 - 200 
5.00 18 - 60 70- 150 
10.00 18 - 60 70- 150 
20.00 18 - 70 40 - 150 
30.00 18 - 90 40-150 





Table IV: Effect of water required for granulation on pore necks and pore bases 
as characterized from intrusion-extrusion curves of mercury. 
Granulation Water Level Pore Necks Pore Bases 
(% w/w) (nm) (nm) 
60.00 15 - 90 50- 110 
65.00 15 - 90 50- 110 
70.00 20-60 60 - 100 
Cwnulative intrusion volwne vs pore diameter of pellets with different drug loading(% 
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Pore size distribution of pellets with different drug loading (% w/w). (pellet size: 2.0 mm, 
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Effect of drug loading (% w/w) on total pore surface area and mean pore diameter of 
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Schematic surface representation of the effect of drug loading on 
the pore diameters and total number of pores. 
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Effect of drug loading(% w/w) on drug released(%) from pellets. (pellet size: 2.0 mm, 
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/ 
Effect of granulation water level (% w/w) on pore size distribution of pellets. (pellet size: 
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Effect of granulation water level (% w/w) on total pore surface area nad mean pore 
diameter of pellets. (pellet size : 2.0 mm, drug load: 10% wlw, spheronization time: 20 
minutes, n = 3±SE) 
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Schematic representation of the effect of increasing water required 
for granulation on the pore diameters and total number of pores. 
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Effect of granulation water level (% w/w) on drug released from pellets. (pellet size: 2.0 
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Effect of spheronization time on cwnulative intrusion volwne of pellets. (pellet size: 2.0 
mm, drug load: I 0% w!w, n = 3±SE) 
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Effect of spheronization time on total pore surface area and mean pore of pellets. (pellet 
size: 2.0 mm, drug load: 10% w/w, n = 3±SE) 
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Schematic representation of the effect of spheronization 
time on the pore diameters and total number of pores. 
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Abstract 
Nifedipine (N) and nifedipine:Pluronic® F-68 solid dispersion (SD) pellets were 
characterized for drug release mechanisms from a multi-unit erosion matrix system for 
controlled release. N was micronized using a jet mill. SD with Pluronic® F-68 was 
prepared by the fusion method. N and SD were characterized by particle size analysis, 
solubility, DSC and XRD studies. Samples were subsequently processed into matrix 
pellets by Extrusion/Spheronization using Eudragit® L 100 SS and Eudragit® S 100 as 
release rate controlling polymers. Drug release mechanisms from pellets were 
characterized by microscopy and mercury intrusion porosimetry. DSC and XRD studies 
indicated no polymorphic changes in N after micronization and also confirmed the 
formation of SD of N with Pluronic® F-68. Pellets of N showed a 24 hour drug release 
profile following zero order kinetics. Pellets of SD showed a 12 hour release profile 
following first order kinetics. Aqueous solubility of N after SD formation was found to 
be increased by IO folds. Due to increased solubility of N in SD, the drug release 
mechanism was found to be changed from pure surface erosion to erosion/diffusion 




Nifedipine is a poorly water-soluble drug and when administered orally in the crystalline 
form has poor bioavailability. For poorly soluble drugs, dissolution is the rate-limiting 
step for gastrointestinal absorption of the drug from solid dosage forms. Since 
dissolution rate is directly proportional to surface area, decreased particle size may 
increase the dissolution rate. Numerous attempts have been made to modify the 
dissolution characteristics of drugs to attain more rapid and complete absoqition ( 1-5). 
Controlled release Oros® tablets of nifedipine are commercially available. The drug 
releases in the form of a microfine suspension through a laser drilled hole in the tablet via 
osmosis following zero order kinetics for 24 hours. Osmotic controlled release multi-unit 
pellets and granules of nifedipine have also been reported (6). 
The mechanism of polymer controlled surface erosion that provides a constant delivery of 
a poorly soluble drug via multi-unit erosion matrix was reported in our previous study (7). 
In such a system the drug release was found to be proportional to matrix erosion. Hence, 
matrix erosion could be used to predict drug release. This system consisted of Eudragit® 
L 100 55 and Eudragit® S 100 which were used as matrix forming and release rate 
controlling polymers. These are anionic polymers based on methacrylic acid and 
methacrylic acid esters. The ratio of carboxyl groups to ester units is about 1: 1 in 
Eudragit® L 100 55 and about 1:2 in Eudragit® S 100. These polymers are soluble above 
pH 5.5 and 7.0 respectively. The model drug (nifedipine), Eudragits® and 
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polyvinylpyrrolidone (binder) were wet granulated and later pelletized using an 
Extrusion/Spheronization technique. The effects of dissolution stirring rate, polymer 
ratio, granulation water requirement, drug loading, pellet size and spheronization time on 
the release patterns were reported earlier (8). 
Solid dispersions of poorly soluble drugs provide alternatives to increasing drug solubility 
and bioavailability. Law et al. (9) showed increased oral absorption and bioavailability of 
nifedipine-polyethylene glycol and nifedipine-phosphatidylcholine-polyethylene glycol 
solid dispersions in rats . Solid dispersions of nifedipine with different carriers such as 
urea, lactose, PEG 4000, 6000, 10000 and PVP K-30, K-90 have been studied by Sumnu 
et al. (10). However none of these solid dispersions were evaluated for their release 
patterns from the final controlled drug deli very system, and there are no studies 
determining the influence of solid dispersions on drug release mechanisms via solid 
dosage forms. 
Release mechanisms of a drug from solid dosage forms may be related to the porosity. 
Porosity is a result of the presence of voids and pores in a sample where voids are the 
inter particulate spaces and pores are typically the crevices, cracks and fissures located in 
the particle (11). The porosity can be characterized by mercury porosimetry. The pore 
structure of a solid can provide valuable information regarding its dissolution and 
diffusion properties (12). Therefore, porosity and pore size distribution measurements 
have been extensively used to study tablets ( 13-18), granules (I 9-23) and pharmaceutical 
powders (24,25). Void porosity can be characterized by low pressure mercury 
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porosimetry (upto 30 psi) and is detemtined by calculating the pore volume diameter. In 
contrast, pores are analyzed by high pressure mercury porosimetry (upto 30,000 psi). 
According to this method, the cumulative volume of mercury intruded is a function of 
porosity, increased volumes indicate an increased porosity. 
The present study was undertaken to develop, characterize and evaluate the multi-unit 
erosion matrix as described previously (7) with nifedipine and nifedipine:Pluronic® F-68 
solid dispersion. A physical characterization of nifedipine solid dispersion by particle 
size analysis, aqueous solubility, DSC and XRD studies were conducted before they were 
pelletized. Later, pellets containing nifedipine or nifedipine:Pluronic® F-68 solid 
dispersions were prepared by a Extrusion/Spheronization technique. The effect of 
porosity parameters (cumulative intrusion volume, pore size distribution, pore volume 
diameter, total intrusion volume and total pore surface area) on dissolution time of the 
pelletized nifedipine and nifedipine:Pluronic® F-68 solid dispersion were detemtined to 
better explain the mechanism of drug release from controlled release matrix pellets and to 
detemtine the differences that were introduced by the nifedipine:Pluronic® F-68 solid 
dispersions. 
2.0 Materials and methods 
Nifedipine (USP/BP) was purchased from Vinchem, Inc, (Chatham, NJ, USA) and was 
micronized by using a Fluid Energy Aljet Mill (Plumsteadville, PA, USA). Inlet air 
pressure of 60 psig and grinding air pressure of 80 psig for micronization were used. 
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Eudragit® L 100 55, Eudragit® S 100 (Huls America, Inc., Somerset, NJ, USA), 
Kollidon® 90 F (BASF, Inc., Parsipanny, NJ, USA), Avicel® PH IOI (FMC Corporation, 
Philadelphia, PA, USA), Triethyl Citrate (Morflex, Inc., Greensboro, NC, USA) and 
Pluronic® F-68 (BASF, Inc., Parsipanny, NJ, USA). All other chemicals were used as 
received. Since nifedipine is sensitive to light, all experiments were performed under 
yellow light. 
2.1 Particle size detennination 
Particle size determination was carried out with Master Sizer X, Malvern Instruments 
Inc., Southborough, MA, USA. An excess amount of drug was suspended in 1.0 % v/v 
Tween 80 in 100 mL of distilled water and was sonicated for 30 seconds for a thorough 
dispersion. This suspension was circulated at medium speed for particle size distribution 
studies. 
2.2 Preparation of nifedipine: Pluronic® F-68 solid dispersions 
Solid dispersion with different drug:pluronic ratios were prepared by the fusion method 
(26). The required amount of Pluronic® F-68 was weighed accurately and heated to 100° 
C until it formed a transparent melt. Nifedipine (mean particle size: 2.31 µm) was added 
to this melt in small portions with a constant stirring rate of 750 rpm. The temperature of 
the mixture was kept constant at 100° C. This mixture was stirred for 45 minutes until a 
clear transparent melt was formed. The melt was then poured on to a glass plate and was 
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allowed to solidify at room temperature. The solid mass was powdered and uniformly 
mixed in a mortar and 80/100 mesh (150-180 µm) particles were used for pelletization. 
2.3 Solubility of nifedipine and nifedipine in Pluronic119 F-68 solid dispersion 
Solubility of nifedipine alone and nifedipine in the Pluronic® F-68 solid dispersion ( 1: 1) 
was determined by placing an excess amount of sample in amber glass vials with 10 mL 
deionized water. The samples were then subsequently allowed to equilibrate at 25° C in 
an incubator shaker for 24 hours. Samples were filtered and the filtrate was analyzed for 
nifedipine by an HPLC method. A Waters 600E multi solvent delivery system (Waters 
Corporation, Milford, MA, USA) connected with a variable wavelength absorbance 
detector (Model Spectra 100, Spectra-Physics, USA) and a Waters 717 plus auto sampler 
(Waters Corporation, Milford, MA, USA) was used. The stationary phase consisted of a 
micro bondapak C18 reverse phase column (3.9 x 300 mm, Waters Corporation, Milford, 
MA, USA). Mobile phase used was acetonitrile : methanol : distilled water (2 : 3 : 5) and 
the flow rate was 1.0 mIJmin with 30 minutes of total run time per injection. Nifedipine 
was detected at a retention time of 15.8 minutes. The sensitivity of the assay was I 
µg/mL. All studies were performed in triplicate. 
2.4 Differential scanning calorimetry (DSC) and X-ray diffraction (XRD) studies 
DSC was carried out with a Seiko Instruments Inc., Japan, Model SSC5200 system. 
Approximately 10 mg of sample was placed in a hermetically sealed aluminium pan and 
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was scanned at the rate of 10° C/min from 0 to 200° C. Qualitative powder X-ray 
diffraction was performed by a Scintag X-Ray Diffractometer System, CA, USA by using 
nickel filtered copper potassium alpha radiation. 
2.5 Preparation of pellets 
Eudragit® L 100 55 and Eudragit® S 100 were mixed in a Turbula mixer (Impandex Inc., 
Maywood, NJ, USA) for 30 minutes. Triethyl citrate was added to this mixture as a 
plasticizer by trituration in a mortar. Nifedipine or nifedipine solid dispersion was then 
added followed by Kollidon® 90F used as a binder and they were mixed for 30 minutes in 
a Turbula mixer. The resultant mixture was then granulated with deionized water in a 
mortar. The granulate obtained was then fed through an extruder (LCI Xtruder, Model 
DG-Ll by Fuji Pauda! Co., Ltd., Japan) which was equipped with a single screw and a 
screen of 2.0 mm size. Extrusion was conducted at 40 rpm. Extrudates obtained were 
immediately processed into pellets by spheronization (Spheronizer: Model 120, G.B. 
Caleva Ltd, Dorset, England attached with a 2.0 mm cross hatched friction plate). The 
spheronization speed was maintained within 800-1000 rpm and spheronization time was 
limited to 10 minutes. During this p'rocess Avicel® PH 101 (5% w/w of total batch size) 
was sprinkled on to the pellets to prevent inter pellet sticking. Pellets thus obtained were 
dried on trays in a hot air convection oven for 12 hours at 50° C. They were then sieved 
(Rotap Sieve Shaker, Model RX-29, W.S. Tyler, Inc., OH, USA) to obtain 2.0 mm sieve 
fractions. The quantitative composition of the pellets formulated is given in Table I. 
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2.6 Detemzination of In Vitro drug release 
In vitro dissolution was performed using USP XXII Apparatus I in 500 mL of pH 6.8 
phosphate buffer with ionic strength of 0.05 M, at 50 rpm and 37.0 ± 0.5° C (Distek Inc., 
NJ, USA). Pellets obtained after dissolution were characterized for their shape and 
structure by an optical microscope by Nikon HFX, IA, Japan. Transverse sections of 
pellets obtained after 2 and 4 hour dissolution times were analyzed for the distribution of 
drug in the matrix. 
2. 7 Determination of porosity parameters 
Pellet dissolution time as a function of cumulative intrusion volume of mercury, pore size 
distribution, pore volume diameter, total intrusion volume and total pore surface area 
were determined by mercury intrusion porosimetry. A Micromeritics PoreSizer Model 
9320, Micromeritics Inc., Norcross, GA, USA was used 1·or the determinations. Each 
sample was measured in triplicate. 
3.0 Results and discussion 
Results of particle size determination are tabulated in Table II. The solubility of 
nifedipine and nifedipine in the nifedipine:Pluronic® F-68 (1: I) solid dispersion was 
found to be 9.72±Q.13 and 103.06±0.07 µg/mL respectively demonstrating that Pluronic® 
F-68 increased the solubility of nifedipine by approximately ten fold . 
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DSC thermograms and XRD pattern of micronized nifedipine indicated no changes in its 
thermodynamic and crystalline behaviour (Figures la and lb) . Data obtained indicates 
that nifedipine remained the same after micronization. Figures 2a and 2b are the 
thermograms of nifedipine:Pluronic® F-68 solid dispersions that were prepared in ratios 
of 1:0.5 w/w drug to polymer (Tm= 167.8° C, 6.H = 50.7 mJ/mg) and 1:1 w/w (Tm= 
152.6° C, 6.H = 24.2 mJ/mg) respectively. From these thermograms it was clear that the 
melting point of nifedipine was reduced in the solid dispersion with consequent reduction 
in enthalpy Figures 3a and 3b are XRD patterns of nifedipine:Pluronic® F-68 solid 
dispersions in ratios of 1:0.5 w/w and 1:1 w/w respectively. The characteristic nifedipine 
peaks were found to be reduced with increased concentration of Pluronic® F-68 in the 
solid dispersion. These results provide evidence of decreased drug crystallinity due to the 
formation of a solid dispersion. Similar results were reported for nifedipine solid 
dispersions with various other substances (9, 10) such as polyethylene glycol, urea, 
lactose, polyvinylpyrrolidone etc. 
A linear relationship of drug release via matrix erosion of a poorly soluble drug, similar 
to nifedipine, was described in our earlier study (7). The validity of this matrix erosion 
hypothesis was tested with nifedipine and nifedipine:Pluronic® F-68 solid dispersion 
pellets. The in vitro release profiles of nifedipine pellets before and after micronization 
and nifedipine:Pluronic® F-68 solid dispersion pellets are shown in Figure 4. Pellets 
prepared with nifedipine of three different particle sizes provided a zero order 24 hour 
drug release profile. On the other hand, drug release from the pellets prepared with 
nifedipine:Pluronic® F-68 solid dispersions was changed from zero to first order and the 
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release rates had significantly increased compared to the pellets prepared with nifedipine 
alone. Drug release rates from the solid dispersion pellets was increased as Pluronic® F-
68 increased from 0.5 to 1.0 part in the solid dispersions. Dissolution from these pellets 
followed first order kinetics for about 12 hours for both the strengths. From Figure 4 it 
can also be concluded that particle size differences of nifedipine did not significantly 
influence the release pattern and rates from nifedipine pellets. 
In order to understand the underlying release mechanism, the pellets collected at different 
time intervals during dissolution testing were analyzed under the microscope. Figure 5 
shows pellets prepared with nifedipine:Pluronic® F-68 (I: 1) solid dispersion after 12 
hours of dissolution. The size of the pellets was decreased due to surface erosion. 
Nifedipine pellets also eroded in a similar fashion over a period of 24 hours. Both these 
pellets maintained their geometrical shape but were reduced in size. Furthermore, pellets 
of nifedipine and nifedipine:Pluronic® F-68 (1:1) solid dispersion that were removed 
from the dissolution medium on the 2 and 4 hours of dissolution were dried at 50° C for 
12 hours and transverse sections of these pellets were investigated. After 4 hours the 
pellets became very soft which made it impossible to obtain the transverse. Transverse 
sections of nifedipine pellets (Figures 6a and 6b) showed that the drug remained 
unifomtly distributed in the matrix at 2 and 4 hours, whereas nifedipine:Pluronic® F-68 
( 1: 1) solid dispersion pellets showed release of the drug from the core by diffusion. The 
increased aqueous solubility of drug in the solid dispersion explains the enhanced erosion 
and release rates from nifedipine:Pluronic® F-68 solid dispersion pellets as compared to 
nifedipine pellets. Increased aqueous solubility had also increased the release of drug 
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from the pellets of solid dispersion which occurred by erosion and simultaneous diffusion 
from the matrix. Whereas release of drug from nifedipine pellets was purely by erosion 
mechanism. 
To further confirm the release mechanisms of both the pellets, their porosity parameters 
were measured and determined by mercury intrusion porosimetry. The porosities were 
determined after the pellets were exposed to 2. 4, 6 and 8 hours of dissolution media. 
Figures 7a and b show the cumulative intrusion volume of mercury against pore 
diameters obtained at different dissolution intervals of nifedipine and 
nifedipine:Pluronic® F-68 solid dispersion pellets, respectively. Figures 8a and b show 
changes in the pore size distribution during dissolution. Figure 7a shows that the 
cumulative intrusion volumes of mercury for nifedipine pellets following dissolution at 2 
to 8 hours mainly remain constant with minimal changes, whereas from Figure 7b, pellets 
of nifedipine:Pluronic® F-68 solid dispersion showed increased pores as the dissolution 
time increased from 2 to 8 hours. Further from Figure 8a, a trimodular pore size 
distribution is observed with maximum pores lying within the range of 0.1 to 0.01 µm 
indicating that the voids and fine pores contribute to the overall porosity of the pellets 
with the pores occupying a much higher volume than the voids . A reverse pore size 
distribution was observed (Figure 8b) for pellets of nifedipine:Pluronic® F-68 (I: 1) solid 
dispersion indicating that the overall porosity was due to the voids which were increasing 
with dissolution time. Figure 9 shows the effect of dissolution time on the pore volume 
diameter of the pellets. No significant changes were observed in the pore volume 
diameters of nifedipine pellets indicating no increase in void porosity during the 
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dissolution period of 8 hours, whereas pore volume diameters of pellets formulated with 
nifedipine:Pluronic® F-68 (I: 1) solid dispersions increased with dissolution time 
indicating an increase in the void porosity which is the result of increased void diameters. 
This increase may be due to the enhanced solubility of drug in the solid dispersion which 
diffused out of the matrix. Figure 10 shows the total intrusion volumes that were 
obtained at different dissolution times that summarizes the overall effect of dissolution 
time on pellet porosity. From this Figure the porosity of nifedipine:Pluronic® F-68 solid 
dispersion pellets increased linearly with dissolution time whereas, the porosity of 
nifedipine pellets did not change significantly. Total pore surface area is the cumulative 
surface area of all the pores and voids present in a sample. Figure 11 shows the total pore 
surface area against dissolution time. The total pore surface area of nifedipine:Pluronic® 
F-68 solid dispersion pellets increased linearly from 2 to 8 hours of dissolution time. 
This maybe due to the formation of voids and pores as nifedipine and pluronic was 
diffusing out of the matrix. However, it is postulated that the total pore surface area is 
being reduced during dissolution because the size of the pellets becomes smaller. Such a 
phenomenon can only occur if surface erosion is the only mechanism of release which in 
fact was observed with nifedipine pellets. Their total surface area decreased linearly with 
dissolution time (Figure 11). This confirms that surface erosion is the release mechanism 
of nifedipine pellets. In addition, the results demonstrated in Figure 11 strongly indicate 
that upon incorporation of a poorly soluble drug like nifedipine in erosion matrix pellet 
systems, a zero order release for 12-24 hours as described previously (7) is obtained. 
However, a change in the physical properties and solubility of the drug as it occurs with 
nifedipine: Pluronic® F-68 solid dispersions alters the release profile and kinetics. 
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( 4.0 Conclusions 
In conclusion, controlled release of nifedipine (poorly soluble drug) following zero order 
kinetics for 24 hours from a multi-unit erosion matrix was achieved. It was proved that 
multi-unit erosion matrix systems as described earlier (7) are universal in their application 
for controlled release of poorly soluble drugs . Drug release from nifedipine pellets 
occurred by matrix erosion. Whereas for pellets of nifedipine:Pluronic® F-68 solid 
dispersion, release occurred by a combination of matrix erosion and diffusion 
mechanisms for 12 hours following first order kinetics. The solubi lity of nifedipine was 
increased by 10 times due to solid dispersion formation in I: I nifedipine:Pluronic® F-68 
ratio. Porosity parameters studied by mercury intrusion porosimetry proved that drug 
release was not influenced by the porosity for nifedipine pellets, however the drug release 
was predominantly porosity controlled for nifedipine:Pluronic® F-68 solid dispersion 
pellets. 
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Table I : Composition of pellets prepared with nifedipine and nifedipine:Pluronic® 
F-68 solid dispersions. 
Formulation Nifcdipine Kollidon® 90F Eudragit® L 100 55 : S * Plasticizer 
1J'.E_e (% w/w) J_%w/w_l 100 ratioJ.% w/w_l (% w/'2 
nifedipine pellets 20.00 2.00 I : 3 I 1.70 
DJ_v, 5Ql_ = 7.06.l!._ 
nifedipine pellets 20.00 2.00 I : 3 11.70 
DJ_v, 5Ql_ = 2.66.l!._ 
nifedipine pellets 20.00 2.00 I : 3 I 1.70 
Dj_v, 50)= 2.3 !J:I. 
nifedipine:Pluronic® 20.00 2.00 I : 3 11.70 
F 68 SD _JJellets J..J : 12_ 
nifedipine:Pluronic® 20.00 2.00 I : 3 11.70 
F 68 SD pellets 
_D:O.~ 






Table 2: Results of Particle Size ofNifedipine and Nifedipine in Pluronic F-68 
so lid dispersions. 
SAMPLE DJY, O.~ (µ) • D(V, 0.9) (u) •• 
Nifed_!Eine 7.06 17 .29 
Nifed_!Eine micronized once 2.87 8.72 
NifediIJine micronized twice 2.31 6.96 
Nifed_!Eine:Pluronic® F-68 (1:1) SD 3.10 12.93 
Nifedipine:Pluronic® F-68(1 :0.5) SD 2.66 8.40 
• 501h percentile mean volume particle size. 
•• 90tltpercentile volume particle size. 
' 
( Figure I a 
Melting point endothenns of nifedipine before and after micronization 
micronized 
Tm= 174.7 •c Ml= 103.5 mJ/mg unmicronized 
Tm= 174.7 •c Ml • 103.3 mJ/mg 
97 . !5 14!5 192. !5 
TacP c . IHutfnol 
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( Figure I b 
X-ray diffraction pattern of nifedipine before and after micronization. 
10.0 13.0 16.0 19.0 22.0 25 . 0 28.0 31.0 
20 
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( Figure 2 a 
Melting point endotherm of nifedipine:pluronic F-68 solid dispersion (I :0.5) 
-4-'.:L~~ .. r----------~-L!"f!'l_. 










Figure 2 b 
Melting point endotherm of nifedipine:pluronic F-68 so lid dispersion (I: I) 
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Figure 3 a 
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Figure 3 b 
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Effect ofnifedipine mean particle size and ratio of nifedipine:pluronic F-68 so lid 
dispersion on the release profiles obtained with 2.0 mm pellets. 
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~! ic ruscop ica l eval uat io n of ni f~dip i ne: pluronic F-68 ( I : I ) so lid d ispersion pelle ts after 
disso lutio n time interv a ls. 
.\. 0 hours B. 2 hours C. 4 houn 
··-
·.' . ~ . 
' . 
. . 
·- .. ~-.:,. 
, 
n. 6 houn E. ~ houn f . Ill hn u r.1 
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Figure 6 a 
Transverse section of nifedipine pellets after 2 and 4 hour dissolution time intervals 
showing uniform drug distribution in the matrix. 
l · 
2 boun 4boun 
13 I 
Figure 6 b 
Transverse section of nifedipine:pluronic F-68 (1: l) solid dispersion pellets after 2 and 4 
hour dissolution time intervals showing drug diffusion through the matrix. 
2 hours 4houn 
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Cwnulative intrusion profiles ofnifedipine and nifedipine:pluronic F-68 solid dispersion 
pellets during dissolution. 
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Pore size distribution of nifedipine and nifedipine:pluronic F-68 solid dispersion pellets 
during dissolution. (spheronization time: I 0 minutes, n = 4±SE) 
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Changes in the pore volwne diameter of pellets during dissolution. 
24 
• Nifedipine:Pluronic Solid Dispersion (I: I) 
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Changes in the total intrusion vo lume of pellets at various dissolution intervals . 
• Nifedipine:Pluronic F-68 Solid Dispersion (l · J) 
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Effect of dissolution time on the changes in total pore surface area of the pellets . 
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e Nifedipine:Pluronic F-68 Solid Dispersion ( 1: 1) 
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MULTI-UNIT MATRIX SYSTEM 
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ABSTRACT 
The development, characterization and in vitro evaluation of a novel multi-unit erosion 
matrix pellet system of nifedipine was described earlier. The purpose of this study was to 
evaluate in vivo performance of the erosion matrix pellets prepared with nifedipine and 
compare their bioavailability with nifedipine irrunediate release soft gelatin capsules 
(Adalat® !Omg and 20 mg gelcaps administered togethe: as one dosage form) in fasted 
dogs . A randomized two way comparative cross-over design was employed for 
bioavailability studies and four dogs were used. Blood samples were collected over 
predetermined time intervals up to 12 or 24 hours and analyzed for nifedipine plasma 
concentrations by an HPLC method for both the dosage forms. Data obtained was fitted 
to a non-compartmental pharmacokinetic model to determine parameters such as Cmax, 
Tmax, AUYl-24 h. and MRT0-24 h· Results indicated that the bioavailability of nifedipine 
erosion matrix pellets was four times higher than Adalat® gel caps. Nifedipine was 
detected in plasma within one hour of administration of erosion matrix pellets, thus no 
significant lag time was observed. Nifedipine multi-unit erosion matrix pellets showed 
controlled release for more than 24 hours following zero order kinetics. 
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1.0 Introduction 
Nifedipine is a calcium antagonist which is widely used as a coronary dilator in 
hypertension. Clinical studies have shown that the hypotensive effect of this drug could 
be correlated with the plasma nifedipine [l] . It is therefore important to prolong the 
plasma concentrations so as to control and regulate the therapeutic effects of nifedipine 
over a longer duration. Nifedipine is a poorly soluble drug and its absorption in GIT is 
rate limited. It has a short biological half life of about 2.3 hours. When administered 
orally via solid dosage forms, absorption of nifedipine is poor. 
Nifedipine is commercially available as soft gelatin capsules and tablets for short term 
and extended treatments. Controlled release nifedipine is available as an extended release 
film coated tablet and also as a GITS system. The extended release film coated tablet 
contains a tablet core coated by a slow releasing layer comprising of the drug and the 
hydrophilic polymers such as hydroxypropylcellulose and hydroxypropylmethylcellulose. 
The outer slow releasing layer provides the initial drug release followed by rapid drug 
release from the tablet core. Drug release from such a tablet typically follows first order 
kinetics . One of the most desirable outcome in controlled drug delivery is to achieve zero 
order kinetics in vivo so as to obtain a constant therapeutic effect of the drug for a 
maximum duration. This is achieved by the nifedipine GITS system for controlled 
delivery. 
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The GITS system releases finely powdered nifedipine in a suspension form into the 
gastrointestinal lumen at a controlled rate over a 24 hour period. The release mechanism 
involves a "push-pull" process. As water is absorbed across the semi-permeable 
membrane surrounding the bilayer tablet, nifedipine particles become suspended in 
solution and are then "pushed" into the intestinal tract as the osmotically active polymers 
expand. Hydration of the GITS tablet occurs for approximately 2 hours before substantial 
amounts of nifedipine is detected in plasma. Dose dumping of nifedipine does not occur 
from the GITS system however approximately 10% of the total GITS tablet content 
remains unabsorbed after the tablet is emptied [2]. The dosage forms described above are 
examples to current nifedipine formulations that are available commercially for 
controlled delivery. 
The development, characterization and evaluation of a novel multi-unit erosion matrix 
pellet system of nifedipine was described elsewhere [3]. It was designed to release a 
poorly soluble drug by surface erosion as a consequence of the polymer erosion from the 
matrix pellets. The drug release mechanism from this system is illustrated schematically 
in Figure !. In vitro evaluation of this system in pH 6.8 phosphate buffer demonstrated 
zero order drug release in 24 hours [ 4]. 
The purpose of this study was to determine the bioavailability and pharmacokinetic 
parameters such as Cmax. T """'' AUC 0-24 h· and MRT 0-24 h of nifedipine from this novel 
erosion matrix pellet system and compare the bioavailability with Adalat® immediate 
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release soft gelatin capsules used as a control in a randomized two way cross over design 
in four fasted dogs. 
2.0 Materials and methods 
Nifedipine was purchased from Vinchem Inc., Chatham, NJ. Eudragit® L 100 55 and 
Eudragit® S 100 (polymethacrylic acid esters) were provided as samples by Huls America 
Inc., Somerset, NJ. Kollidon® 90 F (polyvinylpyrrolidone) was obtained from BASF Inc., 
Parsipanny, NJ. Avicel® PH 101 (microcrystalline cellulose) was purchased from FMC 
Corporation, Philadelphia, NJ. Triethyl citrate was provided as a sample by Morflex Inc., 
Greensboro, NC. Butamben (n-butyl-p-amino benzoate) was provided as a free gift by 
Abbott Laboratories, North Chicago, IL. Methanol and acetonitrile (HPLC grade), 
chloroform, acetone, 0-phosphoric acid (80% v/v) were purchased from Fisher Scientific., 
Springfield, NJ. All the chemicals were used as received. 
All work was carried out under yellow light. Turbula mixer (lmpandex Inc., Maywood, 
NJ, USA) was used for mixing dry powders. Extruder utilized was LCI Xtruder, Model 
DG-Ll, Fuji Pauda! Co., Ltd., Japan. (Single screw extruder, capable of extruding at 
speeds upto 100 rpm, with variable screens to obtain extrudates of different size). The 
Spheronizer used was a G.B. Caleva Ltd, Model 120, Dorset, England. [It consists of a 
stationary vertical cylinder which has at the base a friction plate (diameter 32 cm) with a 
2 mm cross hatched friction pattern and a rotation speed of 200-3000 rpm]. Rotap Sieve 
Shaker, Model RX-29, W.S. Tyler, Inc., OH (Fitted with sieve# 8, 10, 12, 14, 16, 18 and 
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20) was utilized to collect pellets of the desired particle size. In vitro analysis of the 
pellets was performed in a Hewlett Packard 8452A Diode Array Spectrophotometer 
(Hewlett Packard Company, Paramus, NJ). 
A vortex Mixer with 40 test tube holding capacity Model Typ VX 2V (IKA ®Works, Inc., 
Cincinnati, OH) was used to equilibrate the frozen blood samples at room temperature 
prior to analysis . Fisher Vortex Genie 2™ with 40 micro-centrifuge tube holding 
capacity (Scientific Industries, Inc., Bohemia, NY) was utilized for sample processing. A 
Centrifuge, Model HN-S II (International Equipment Company, Needham Heights, MA) 
for separation of plasma proteins after drug extraction from the blood samples was used. 
Turbo Yap® LV Evaporator with nitrogen gas pressure of 1.0 bar (Zymark Corporation, 
Hopkinton, MA) was used as a sample concentrator for the assay. 
2.1 Formulation of pellets 
Eudragit®L 100 55 and Eudragit®S 100 powders were mixed in a turbula mixer for 30 
minutes. Triethyl citrate was added as a plasticizer and the resultant mixture was 
triturated in a mortar for 5 minutes. Drug and polyvinyl pyrrolidone (Kollidon®K90F) 
used as a binder, were added and mixed for 30 minutes in a turbula mixer. This mixture 
was then granulated in a mortar with deionized water and later extruded at 40 rpm screw 
speed. The extrudates were immediately transferred into a rotating plate in the 
spheronizer. Spheronization was carried out for 10 minutes at 800-1000 rpm. During 
this period, 5% w/w of total batch size Avicel® PH 101 was sprinkled over the rotating 
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extrudates to prevent pellets from sticking. Pellets obtained were dried on trays at 50°C 
for 12 hours. The pellets consisted of nifedipine (20.0% w/w), Eudragit®L 100 55 and 
Eudragit® S 100 (78.0% w/w total in ratio of 1:3 respectively) and Kollidon®K90F (2.0% 
w/w). Granulation water level used was 58% w/w of the total batch size. Pellets (150 
mg) were filled in a size 2 blue colored capsule before they were administered to the 
animals. 
2.2 Assay of nifedipine in pellets 
Nifedipine content of the pellets was determined by UV spectrophotometry. The pellets 
(100 mg) were dissolved in 100 mL of methanol and the resultant solution was diluted to 
obtain 10 ug/mL nifedipine concentration. This solution was analyzed 
spectrophotometrically at 237 nm and nifedipine content of 100 mg of pellets was 
determined 
2.3 In vivo absorption study design and protocol 
2.3./ Test animals 
The bioavailability of nifedipine pellets was tested on beagle dogs using a randomized 
two way comparative cross-over design. 
Dogs were supplied by Marshall Farms, North Rose, NY. They were acclimatized for at 
least two weeks prior to the study and were approximately 9-14 kg in weight and one year 
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old in age. The study group consisted of two males and two females. Each dog had an 
ear tattoo for identification and was housed individually in a stainless steel cage. Each 
cage had an identification card showing the study number, dog number and sex. Room 
temperature and humidity was maintained at approximately 72° ± 4° F and 50% ± 20% 
respectively. During the experiments, the animal room was kept on an approximate 12 
hour light/dark cycle. Each dog was exercised outside its cage at least three times a week 
for at least 15 minutes. 
2.3.2 Dosage forms administered, frequency and method of dosing 
The bioavailability of nifedipine erosion matrix pellets, (30 mg capsules, Lot No. KM 
280/2) was tested against an immediate release soft gelatin capsule (Adalat®. 10 mg 
gelcaps, Lot No 6EAB and 20 mg, Lot No 5 HAX, manufactured by Bayer Corporation, 
West Haven, CT). All the test articles were stored in a locked area at ambient 
temperature protected from light. 
The dogs were fed with Harlan-Teklad certified 25% lab dog diet (W). Approximately 
800 grams diet (approximately 400 grams of dry dog food moistened with approximately 
400 mL of water) was provided to the dogs 8 hours after dosing. Reverse osmosis (RO) 
water was available Jill libitum by means of an automatic watering system. This RO 
water supply for the animal room was monitored for bacterial contamination at least once 
a month by the Department of Laboratory Animal Resources. In addition, chemical 
analysis of water was performed at approximately quarterly intervals by the 
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Environmental Monitoring and Support Laboratory. No contaminants expected to 
interfere with the study were known to be present in the feed or water. 
Each dog received one 30 mg nifedipine erosion matrix pellets capsule or IO plus 20 mg 
Adalat® soft gelatin capsules in fasted state. Following a one week washout period, each 
dog received a different formulation in phase two. The experimental protocol details are 
given in Table I. 
2.3.3 Blood sampling 
Blood samples (6 mL) were taken from each dog at 0, 1, 2, 4, 6, 8, 12, 16, 20 and 24 
hours after dosing for the nifedipine erosion matrix pellets. Blood samples from dogs 
who received Adalat® soft gelatin capsules were collected at 0, 0.5, l, 2, 4, 6, 8 and 12 
hours after dosing. The samples collected were transferred into test tubes containing 
lithium heparin, used as an anticoagulant, and to prevent decomposition they were placed 
in an ice bucket prior to centrifugation. Plasma was separated after cold centrifugation 
and was frozen in amber glass vials at -20° C under yellow light before analysis. 
2.4 Assay of Nifedipine in Plasma 
Nifedipine in all samples was assayed using a modified version of the HPLC method 
described by Miyazaki et al [5]. 
2.4.1 Processing Blood Samples for HPLC 
147 
Methanol (I 00 µI) containing 2 µg/mL butamben, used as an internal standard and 
acetonitrile (2 mL) were added to 0.5 mL of plasma in a test tube and were agitated in a 
vortex mixer for 30 minutes. After centrifugation at 4000 rpm for 20 minutes, 2 mL of 
the supernatant was transferred into a test tube containing l mL of distilled water, to this 
solution 4.5 mL of acetone-chloroform mixture ( l: l v/v) was added. This mixture was 
agitated for l hour on a vortex mixture to ensure complete extraction of nifedipine into 
the organic phase and was then centrifuged at 4000 rpm for 20 minutes to separate the 
organic and aqueous phases. The aqueous phase was discarded and 5 mL of the organic 
phase was transferred to a fresh test tube, and was reduced to dryness in a sample 
concentrator under nitrogen at 45° C for 30 minutes. The residue was dissolved in 100 µI 
of the mobile phase and 20 µI of the solution was injected into the HPLC system. 
2.4.2 Chromatographic Conditions 
HPLC pump used was a Waters multi-solvent delivery system (Waters Corporation, 
Milford, MA) with a Waters 717 plus auto-sampler (Waters Corporation, Milford, MA) 
and a variable wavelength absorbance detector (Model Spectra-Physics, USA). The 
stationary phase used was a reverse phase Zorbax ODS, 4-6 microns 25 cm x 4.6 mm 
column (I.D., Dupont Inc., Wilmington, DE). The column was warmed at 55° C using a 
steel column heater {Model Code 600, Waters Corporation, Milford, MA). The mobile 
phase consisted of 0.0 I M disodium hydrogen phosphate buffer-methanol ( 45:55). 
Before mixing, the buffer was brought to pH 6.1 with 50% phosphoric acid. Run time 
used was 30 minutes and the flow rate was 0.8 mL/min at column pressure of 
approximately 1200 psi. The wavelength of detection was 237 nm. 
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2.4.3 Calibration Graph 
Standard solutions containing 0.05, 0.1, 0.2, 0.4, 0.6, 0 .8, 1.0 and 10.0 µg/rnL nifedipine 
in methanol that contained 2 µg/rnL butamben (internal standard) were prepared under 
yellow light. The standard solution (JOO µI) was added to 0.5 rnL of drug free plasma and 
the samples were processed as described above. The ratios of the peak height of 
nifedipine to that of butamben were used to construct a calibration graph. Stock solutions 
of both nifedipine and the internal standard ( 1 mg/rnL in methanol) were stored in 
complete darkness; these solutions were freshly prepared every 2 weeks. Precision 
obtained using the described technique was ±5%. 
2.5 Pharmacokinetic Analysis 
The most suitable model to describe the pharmacokinetics of nifedipine was determined 
by fitting the data to a hierarchy of models using WinNonlin software. The data most 
appropriately fitted to a non-compartmental model and pharmacokinetic parameters such 
as Cmu. T =• AUCo.24 h and MRTo.24 h (mean residence time) were calculated by a 
computer using WinNonlin software by Scientific Consulting Incorporated (Lexington, 
KY). 
3.0 Results and Discussion 
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The UV assay demonstrated that nifedipine erosion matrix pellets administered to the 
dogs contained 98 - 102 % of the original nifedipine loading. The Adalat® soft gelatin 
capsules were not assayed for nifedipine content. Nifedipine plasma concentrations 
obtained after dosing with Adalat® soft gelatin capsules and nifedipine matrix erosion 
pellets are tabulated in Tables II and ill respectively. Table IV shows the mean 
pharmacok.inetic parameters (Cmax. T max. AUCo.24 h· MRT 0.24 h) determined for both 
dosage forms. Figure 2 shows the nifedipine plasma concentration profile for 24 hours 
following administration of the pellets and the immediate release capsules. The mean 
T max for nifedipine erosion matrix pellets from Table IV was 15.50 hours whereas for 
Adalat® capsules was 0.5 hours. This indicated that time taken to reach maximum 
plasma nifedipine concentrations was 15.5 hours thus providing controlled release of the 
drug. The MRT0_24 h was 12.5 hours for the pellets and 1.72 for the Adalat® capsules, 
indicating the presence of pellets in the GIT was prolonged. The mean AUCo.24 h of the 
pellets was four times higher than the conventional immediate release Adalat® soft gel 
capsules. 
Adalat® capsules contain nifedipine in the solubilized form in a polyethylene glycol based 
co-solvent system. The bioavailability from Adalat® 20 mg soft gelatin capsules was 
reported earlier by Sallam et.al. [6]. Accordingly, the lower AUC obtained with Adalat® 
soft gelatin capsules might be due the precipitation of the poorly soluble nifedipine in the 
gastric fluid. As a result the particle size of nifedipine may also have increased, which 
can be the cause of reduced nifedipine absorption. 
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Nifedipine release from the matrix pellets is governed by the polymer controlled surface 
erosion process. In this mechanism, drug release occurs in a constant fashion in the form 
of a microfine suspension in the gastrointestinal tract and thus is readily available for a 
prolonged period. lt is also interesting to observe that the nifedipine plasma 
concentrations were obtained one hour after administration without any significant lag 
time, Figure 2. The pellet matrix contains Eudragit® L 100 55 and Eudragit® S LOO 
polymers which dissolve at pH 5.5 and pH 7.0 respectively. Considering that the pellets 
were very small multi-unit systems (particle size: 2.00 mm), they are expected to have a 
small gastric residence time after which exposure to pH 5.5 and higher pH's may have 
caused the pellets to release the drug. The most significant effect that is shown in Figure 
2 is that nifedipine release from the multi-unit pellets continued for over 24 hours. Thus, 
the elimination rate constants could not be calculated for this period 
4.0 Conclusions 
Controlled delivery of nifedipine via polymer controlled surface erosion of nifedipine 
provided zero-order drug release both in vitro and in vivo for 24 hours. Bioavailability 
from the controlled release pellet system was four times more than the conventional 
immediate release Adalat® soft gelation capsules of nifedipine. 
Thus it was demonstrated that the surface erosion mechanism may be used in pellets to 
obtain a controlled release system that delivers a poorly soluble drug like nifedipine 
effectively and in a constant fashion. 
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In vivo absorption study protocol details 
Dose No. of 
Condition (mg/dog/day) Tablets/Capsules Males Females 
Phase I 
Fasted 30 I 1-2 3-4 
One week Washout period 
Phase II 
Fasted 30 2 1-2 3-4 
V> 
V> 
Table II : 
\ 
\ 
Nifedipine plasma concentrations (12 hours) obtained in dogs (n ~ 4) after administration of Adalat® soft gelatin 
capsules (30 mg/dog/day). 
Nifedipine Plasma Levels (µg/mL) 
Time (hours) Dog I Dog II Dog III Dog IV Mean±SD 
0.0 0.0000 0.0000 0.0000 0.0000 0.0000 ± 0.0000 
0.5 0.2216 2.2628 0.6358 1.6288 1.1872 ± 0 9288 
1.0 0.2079 0.6548 0.2530 0.7226 0.4595 ± 0.2666 
2.0 0.2097 0.2387 0.0940 0.3394 0.2204 ± 0.1009 
4.0 0.0897 0.0648 0.0518 0.1293 0.0839 ± 0.3410 
6.0 0.0365 0.0321 0.0215 0.0494 0.0348 ± 0.0115 
8.0 0.0243 0.0000 0.0307 0.0228 O.Ql 94 ± 0.0134 
12.0 0.0387 0.0000 0.0239 0.0000 0.0156 ± 0.0190 
"' 
°' 
Table Ill: Nifedipine plasma concentrations (24 hours) obtained in dogs (n = 4) after administration of matrix erosion pellets 
capsule (30 mg/dog/day) . 
Nifedipine Plasma Levels (µg/mL) 
Time (hours) Dog I Dog II Dog III Dog IV Mean±SD 
0.0 0.0000 0.0000 0.0000 0.0000 0.0000 :±: 0.0000 
1.0 0.0000 0.1331 0.1536 0.3551 0.1604 :±: 0.1465 
2.0 0.1333 0.0933 0.0699 0.4714 0.1919 :±: 0.1881 
4.0 0.0586 0.0952 0.0867 0.3419 0.1456 :±: 0.1317 
6.0 0.1454 0.1617 0.7161 0.0953 0.2796 :±: 0.2923 
8.0 0.0727 0.0674 0.7945 0.1438 0.2696 :±: 0.3516 
12.0 0.1252 0.1035 0.6778 0.0733 0.2449 :±: 0.2893 
16.0 0.1636 0.1654 0.8409 0.0985 0.3171 :±: 0.3505 
20.0 0.1869 0.1858 0.8629 0.1449 0.3466 :±: 0.3487 






Mean phannacokinetic parameters of nifedipine matrix erosion pellets and Adalat® soft gelatin capsules obtained ny 
non-compartmental analysison four beagle dogs. 
Dosage Form Cmu±SE Tmu:!:SE AUC0-24h :!: SE MRT 0.24 h :!: SE 
(µg/mL) (h) (µg h/mL) (h) 
Nifedipine Matrix 
Erosion Pellets 0.4268 ± 0.1602 15.5000 ± 4.5000 6.1123 ± 2.8690 12.5561 ± 1.2853 
Adalat® Soft 
Gelatin Capsules 1.1873 ± 0.4644 0.5000 ± 0.0000 1.5049 ± 0.3980 1.7280 ± 0.2959 
Schematic representation of a novel multi-unit erosion matrix for 
controlled release of a poorly soluble drug. 










,' intact matrix pellet 
, 
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Appendix !, 2 ,3a ,3b ,3c and 4. 
Complete listing of references cited. 
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APPENDICES 
I. Solubility studies ofnifedipine and nifedipine:pluronic® F-68 solid dispersion (I 1) in 
water at 25°C. 
2. Particle size determination of nifedipine samples before and after micronization and 
after formation of solid dispersions with pluronic® F-68. 
3. Determination of porosity parameters by mercury intrusion porosimetry. 
(a) Pellets formulated with different drug (D4 Leukotriene antagonist) loads 
and spheronized at different times . 
(b) Pellets formulated with different granulation water levels. 
(c) Nifedipine and nifedipine:pluronic® F-68 (I I) solid dispersion pellets after 
different dissolution time intervals. 
4. Determination of nifedipine in plasma after oral administration of nifedipine erosion 
matrix pellet capsule and Adalat® soft gelatin capsule in fasted dogs. 
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Appendix 1 
Solubility studies ofnifedipine and nifedipine:pluronic® F-68 solid dispersion (1 I) in 
water at 25°C. 
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HPLC METHOD VALIDATION: 
SOLUBILITY DETERMINATION OF NIFEDIPINE AND NIFEDIPINE:PLURONIC® 
F-68 SOLID DISPERSION (1:1) IN WATER AT 25°C EQUILIBRATED FOR 24 
HOURS 
I. SOURCE of STANDARD: 
Nifedipine, Lot # 9S 1172, was purchased from Vinchem Inc., Chatham, NJ, USA. 
Pluronic® F-68, Lot# 22415, was obtained as a gift from BASF Inc. , Parsipanny, NJ, 
USA. 








Waters 600E Multi-Solvent Delivery System 
Waters 717 Plus Auto Sampler 
Micro Bondapack C18 Reverse Phase, 3.9 x 300 mm, Waters Corp. 
Model Spectra 100, Spectra-Physics,UVNIS 
1.0 mUmin 
Injection Vol: 20 µL 
Temperature: Ambient 




In a suitable flask combine 200 mL ofacetonitrile, 300 mL of methanol and 500 mL of 
distilled water. Mix well and degas under vacuum for l 0 minutes. Filter through a 0.5 µ 
Millipore filter, or equivalent, before use. 
3. REPRESENTATIVE CHROMATOGRAMS: 
Figures l through 3 are the chromatograms of nifedipine samples after injection. Figures 
4 and 5 are the chromatograms ofnifedipine:pluronic® F-68 solid dispersion (l:l) 
samples after injection. 
4. LINEARITY: 
The linearity of nifedipine in the mobile phase was determined by simple linear 
regression. Figure 6 depicts the standard curve and linear regression of nifedipine in 
mobile phase. 










Correlation coefficient for linearity determinations in mobile phase was 1.0000. 
5. PRECISION: 
Assay precision was determined by plotting the peak areas of triplicate injections of 
nifedipine samples of known concentration against the standard curves generated in the 
previous section. The mean % difference between the actual concentration of the 
samples and that determined by the standard curve were below 4.0 %. 
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Chromatogram ofnifedipine solubility sample 2 
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Chromatogram of nifedipine solubility sample 3 
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Chromatogram of nifedipine:pluronic® F-68 so lubility sample 2. 
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Appendix 2 
Particle size determination of nifedipine samples before and after rnicronization and after 
formation of solid dispersions with pluronic® F-68 . 
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Particle size distribution of unmicronized nifedipine 
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Particle size distribution of once micronized nifedipine . 
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Particle size distribution of twice micronized nifedipine 
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MastcrSac:r X Va . 1.2 
S<rial No. 6376 
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Particle size distribution of nifedipine:pluronic® F-68 solid dispersion (1:1). 
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Particle size distribution of nifedipine:pluronic® F-68 solid dispersion (I :0.5). 
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Appendix 3a 
Determination of porosity parameters by mercury intrusion porosimetry. Pellets 
formulated with different drug (D4 Leukotriene antagonist) loads and spheronized at 
different times. 
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Drug Load: 0 % w/w, Spheronization Time: 2.0 minutes. Run # l 
POUSlZU 9320 ¥2 .07 
SA,.,LE OUECTOltY/Hl.lft8Elt: OUA1 166 
OPERATOR: l(eun ll<et\U 
SA.lll"LE 10: 'l•c:rbo2-Z• in11Ufill1 
SU8"lnElt : (ctan ,._.,u 
PEHET"°"ETU Hl.mafll : 13-Q241 
PEHETltOflETU CtlHSTAHT : 10. '1'9 11L/pF 
PEHETKlflETU llEIGl-IT : 68 . 9270 g 
STE" VOLIAIE: 0 . 4120 Ill 
IU.Ufl.#I HOO PllESSUllE: 4 . UQJ pt; 
PEHETIKlflETU VOLUf!E: 3. 541.) Ill 
LOii PllESSUU : 
OJ:43:"3 02t2St97 
HP 04 ;54;.}4 02/25/"7 
UI" 04 :54: 34 02125197 
AOVAHCIHG CONTACT AHG LE: 130 .0 deog 
UCEl>ING COHTACT AHGLE : 1'0 . 0 Hg 
MEll:CUIY SUll:fACE TEHSIOH: 4aS .O dyn/u 
PIEllCUllTOVISITY : 13 . S]JSg! -.. 
SAllPLE \/EIGHT : 0 . 4022 g 
SAllPLE•f'EH->Hg WEIGHT : 110.8710 g 
llOCUllYFILLlMGPltESSUltE: 0.1'il03ptit 
LAST LOii l"ltESSUlE '°INT ; 2S.5791 pti• 
HIGH PA.ESSUllE : 
ltlJf4 TYPE: 
l\JN .llETHOO : 
AUTOMTIC 
E<IJJLISAATU 
10 tec:ondt EClJILlBRATIOH TUIE: 
lHTIUSIOfil OATA SUNU.ltY 
TOTAL lHTltUSlON VOLUl'IE • 0 . 4'09 ..._/g 
TOTAL l'Ofl:E HU. • 36.076 sq-•/g 
llEOIA/ol PORE OtAltETEll CVOUJlllE> • 0.0469 11• 
llEOlAM P<llE OIAl'IETElt CAllE.O • 0 . 0353 JI• 
AYEAAGE l'OftE OIAllETU ( 4Y/A) • 0 .0444 11• 
euuc :IENS lT'Y • O.Mn g/llt. 
A,,AltEHT CSKfLETAU 0£NSITI • 1.2828 g/llt. 
l'OltOSlTY • 33 . 96 X 
ST£11 YOllllk USED • 39 X 
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Drug Load: 0 % w/w. Spheronization Time: 2.0 minutes. Run # 2 
SAIU'U 011ECT04tYll«JMSEI : OATA1 /67 
SU81'UTTER : ic:u .... 11..+ou 
06:15:38 02t ZS t97 
HP 07:1 8 : 23 02/ ZS/97 
llEI'' 2J :07: 41 02flS / 97 
PEHETllOMETER NIJNIER: 1l-0Ma 
PEH£TllOltETElt tottSTAllT : 10 . 79 JIL/pf 
l'EHETltOPIETElt WEIGHT : 68.4592 'ii 
AO\IAHCIHG CONTACT AHGLE : no.a d9g 
llECEDU«f COIHACT AllGLE : 130.0 d.g 
llEltCUllY SUltfACE TEHSJaot: 43S . 0 ctynl'• 
STEii YOLLl'IE : 0 . 4120 .._ llUCUllY OEl!stn : 1l . SllS g/ .i.. 
IU.lllU!HEAO,.ESSUllE: 4.6llOOpti 
PEHETllOltETU 'IOLLl'IE : ] . 6991 ml. 
SMl'LE lllEIGHT : 
LOUPHSSUlE : 
llERCUll:l' FILLJHG PltUSUllE : 1 . 0065 pti• 
LASTLOllPllESSURE l'OIHT : 25.5541 p1h 
HIGH PllESSUllE : 
ltlJM TYPE : 
10 neond• 
lllTkUSION OATA 5'.ft\AllT 
TOTAL INTlllJUOM YOlUflf • 0.]944 111.. / g 
TOTAL 'OlllE AlltEA • 15 . 541 1q-•/ g 
llEOUH l'O«E 01.&JIETEI (VOUME) • 0 . 0463 ll• 
llEOUJI '°4tE OIAllETU (.UEA) • o .~o ~· 
AVERAGE P'O«E OUJIETU u.v/.O • O.Q4.l.O JI• 
8ULK 091S1TY • 0.6633 g / 91.. 
A,,.U:atT CSKELETAU OEMSlTY • 1.3099 g/-.. 





Drug Load: 0 % w/w, Spheronization Time: 2.0 minutes. Run # 3 
'Oll:ESIZER 9J20 Y2 .07 'AGE 1 
Of'UATOll : (etanll~U L' 06 : JS: la (1/.JlS /91 
21 : 49 · 16 02/ 2S t9? 
ll:E' 23 : 49 : 17 02/25197 
AOYAHClHG COHTACT IJllGU : 130.0 d.g 
'ENET!tOflHU COHST,Ullf : 10 . 7'9 11Llp' ltECEOlltG COHT.lCT ANGLE : 1l0 . 0 "9 
'EHETltOftETU \lflGKT: 69 .ooes 'ii l\UCUlY SUUACf tatSl(lll : 48S .O dyn/c• 
STEJll YOlUltE: 0.4120 Ill "UCUIT OOSlTI': 13 . SllS g/lll 
IU.XI~ HEAD 'RESSURE : 4 . 6PJOJ psi 
'EHETltOltETU V'OLUllE ; J.5541 -'.. 
S.ull'U WEIGHT : 
LCW PlUSUllllE : 
l\UCUllT FILLIHG PIESSlHtE : 1.CJJ6S ps i • 
UST LOW 'RESSUllE POINT : 25 . 5541 psh 
HIGH "tUStJRE; 
l\JlllfYPE : 
lt\M HETHOO : 




l NTR\JSION DATA SlM,U:Y 
TOTAL lNTltUSIOH 't'OLIJ'IE • 0 . 3970 lll/ g 
TOUL l'OllE AAl.l • 15.552 sq- • / 9 
llEDIAH JIOllE 01.IJIETU (VOl...U'IEJ • 0.0461 , . 
llEOIAH JIOllE OlMETU ( A':EA) • 0.0359 11• 
.lYEllAGE l'OllE OIMETU ( 4Y/ U • 0 . 0447 •• 
9U1..K DENSITY• 0 . 4574 9 / .C. 
A,,ARENTCSltELETAL)OEHSJTY• 1 . 2'991Sg/ 9L 




Drug Load: 0 % w/w. Spheronization Time: 10.0 minutes. Run # I 
l'OoltfSIUJI 9l20 V2.a7 
SAl.,LE OtUCTOlY/111.NEl : O-.TA1 / 69 
O'EU.TC>tt : l(•t¥tllM'IU 
SAlll>Lf ID : ' l • t ir0ol•10. inlt\Mfi 
su•H TTU : IC•ten l'lhtl 
04 :05 : 15 02. /26/97 
Hf' 04 :43 : 20 02/ 26/"7 
lEI' 04 : 43 : 21 02./ 26197 
ADVMClNG a:iMTACT A*ilE : 130 .0 ff9 
t>EMETllOl'tETU COHSTAHT : 10 . 7"9 "VpF UCHlNG C091T.lCT .u.Gl.E : 130 .0 6M;I 
l'EMETAOl'ETU llUGHT: 68 . 0ISl.4 g llUOJIY SIJl:fACE TOtSIOlil : '8S . 0 ~le. 
STEN VOLL.ltf : 0 . 4120 ._ l'IHOJJIY ODSITY ; 1] . 5335 g} ._ 
0 ."116 g IWllllUfll HEAD l'ltfSSUJIE : 4 .6800 p~li 
l'ENIETllOMTU V'OUl'IE : 3 . S&aS ..._ Wl~+l'Elttff; llt:IGHT: 111.'664 g 
lOlll'lfSSUltE : 
ltUCUlT 'ILllMl l'JIUSOU: : o.nn p•i• 
U.ST LOW l'JIESSUJIE l'OINT: 25 . 5592 pa 1• 
Hl~l'ltESSUlE: 
ltJN TYPE : 
ti.Ill llETHOO : EGUlllll.ATEO 
ECIUILlBUTIOfl TlllE : 10 •«One!' 
IHTll\ISIOlllOATA~Y 
TOTAL lln!tuSIOIC 'IOt...UlllE • 0 . 382S 9l./ g 
TOTAL l'Oll:E .UfA • 40. 193 .q-./ 9 
l'lf0 1AH l'Oll:E OINtEiEl ( \IOl.1.ltf ) • O.CJ37a ,. 
llEOINt POllE OlN1£TU (.UEA) • 0 . 0114 ,. 
AVERAGE l'Oll:E 01.&llETU C4V/.l) • 0 .031'1 ,. 
!t.'LC eEMs:-. C.7Tl3 ,1 .... 
ArP.t.llEIO' CSJCfLETAL) OVtSlTY • 1 . SSOS gt-. 
~lfY. l7.Zl x 
STDt YOLUf'IE USEO • 37 X 
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Drug Load: 0 % wlw. Spheronization Time: I 0.0 minutes. Run # 2 
1'0llESIZU 9320 V2 .07 
S.U.,LE Ol JIECTOllY/ NUMU : OATA1 f10 
Of'UATOfl : !CetM .... t8 
SAlll'U: IO : Pl1ceOol-10.1nltUHl2 
SUM1nu: Ket., II.tit• 
I.I °' :OS :1S 02/26/97 
"' 06 :19: 40 02126/"7 
lf, 06 :19 : 41 02f26/97 
l'EHETllO'ETU lilJfllU : 1]~41 
l'atETltOf!ETU CONSTANT : 10 -~ 11L/pf 
l'EHETll°'£TU VUGHT : 61 . 3061 i 
AOVAHCUG CONTACT AHGU: : U0 .0 ~ 
UCUUG ct:IMTACT N«iU : 1Xl . 0 cieoa 
llUCUIY SUltFACE TalSlCN ; 41S . 0 ~/ca 
0 . 4120 .... 
IUJWUI KUO ,.USlJ•E : 4 . 6eCO p .. i 
mitETllOl'IETU VOUJNE : l . 544.J .i. 
LOW l'lUSU•E : 
"UCUAY DENSITY : 
S""'U VUGHT: 
llUC\lltY '1LL1Nli ,.UsutE : O. TTT2 p.s i 1 
LAST LOW l'IUSUllE l'OIHT : ZS . 5592 p1 l 1 
HIGH l'ltESSUllE: 
JIUM TYPE : 
Ill.I' llETHOO : fQlllLISAATEO 
E<IUllllSAATJOH flllE: 
lHTltUSIOfll o.t.TA Sl..MAIT 
TOTAL lllTtlJSION YOlUME • 0 . ]791 -.Jg 
11 . SJJS;l lll.. 
0 .4C26 i 
TOTAL. ~E U:EA • ]9 .202 tq ..... / g 
AEOIAll l'Olf 01.METEll (YOl..t.IW:) • 0 . 0390 ~ 
M:DlAH '°4tE OlMETtl (U:EO • O.Cll17 11• 
AVUMiE l"OltE OWtfT'U (4Y/ .O • 0 .0387 ,_ 
II.A.JC OEMSlTY • 0 . !5l.O g/ lt. 
A,,,U:EHT CSIC..ELETAL) OEHSlTY • 1.2~1 ; l .i.. 
il'OltOSlTY • 12 . ]7 1 
STV!'IOU.M(USEO• 37% 
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Drug Load: 0 % w/w, Spheronization Time: 10.0 minutes. Run # 3 
l'OllESUEll 9320 \12 .07 
SAPIPlE OIRECTORY/ IUl8Ell: : OAU1 171 
Of'UATOll : l:<ltan Kef'IU 00:3] ;56 03103197 
SAllP LE 10 ; 'l • cetlo2• 10.inNlt.l HI' 01 : 11 ;4S 03103/97 
SUBIH nEll: : ICU..., f'letit• llt" 01 : 11 : "6 03/ 03/ 97 
PVtETlel!ETIEll Hl.l'IBEll : 1]-Q'l]l AOVAflC I HG CONTACT ANCM.E : 130.0 d..:;i 
PEM£Tltclf!ETH COHSTAl4T : 10. 7'9 Ill/ pf ltECHING CtWTACT ANGLE : 1l0 . 0 ~ 
POIETllOMTEI VflGHT : 67.llOTl g llEICUIY SUUACE TEHSlOH : '8S . O rl'{n / eia 
stEfl YOLUPIE : 0 . 4120 .._ "UCUl:Y OEMSlTY : 1l . 533S 'il l .._ 
ltAXI ..... HU.0 PllESSUltE : 4 . 6ll00 p1i s..utPLf VElGHT : 0 . "IXl'S 'ii 
PEMETl!Of!fTU V'OLUPIE : ] . Saas.... SAltl'U .. PEH+Hg VfJGHT: 111 . 131] 'ii 
LOllPlESSUU : 
llUC\Jlt'I' '1LLIHG Pll:ESSUltf. : 0 . 76'0 p11• 
LAST LOii Pll:ESSUlllE '°un: ZS .6757 p1il 
HIGH PltESSUllE : 
IMITYl'E ; 
1M1 llETl«>O : 
AUTOM.TtC 
EQIJlll81lATEO 
EQIHL181lAf10N TlllE : 10 HeondS 
TOTAL IHTIUSION VOLLME • 0 . 3643 -.Jg 
TOTAL ~E A.llEA • C.0 . 1M sq-•/ g 
1tEOUJ1 l'OlE OIAllETD '. YOlUPtEl • 0.034S ..-
PIEOIAll' l'OlE 01.u!ETUI (AlfA) • o.m11 JI• 
AVE!lAGE JIOlllE OloU1£TU C4V/A) • 0 .~ JI• 
llllU: OVtSITY • 0 . 9608 g/ tlt.. 
A,,.U:EltT CSICEU:TAL ) 0£JfSITY • 1.5Zl1 9 / 91. 
'°"°SITY • 36 . 92 X 
STEll't'Olt.1"EUSED• ] 7X 
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Drug Load: 0 % w/w, Spheronization Time: 20.0 minutes. Run # I 
POllESllElt 9320 V2 . 07 
SAllPLE OillECTOllY/Hlltl8ER : 0ATA1 m 
LP 00 :.33 : 56 Ol/0]/97 
HP 03 :01:05 03 103197 
llEP 03 :01 :06 03103~7 
PENETROl'IETU ldleU: 13--0968 
l'ENET9ClfllETH COHSTAHT; 10 . 79 ,wL/pf 
AO'OJtCING CONTACT Al'IGL£: no.a det01 
ll:ECEOING COHTACT u.GU : 130 . 0 d~ 
llEICUltY SUUACE TENSlOH : 4&S . 0 dyn / c• l'fHETROfllETU WEIGHT : 68 .9255 ; 
STEii VOLUllE: 0.4120 Iii. llEICUAT DENSITY ; 13 . SllS 'il /.i,. 
IUilllUfl HE.AO PUSSUll:E : 4. 6800 p1i 
l'EHETIKlllETElt YOU.HIE : ~.699i "'-
SAJl.,U WEIGHT : 0 . '-COJ 'ii 
SAPIPLf•PEH++tg WEIGHT: 11l. 1216 11 
LOW "l:ESSUllE : 
11EllC1JllY flLllNG "l:fSSlJllE : 0.7640 pti• 




ECUILJBAATIOH TUtf: 10 Heoncb 
l NTl:USIOH OAT.I. SUPtltAllT 
TOTAL lHT~SlOH YCUJflf • 0.le04 llL / 9 
TOTAL POA" .OU• 39. 514 sq-• / 'il 
llEOI>JI PORE OIMETEll (V'OLl.lflf) • 0.03156 11• 
llEOU.H l'OllE OIAl'IETU C.UEAI • 0.0315 11 • 
AVERAGE il'ORE OlAflETU C4VfA) • 0.0385 11• 
9UlJ( OfHSlTY" 0.8640 'ill-*. 
A,,AREllT ( SK!LUAL) DOISITY • 1 . 2!70 "1 191.. 
l'O!tOSITY • 32 . 157 1 
STEPI YOLLME USED " J7 1 
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Drug Load: 0 % w/w. Spheronization Time: 20.0 minutes. Run # 2 
l'OllESIZU 9]20 V2 .07 PAlif: 1 
$MPLE DlllECTOllY/ HUftSU : 1n 
Of'EU.Tott ; ltst.,, 11.nu 05 :00 : 46 Ol/OJ/91 
S·U"U JD : Pl•c~-2Q91nlt\JH2 MP 05 :39 ;49 Ol/OJ/91 
sue1"1nu : 1teun "'"'u llEP 05 : 39 :'9 Ol /Ql/97 
PENEfltclftUElt IUllEI : 1].--005 4 AD\llfllCIHCi COHTACT AllGU : 130. 0 d<f9 
PEHt:TllOflETElt COMSTAHT : 10 . '19 pL/ p, lfCED!MG COHTACT AllGU : 130. 0 "' 
PVIETJIOftfTU WEIGHT : 68 . 5376 'ii llUCUIT $UlfACE TUIS!OH : 48S . 0 tlyn/ c• 
na. YOOJNE : o.n20 -.. 11ucvn oatsin: u .nu 91-.. 
P\AXUUI MUD PllESSUllE : 4 . 680:J p11 SA.llPLE VUGHT : O. t.aX> 'ii 
PfH£TllOflETU YOlt.l'IE : l . SS41 111.. SAAPLE•PEK+Hg \/EIGHT : 111 . 051] 'ii 
LOW "tESSUIE : 
11.UCUltT FILllHG PllESSUltf : 0 . 7537 pti l 




fQUILllllUTlOH Ttllf ; 
AUTOIU.TIC 
10 nc:onds 
l HTA USIOH OAU. SUMAllY 
TOTAL IM TlttJSIOH \'Oll.'IE • 0 . 3&]1 -.Jg 
TOTAi. ~E UL\ • Q . 2'11 tq_.,/ g 
ltEDl.ul '<Mt£ 01.utETU CV'Ot..t.l'IEJ • O.OJ28 11• 
MEDIA.II ~E OIMETElt CUU.l a 0 .0354,,. 
AV(lt,.U;f "<Ml:E OIMETElt C4V / A) • 0 . 0363 .W • 
11UU: DEHSlT'T • 0 . 8654 ; I -.. 
-'"A.llVIT { SKfLETAL)OVISlT'T• 1.294.5;191.. 
."'OllOSJT'T• 33.15% 
STEii YOLIME USED • 37 X 
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Drug Load: 0 % w/w, Spheronization Time: 20.0 minutes. Run # 3 
POllESIZEll 9J20 V2 . 07 
SAl'IPLE OlllfCTOll Y/N\R'IBElt ; 174 
OPERATOR : l(eun Pliri!U LP OS :00 : '6 0J/OJ ~7 
SA .. PLE 10 : Plu:d»Z-Z0.1nltUHll HP 06 : 511 : 55 OJ /OJ /97 
SU91!lTTElt : Ktu n "etltl llEP 07 :06 : 47 Ol / Ol/97 
PEllETROMETU HIJ"8U : 1J-Q241 AOYAJllCIHG COfilUCT ANGLE : 130.0 deg 
PEHETllOf!ETU COflST.ulT : 10.79 11L/ pf u:cEOIHG COfilTACT NIGLE : no.ad~ 
PEHETllOflETU WE!Gt4T : 68 . 6054 Q ltEltCUll:T SUllH.CE TEHS!ON : 485 .0 dyl\/C • 
STEii VOl..Ut!E: 0 . 4120 .._ "ERCUllY OEMSJTY: 13 . 5335 91-.. 
llAllf'M'I HUD PllESSUllE : 4 . 680:) p1i SJJll'LE llEll#IT ; 0 . 4012 9 
PEHETl!Of!ETER VOlUllE : l . 5443 ..._ S.fJIPLE+Pfff+Kg llEJGHT : 110.7J14 9 
LOV ntESSUltE : 
ptfltCUllY FILLING PllESSUllE : 0.1'587 pti l 
LAST LOV "l:ESSUllE l'OINT ; 2S . !611 p1i1 
HIGH PRESSURE : 
ltl#CTY,E : 
ll:UH llETltOO : 
EQIJ1LJ8AAT10H TIME : 
AUTOMTIC 
EQUILIMATEO 
10 H«lt'ld l 
lMTIWSlOH DATA SUNlAl'f 
TOTAL lMTltUSlOH 't'Ol!Jf!E • 0 . 3700 9'. /g 
TOTAL l'ORE AREA • 39.224 sq-1 /9 
llEOUJt PORE OIA .. ETU (YOltnlf) • 0.0363 111 
llED1J.M l'OtE DlAllETU (AltEAl • 0 . 0111 11• 
AVEll:AGE l'OltE DIAllETD ~ 4V/I.). o . 01n 11• 
9UU DENSITY • 0.8699 'iJI.,,_ 
A,PAll:EHT <SKELETAL) DEJrlSln • 1 . 2527 'iJ / el. 
l'?"!OSITY • 32. 19 t 
STE!! VOl.UflE USED • J6 t 
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Drug Load: 5.0 % w/w, Spheronization Time: 2.0 minutes, Run# l 
il'OREHZU 9120 Y2 .07 'AGE 1 
5All,UOIRECTOll'f / ....aEll : / 1] 
0'ERATOI : kct.,, 05 ; "6 : '-0 11/19/96 
SA.11,LE 10 : 5X2-2•1,.,llUH1 H, 06 : ]7 : 45 11/19/96 
Sl.181UTTU ; tnan ll:f, 06 : ]7; '6 11119196 
,EllETllOflETU llUMEll: : 11-0131 AOVAHClNG CONTACT AHGLf ; no.ode; 
'l:HETIOftlETU CONSTAllT : 10 . M 11L/ pf llECEOIHG CONTACT .uc;U.: 130. 0 "°I 
'EHETllOftETU WEIGHT : 68. 659] g llEltCUllY SUltfACE TfHSiJM: "85 . 0 ctyn/n 
0 . 4120 ... llEllCUIY O(ltSlTY: 
IWllll.l'I HUD 'ltlESSUllE : 4 . 68CXI P•i 
'fNETltCMETElt VOLUflE : l . 6417 llL 
S""'LE VUGHT : 
LOlil,ll:ESSUll:f : 
llEltCUtt'f Fili.ING ,IESSUllE : 0 . 57'M p1h 
UST LOW 'll:ESSURE il'OIHT: 26 . 0516 p1i • 
HIGH PllESSIJllE : 
ltuHfY,E : 
ltl.14 llETM:>O : 
EQUILUIAATIOlll TUIE : 
AUTOfU.TlC 
EQUILIPATU 
1Q HCond l 
INUIJSIOH OAT.I. St.lllQlllUY 
TOTAL lNTltUS!ON VOl\JllE • 0 . t.236 llL/g 
U.HJS 9/ ..._ 
0.'°27g 
TOTAL il'OltE AREA • l9.a32 sq--..Jg 
llED lAll l'OllE OUJtETU ( VQlt.llE) • 0 . 0491 If• 
llEOIAH l'OllE OIAAETEll (.UE.O • 0 .0412 If• 
AVEIAGE il'Oll:E OIAllETEll '4V / 0 • 0.042S /19 
8UUC OEHSITY • 0 .8290 g/llL 
A,,AllVIT CSXELUALJ OE"SlTY • 1.2777 g/"'-
JIOltOS1TY • 35 . 12% 
STEll'IOlUllEUSEO• 
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Drug Load: 5.0 % w/w, Spheronization Time : 2.0 minutes. Run# 2 
POllESIZEll 9J20 '12 . 07 
SAllPLE IHtECTOllYIHU"80: : OATA1 11! 
OPEil.i. TOR: ~et.,, .nu. 
SAllPLEIO : 5%2-.Z11n~ 
SU8" 1TTEll: ~•tllfl Nf'IU 
PEl'IETltOl'IETU llUlftlEll: 13--0241 
05 : 46 :40 11 /1 9/ 96 
07 : 22 : ll 11 / 19196 
UP 07 : 22 : 24 11119196 
PENETAOf!ETEJI COHSTAHT: 10. 79 flf-/pF 
AOV.fJllCilllG CONTACT Al«>Lf : 130.0 d99 
llECEOING CONTACT AllGLE : U0.0 dee;! 
llERCUllY SUllFACE TOSIOM : 43S . 0 rtyrl / c1 PElllETIOftETEJI llEIGHT : 68 .049] g 
STEl'I VOLUPIE : 0.4120 9l. lllUCUllYOEHSITY : 1l.5lJSg/ .._ 
/Ulll'IUl'I HU.O PRUSUAE : 4 . 6800 pai 
PEHETRMETU VOLUPIE : l .544J 91.. 
SMl'U I/EIGHT : 0 . 40'!8 g 
SAlll'LE•l'EN+ttg llE1GHT ; 109.asoa g 
LOW PllESSUllE: 
llUC\JJIY FtU.lNG "tUSUttE : 0.>188 ptia 




fQUlLISRATION Tll'IE: 10 HCondt 
INTltUSlON DATA SUNUllY 
TOTAL IHT~SIOH vot..lME • 0. 4200 .Ug 
TOTAL MflE .O:EA • 40. Z91 ~·1/g 
llEDIAH ~E 01.AJIETEI (vot..J,Mf) • 0.0491 tr• 
llEDl.ul l'O«E OIAHETU (AIEA) • 0.0405 p 
AVERAGE PORE OUllETEJI (4V/A) • 0.0417 11• 
llUlJ( DENSITY• 0.82llO g/.t. 
A,,AllEMT (SKfLfTAL) DEHSlTY • 1.269S g/ ._ 
l'OllOSITY • 34.71 X 
STE" VOLl.IHE USED • 
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Drug Load: 5.0 % w/w, Spheronization Time: 2.0 minutes, Run# 3 
POAES U Elt 9]20 V2 .07 
SAllPLEl)lltECTOitT /~Elt : OAU.1 11 5 
OPElt.UOlt : kct.n .mu 
SMPLElD : SI2•1n2~ 
SU9fllTTElt : keun .mu 
PEHETllOl'IETU 111,fllBElt : 1]-Q1J1 
LP 06 :39 : 20 11 / 24196 
HP 07 :ll : S1 11/24196 
ltEP 07 : ZJ : S1 11124/% 
PEHETllOflETU CONSTAf!IT : 10 . 7'9 JIL / pf 
AOVAHCING COHTACT Al'IGU : U0. 0 deg 
UCEOIM& CONTACT AHl>LE: 130 .0 d~ 
llEltCUAY SUUACE TEHSION : '4S .0 ~le.• PEHETllOfl£TElt llElGHT : 68 . 70loS g 
STEH YOluttE: 0 . 4120 Ill.. llERCUltYOEHSITY : 1l . Sl1Sg/M. 
f'lAXUI._. HEAD l'ltESSIJllE : 4 . 6l!CO ps1 
PEHETltef!ETU 't'OLUl'tE : ] . 5898 ._ 
SAltPlE WEIGHT : 0.4.QD g 
SAltl"U•PElf+Hg \/EIGHT : 1l1 . !J60 g 
LOU PllESSUllE : 
llEllCUllT flll.lHG PltESSUllE : 0 . 71.91 pti • 
LAST LOW PAESSUllE '°lllT : lS . 9651 P•l • 
HIGH PltESSUltE: 
lt\.lllTYPE : .WTOtA.TIC 
ECllILlBlATEO 
10 s..:onds 
-'UN llETHOO : 
£QUILI81lATIOH TillE : 
TOTAL lHU\JS l ON VOLIJflE • 0. 4209 .. /g 
TOTAL l'OllE AREA• 'IJ . 245 1q-• /9 
llEOIAH l'Oll.E 01.METEll: (VOUIPIE> • 0 . 0490 11• 
llEOIJJI "1lltE OUJIETElt OREA) • 0 . 0412 11• 
AVERAGE l"Otlf OIAltETU (4V/ A) • 0.0418 11• 
81JLX DVISITY • 0 .9J12 g / .C.. 
Al'PAJ:EMT t S.:ELETAU :~MSITY • 1.5312 g / .C.. 
f'()l:l()SlTY • 39 . 19 X 
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Drug Load: 5.0 % w/w. Spheronization Time: 10.0 minutes. Run# I 
l'OllUilER 9120 Y1 . 07 
SNl,LE OllECTOllY/~llU : Oo\TA1 /16 
0'fllATOll ; li::U9n ...nu 
SM,LE lO :~
06 : 39 :20 11 / 24/ 96 
H' oe:oe:os 11124/<16 
u, oe:oe :os 11n41'J6 SU8111tnu : k•ten ""u 
AOVAllCING tc»ITACT .tJllGLE : 130 . 0 deQ 
'EHETltOf!ETU COHSTAHT : 10. 79 Jrl/pF llECEDUG COMTACT AHGLE : 130 .0 deg 
'UfETltOl'IETU \/EIGHT : 61 . 0909 'ii l'IUClll:Y SUttfACE TUISIOH : '-'S . 0 ft'(n/ca 
0 . 4120 .... ltUCUltY DE!ilSlTY : 1] . S]lS 'iJ / 91. 
JU.II"°" HE.lO ,llUSUU : 4 . 68CD ps i 
'EHET!tOftETEll YOLLME : l . S'69 ._ 
UIU'LE VUGHT : 0 . t.016 g 
SNll'l..E•'(IM4ig Vt:lGHT : 110 .0900 !I 
LOW "llfSSUU : 
llUCUIY flll..lNG 'llESSUU : 0 . 72"17 p•l 1 
UST LOW 'll:ESSUU '°!HT : 2S . 9681 J"lll 
HIGH "tESSUU : 
AUTO•tt.TIC 
lt\Jtj ltfn«>O : EQUILlUATIED 
EQUlLJl!IAATIOH TlllE ; 10 seconds 
UITltUSIOH OATA Sl.ll'UJtT 
TOTAL lHUUS IOM \IOLUPIE • 0 . 1955 9l../ 'i1 
TOTAL l'OllE AllEA. 41 .5n sq-af 9 
llEDlAH l'ORE 01.utfTU tYOlUllt:l • 0 . 0420 JI• 
.llEDIAH l'Ollf DUll.ETU tAAEAl • 0 .0354 111 
AVEll.AGE P'OlllE OIAllHU (4V/A) • O. OleO " ' 
euur; r.aistrY • o.asos ; t .._ 
APPAIEHT ( SKELETAL) Da4S1TY • 1 . 2SZ1 g / 11111.. 
'°"°'lTY • JJ . 64 J: 
STUI YOll.lllE USEO • )9 X 
19 1 
Drug Load: 5.0 % w/w, Spheronization Time: 10.0 minutes, Run # 2 
l'OflESIZEI 9]20 '+'2 . 07 
SAll,Lf OllUCTOtllT/HU!t8Elt : OATA1 117 
OPUATOll : ht.n eeftu LP 10: 47 : 16 11/24196 
S.utPU: ID: 5110.in2..itUH2 Kf' 11 : 17 :03 11/24/1J6 
St.181!1TTEll:: tct., .tit• 1.0 11 : ]7 : 0.C. 11 / 24 / 96 
PEHET.aPIETElt .-..aEll: 13--01]1 AOYAHCJNG CONTACT .u<iLE : 130.0 Of9 
PElllETllOflETElt CONSTMIT ; 10 . 7'9 JfL/ pf l.fUOING COMTA CT AHGLE : 130 . 0 d°'9 
PCHETIONETU WEIGHT : 68 . 4074 g llUCUIY SUUACE TUISIOM : 41S.0 dyn/c• 
STOI vot..l.11£ : 0 . 4120 Ill. llEllC\JllY DE,.SITY : 1l . Sl1S gl-.. 
llA.ll"""' HEAD PIUSSUllE : 4 . 6800 p1i SMl'LE llUCiHT : 0 . 4026 g 
PEHETllOIETU YOU.Ill( : l .SMS ._ SAll.JllLE•,EN+Hg llE!GHT : 111 . 5960 g 
LOWPll:USUttE : 
llUCUllY '1LltHG PllESSUltE : 0 . 107l p1i • 








umtuslOH DATA stNARY 
TOTAL lHTRUStOM vot..~E • 0. '°"1 114. / g 
TOTAL POll:E AllE.l • 4] . 5]1 tq-• / g 
llEDIAH l'OlE 01.utETU (vot..Ul'IEl • 0 .0l99 11 • 
llEOUH roll£ OIAltfTU ( AJIE.O • 0 . 0351 11• 
AVfUGE l'Oflf 01.utETU (4V/ A) • 0 .0311 11• 
euu:: :IEHSlTY • 0 . 94]9 g/ .i.. 
A,,.O:EJIT (5'i:ELfTAL) OE"SITY • 1 . 5259 g/ ml. 
'OllOSITY • J.8 .15 1 
ST"EJll'tOLUftcUSEO• ]9t 
191 
Drug Load: 5.0 % w/w, Spheronization Time: 10.0 minutes. Run # 3 
S.l.1t,1.EOlllHTOAY/11Ult8Ell: O.l.TA1 115 
O,UATOll : 'teten ..nu 
SAlll"LE 10 : 5%1 0. 1~.-AlMJ 
SU~lTTU ; 'tu.,, ~u 
10:47: 16 11 124/ 96 
HI" 12 : Z2 : 24 11 / 24 /96 
ltEl' 12: 22 : 2StlJ2t.~ 
l"EHETlla.IHU f11Uf18Ell : 13--0241 
1"£14ETllOftETElt CC»ISU.HT : 10 . 79 11L/ pf 
l"ENETll'OllETU llEIC>HT : 67 .aaso g 
AOYAHCl!«i COHUCT ANGLE ; 130 . 0 de-; 
lf:CEOING CONTACT .t.HGL.f : 110 .0 d~ 
llEltCUllY SUUACE TEHSIOH : '85 . 0 dyt1 /c• 
0.4120 ... ltEICUU DEHSITY: 
SMl'LE WEIGHT: 
1l . Sl1S9/ "'-
0 .4.0'IO g .UXIMUfl HUD l"llESSUllE : 4 . 68CXJ pt i 
l"E'IETllOftt:TU YOlUl'lE : l .5"69 Iii. SM~E+l"Ot+ttg WEIGHT: 109. 5288 g 
LO!il"llESSUIU : 
ltUCVI Y fllllMG l"USSUU : 0 . 7'07) p•il 
LAST LOW l"llESSUll:E l'OINT : 25 . &3]7 p$il 
H!Gli "llUSUIU ; 
"""'TYPE : AUT°"4TIC 
atJN llETMOO : EQUIUIPATUI 
EQUILIBUTIOI( THIE : 
UfTltUSIOH DUA Sl.RtU:Y 
TOTAL lHTNSIOH VOU.11tE • 0 . 3973 91../g 
TOTAL l'Ol\E .UU • 42 .097 ~-1/g 
1muu l'OttE 01.utEl'Elt 1YOU1tU • 0 .°'°6 .. 
ltU lJJi 'OJIE OIA.llETU (AlllfA) • 0 .0353 ,,_ 
AVERAGE '°41£ OIA.lt£TU (4V/U • 0 . 0378 lfS 
i!llJlX OEHSITY • 0 .8410 g/ m_ 
A,,.l.ltfHT ( Sl((L.fTAll OOIStTY • 1 . 2630 <; / ._ 
'°"°StTY • 33 . 41 :Z: 
STEMVOUlltlEUSIEO• 39X 
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Drug Load: 5.0 % w/w. Spheronization Time: 20.0 minutes. Run# l 
l'Oll:ESIZU 9120 '12 . 07 
SAAl'LE OltECTOtlY/HUfeU : 0AU1 
l>'UATOI : l(n .... Menu 03 : S2 :07 11125196 
SJJlll'LE 10 : SX20llin2-'Mf1 04 :19:15 11125196 
SU9ftlfTU: l(nan II.nu ltfl' ()t. ; ]9; S6 11/25196 
l'ENETlllOftETU ..... eu : 13-01]1 AOV.lltCING CQNU.CT AHGLE : 130. 0 ~ 
PENETllOftETU COHSTAltT : 10 . 7'9 11L / pf RECEDING CONTACT .tHGLf : 130.0 89 
l'EtlETltOIUTt:Jt llflGHT : 67 . 906l 11 llUCUlY SIJUACE t£NS!OH : '85 . 0 ctyn/a 
STEii 'IOLLltE : 0 . ,12'0 .._ llUCUlY ODISlTY : 1l.S364 g / 111.. 
llAXUllf'I 11EAO l'ltfSSUll:E : 4 .6a00 p11 SA.l'll'LE \/EIGHT : 0.4007 II 
l'EHfTIKlltETU YOt..LltE : l . 5885 ._ SAIUl'LE•l'Elt+Hg WEIGHT : 111 . 2415 g 
LOii l'USSUIE : 
llUCUltY '1LLING ,IUSSUl.E : 0.7293 p1i a 
L.ASTlOlill'ltESSUltE P'OINT : 26 . 10'l4p1h 
HIGH l'll:ESSUtE : 
llUNT'Yl'E : 
l(llfl llEntoO: 
EQIJlll81U TIOH TillE : 
AUTOfU.TIC 
EQIJIL18AATED 
IHTllUSl<»I OATA SUVUU 
TOTAL IJHftUSIOI' V'OLU..E • 0 . 3&60 91. /g 
TOTAL POii~ UEA • 19 . 525 tq-• /g 
llEOl.IJI P'O':E OUJtETU (\'ClLltE ) • 0.0419 JI• 
llEOIAH l'OllE OI NIETEll UIE.l) • O.OJ61, Jr• 
AVUACiE l'OllE OI AllETEll (4V/A) • 0.0391 11• 
llUU: OUISITY • 0.9616 9 /9'. 
A,,AUIH (SUUTAU DEMSIT'Y • 1 . S290 9/lll 
l'OROSIT'Y • ]7 . 11 % 
STEii YOLUl'IE USED • )& % 
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Drug Load: 5.0 % wlw. Spheronization Time: 20.0 minutes. Run# 2 
l>ORESIHI 9120 '12 . 07 
SAll.PLE D11ECTOIY/HU"8U : OATA1 120 
OfiEHTOll : (IUn "ef'lta 0] : S2 :07 1112'/96 
St2()91n2..itl.IN2 HP 05 : 11 : 2] 11 125 196 
SlJ81HTTU : (eten "9hta UP 05 : 31 : 24 11/25/96 
PEHUltOftfTU NUl't&U : ll . 0241 AOV~lHCii CCMTACT 4"GL£ : 1]0. 0 d199 
JllEH£TaotlETU CONSTANT ; 10. 19 A.Jpl •EcEDUG CONTACT Al'IGLE : 110.0 ff9 
PENETllOl'IETU llElGHT ; 64 . 3124 ; llUCUIY SURFACE TEllSlOfll : 1.35 .0 clyn /ca 
STEii YOl.UflE : 0.4120 IL ltUCVIT OEMSlT'I' : 1l . S]64 9 / .C.. 
ft.lllPIUfl HEAO PllESSUIU: : 4 . 6900 p•i S-"'L'U llUGHT : 0 . 4011 9 
'EMETJl'Of!fT£JI YOlUllE : l . S44l ml. SAllPU•P~ 11EIQ1T : 110 . 3415 9 
Lo.IPltESSIJllE : 
. llUCUltY HLLIHG PllESstHtf : 0 . 7293 p1 i 1 
UST LOW PIESSUllE f"OINT : 26.1014 p1 i 1 
HIGH PllESSUU : 
WM TYPE: 
ltUM ltfll«>O : 
AUTOMTIC 
EQUillPATEO 
ECllJILIBMTlOH TtME : 10 seconds 
urntuSlOfll DAU Sl..R'IAAT 
TOTAL lHTltuUOfll '/Cl.I.'!£ • O. JaS2 .U; 
TOTAL POiit£ AIEA • ]9 . 498 1q-./ 9 
llEDU.M l"Oltf DlAltETH (VOUMU • 0 . 0438 • • 
l'IEOIAH P'Ollf 01 ..... mlt UREA) • O. Ol6J • • 
AVEIUGE l'Olf OIME'TEI (4V/Al • 0 . 0390 • • 
11M..K OEHSITY • 0.8552 g f9L 
Al'PAAfl(T CSKELETAll OEMSlTT • 1 . 27S2 g/ 9L 
l'OltOStT'f• 12:.9"% 
STU VOUll'IE USEO • 14: 
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,.. -,,.· 
Drug Load: 5.0 % wlw. Spheronization Time: 20.0 minutes, Run# 3 
'<lllESIZEll 932() V2 .07 
SAll,LE OUECTOA1'/NUfl8HI : OAT.1.1 121 
MEllATOll : Kn .... 11.nu LP 09 :18 : 22 11/25/96 
$AllPU ID : $120io1"'2~ "' 11 :12 : l3 11/l5/96 
SUMt n u : l(eUn ~u U:P 11 :12 :14 11/25196 
PEJrlETllOl!ETU Hl.llfJEll : U-0241 AOVAHCU«i COHTACT AllGU : 130.0 cl..; 
PV•ETAOflETU COHSTAHT : 10. 79 111../ pf IECEDIHli COHTACT N«>Lf: 130.0 Mg 
PEHETltOftfTU llUGHT : 68 . 1909 g llEJICUllY SUllFACE TEHSIOH : 48$ .0 lf'fn/ca 
STVI 'IOluPIE : 0 . 4120 111.. "UCUllT OENSlTY : ll . $:!64 9/"'-
MXIM.111 HUD PllESSIJllE : 4 . 6800 psi SMPU \/EIGHT : 0 . '-008 g 
PEllETROllETU YOLLl'IE : J . S44J .._ SAlll'LE+PfH+Mg \IEIGHT : 110.0498 g 
LOW PllUSIJllE : 
llEJICUltY Fii.UNG ,.ESSURE : 0 . 744] psia 
LAST lOlil PltESSUl.E l'OINT : 26 .0912 ps i a 




ECIU1Ll8lAT10H Tll•E: 10 HC:ondt 
TOTAL IHTlt\JSIOH VOll.ME • 0.l862 .U9 
TOTAL l'Ol:E AltU • 39 .090 ~-•/g 
"EDIAH POllE OlAllETElt (VOU.lltU • O. Ot.SO ,_ 
llEDU.11 il'OflE OIAllETU CHEA) • 0.03n ir• 
AVERAGE ~E OVJIETEll (4'1/A) • O.Ol9S 11• 
8UtJ( DENSITY • 0.43Z2 g/91. 
A"UEHT CSKELHALl OOIStTY • 1.2265 9 f 9l 
l'OAOSlT"r • , 32.14X 
STEl!VOlUflEUno. lat 
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Drug Load: 10.0 % w/w, Spheronization Time: 2.0 minutes. Run# I 
'°"ESllU 9120 Vl . 01 
S.utPLE OIRECTOlt'ffNUllllU : OATl1 122 
OPERATOlt : IC•tan lletlta 
SAHl"LE lO : 10X2• 1n2..-ut11 
su&111nu : .:et enit.nt a 
v 08 : 111 : 22 11/25 / 96 
HJll 11 : 59 : 57 1112S/96 
IEP 11 : 59: $7 11/ZS / 96 
AD'IA14CUG CONTACT AllGlE : no .a O<t9 
PEltETIDIETElt CONSTAHT: 10.79 ~/pf IEC£Ot"6 COIHACT Al«iLE : no.a deo;i 
PEMETIKll"IETU WEIGHT : 6& . 6221 g lt(ltCUll:Y SOllUCE TEHSION : 485 .0 Oyn/c• 
STEii 'IOLLlllE : 0.t.120 ._ "Ell:C\ll:Y OOSITY : 13.5:561. Q/91. 
Mllf'\Ufl HUD 'llESSUllE: 4.6800 p• i 
PEHET1t0f!ETU YOLUllE : l.SMS tll 
LOW f'llESSUllE : 
ftUCUll:T '1U1HG PllUSUJI! : 0.7443 p1 ia 
LAST LOii/ PltESSU•E l'OJMT : 26 .0932 p1i a 
HICOH PllUSUllE : 




EQUlllllllUIOfll TUIE: 1Q HUJndl 
TOTAL IHTllUSION 'tOU.lltf • 0 .UOJ k /9 
TOTAL~'!: .t.ltU. • ]7 . 712 ,q-a / g 
llEDlAH l'OllE OIAllfTU (VOUMEl • 0 . 0609 J• 
ftEDIAM l'OllE OIME'TU ( AIEA l • 0.0412 ¥"' 
AVERAGE ~E OlMETU (4V/A) • 0.°'61 11• 
&UU: '""MSlTY • 0 . 9101 g/ 111.. 
APPARENT (SXELETAL) DENSITY • 1.5184 g/"'-
l'OllOSITY • 40 .07 % 
ST£1t VOUJP1£ USED• '3 I 
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Drug Load: 10.0 % w/w, Spheronization Time: 2.0 minutes, Run# 2 
SAl\PLE Ollll!CTOU/Nt,NU : OATA1 12~ 
Of'EIUTOll : ICetMA<ttlt• 
SAl"lE 10 : 10%2•11'\2..it\MZ 
SUMlrTH : ic.un "-"U 
LP 00 : 27 : 56 11/26/96 
HP 01 ; 11 ; 11 11/26/ 96 
llEP 01 : 11 :19 11126/96 
AO'OJllCllllG CONTACT AHGU : no.a ff9 
P9'ETJIOf!ETll CONSTIMT : 10.7' •L/pf IECEOIHG CONTACT AHGU: : 130.0 dit; 
PatETllOflETH \llEIGHf : 67.1749 II llUCUllY SIJllfACE TENSION : .c.as .o rtyn/u 
STE" VOlt.N: : 0 . 4120 .._ PIUCUllY DatSITY : 13 . S:s.M g/ ._ 
IWlll'l.ll' HEAD PllESSUllE: 4. 61JOO p1 i 
PENETJIOflETU YOlUltE : J .WS ..._ 
LOW Pll:USUIE : 
MllCUltY llUIJIG .n:USUllE: o .• ~10 p•i• 
UST LOW Pl.ESSUU l'OIMT : 25.P19 p1 i 1 
HIGH PHSSl.nl( : 
llllltTYPE : 
lllllt llEntOO : 




lNTltUSlON OAU. Sl.IUU.IT 
TOTl.L UITltUSlON VCllJf!E • 0 . "3SS .Ug 
TOTAL l'OllE AllfA • ]7 . 09e .,q-.i/ g 
l'IEDlA.lt l'OlE DlA.ltETD ('tOl.J.ME) • 0 . 0606 .r• 
llEOlAH l'OllE Ol.UETU CUU) • 0.0410 11• 
AVEAAGE l'OllE 01.IJIUU (4V/0 • 0 . 0410 11• 
91.JU:: DENSITY• 0 .9Zl! gt-.. 
A,,UENT (SU:LETAl> DEJilSITY • 1 . S456 g/ IM.. 
l'OltOS1TY • t.Q.23 X 
STEii YOlllftE USED • 4.2 X 
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Drug Load: l 0.0 % w/w, Spheronization Time: 2.0 minutes, Run # 3 
l'O•E SIZElt 9320 V2.07 l'AGE 1 
SMPLE OIREC TORY / HOPISEll : OAT.1.1 124 
OfERATOf: : (etati l'lef'IU U' 00 :27 : 56 11 /l6 /96 
SMPLE ID: 10X2• i "'2-lllJIO 01 : Sl : OIS 11/26196 
Sl.IMITTU : K•t.tn l'lenu REP 01 : 53 :09 11/l6/ 96 
l'ENETltOflETER Hl.'"8U : 13--0241 ADVAllCIHG CONTACT ANGLE : 130 . 0 d"9 
'EllfUOflUU C°"STAIH : 10, -,q 11L / pF ltECEOI HG CONTACT AHGLE : 130 . 0 deg 
l'EllETllOl'IETU WEIGHT: 6a .9'17l !1 llUCUR'f' SURFACE TEHSIOH : '85 .0 ctyn/ u 
STU! 'IOlUltE : 0 . 4120 «. llUCUllY OEllSITY : 13 . 5364 !1 1._ 
llAXlllJM HUD Pll:ESSURE : 4 . 6800 ps1 S.tJIH.E llEICOHT : 0 . 4003 !1 
l'EMETROltETU YOllll'tE : ] . 5443 «. S.tlll'LE•l'fH+Hg WEIGHT : 1l0 . 69S7 !1 
LOW l'llESSUltE : 
llEllCURY FIUU«i PRESSURE : 0 . 6510 ps i • 
l.lST LOW l'llESStJllE '°Utf : lS .8919 p11• 
HIGH "lESSUllE : 




EQJIL I BIUTIOH TUtE : 
TOTAL l HTRIJSUlH VOL~E • 0 . 4355 ._,!I 
TOTAL l'ORE .UEA • 37 . 260 .q-•/g 
llEDIM l'OllE 01.utETU (VOUJPIEJ • 0 . 0607 ll• 
llEO I AH l'Oll:E OIAl'IETU ( .U:E.l) • 0.0409 ,,_ 
AVUAGE 1'011£ OlAJllETEll 1 4V/A) • 0 . 0468 _. 
BUU: D£HSITY • 0 .1211 ;/& 
A,,ARElilT ( st.ElEUl) DEJISITY • 1.27&3 g / & 
35 .761 
STEii YOl°"E USED • 42: l 
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Drug Load: 10.0 % w/w. Spheronization Time: 10.0 minutes Run# l 
}(;1£SllU 9320 Y2 .07 
SAllPlE OllECTOllT/ NUflBU : OAfA1 /~ 
Of'EIUT041 : K1tt...,l'l«lt • 
SAlt'U: lO : 10X10.i n2..mN1 
SUMtnu : Ket.,, 11ct1u 
LI' or. : S6 : 4l 11/26 196 
HP OS : l9 : 1S 11/26/ 96 
UP OS : l9 :15 11/26196 
'f:tlETllOflETU HUftUlt : 1]-()'131 
l'afETIOflfTEI CONSTAlllT ; 10 . 79 '1./pf 
•ovAMCIHG CONTACT AllGU : 1:50 .0 d~ 
ltt:CfOlHG C.ONfACT AJtGU : 130. 0 ~ 
llUC\MT SUUACIE T£HSIOH : 485 .0 ~/u 1'£HETllOf!ETU WE I GHT ; 67 . 9940 9 
STVI VOLIME : 0 . 4120 ._ AEllCUAT 0£Hst1'Y: 13 .5364 g / lll. 
AAJ:llU'I HEAO 'U:SSUU: : 4 . 6ll(X) p1.i 
1'£HEU0fl(TU VOLLllE : J.saas .... 
SNll'U lfflCOHT : 0 . '°12 9 
SNU"\.f+l'EH+Ho; \!EIGHT : 111.1876 g 
LOIJl'llUSUllE: 
llUCVJl:T 'lLllHG "IUSUIE : 0 . 7328 p1h1 








lHTllUSlOH OAU. Sl ..... U Y 
TOTAL UCTllUSION VOlt.1"E • 0.4189 llL./ 9 
TOTAL il'Oll:E .UE.l • la . 994 sq- • / 9 
HEDI.AH l'Ollf OUJIETU (VOl.UfllE} • 0 .0La4 /19 
l'IED IAM l'Oaf Ol.METU (.U:EAl • 0 .0428 jl • 
AYfu.6£ l'Ol:E Ol.ulETU (4V/A) • 0.000 11• 
llULK OfHSlTY • 0 . 939'1 91-.. 
Arl'AltEHT ( SICELETAl) D£HStTY • 1 . 5.cal 9 / -.. 





Drug Load: 10.0 % w/w, Spheronization Time: 10.0 minutes. Run # 2 
SA.ltPLE OIRECTORY / NUf!8E ll: 0AU1 l'Zl 
O,UATOi!. : ICet.., "ttH• 04 : S6 : 4l 11/26/ 96 
10:10.t n2- lllJH2 HP 06 :1 11 :09 11 / 26/ 96 
SU8"1 TT Elt ; Keun ,.<ef'IU REP 06 : 111 : 10 11/26 / 96 
PEHETltOftETU HUMEll : 11-02.41 AOVAHClNG COltU.CT AHGU : 130. 0 de<J 
PEHETltOMETER COtlSTAHT : 10 . 'T'i 11l/pl RECEDING COftT.l.CT AH:iLE ; 130. 0 d"'J 
PEHETltOllETU I/EIGHT : 68 . nJO 9 llUC\lltY SURFACE TUISION : "35 . 0 lfyn/ e• 
STEJ'f YOt.\Jf!E : 0. 4120 .._ llERCUU OUIStTY: 1l . S164 g / lll 
PLUHIUfl HEAD PRESSURE : 4.6l!QJ ps i SA.ltl'LE VEIGHT : 0 . 4020 g 
PEHETltOltETU 'IOlllf!E: 3. 544] • l SA.ltl'lE•PE,..Hg WEIGHT : 110. 5390 g 
LOW PRESSURE : 
ltEltCURY flLLING PRESSURE: 0 . 1'1211 pa i • 
LAST LOW Pll:ESSURE '°1111 : 25 . 9'104 p1 i • 
HIGH PRESSURE : 
lttMTYPE : 
ltUHllETl400 : 
EOUILISAATlOH TlllE : 
AUTO.U.T1C 
EQU I LIBUTED 
10 ucooda 
TOTAL IHUUSIOM YOl.Uf\E • 0 . 4185 .._/ g 
TOU.Ll'O«E.U:EA• l9 .416s.q-• / g 
.llEDIAH POU 01.utETER ( VOUJf1E> • O.Qt.Q 11 • 
llEOI.1.14 l'OllE OIA.ltETER ( Allf.O • O. Ot.29 ,1111 
.1.VUAGE l"Oltf DIA.ltETElt ( t,V/ A) • 0.Ql.25 11 • 
!tJU( OEHSITY • 0 . !291 g / ml 
.l"'UENT ( SKELETAL) OEMSlTY • 1.2697 g/ .i. 
l'O«OSl TY • 34 . 70 X 
STEN vou mE useo • 41 x 
201 
Drug Load: I 0.0 % wlw. Spheronization Time: I 0.0 minutes. Run # 3 
SAllnE 011.ECTORY/MIJflBU; OAU.1 /27 
MUATOll : tu .... ..tin 03 :09 :15 12102/ 96 
10X10.11'\2-.AUHJ "' Ol : Sl :27 12102/96 
w&l'ltnu : 11;.can ect\U U, Ol : Sl :29 12102196 
'EMETllOflETU II.NU: 1]-Q241 AOVAHClHG COtHA CT AHGLE : 130 .0 o~ 
PEHETllOftETU COHST.ulT : 10 . 79 ~Ip' llECEOING CONTACT J.HGLf : 130 .0 deg 
lllUC\llllY SURFACE TEJtSI°" : 485 .0 rt>fn/c• 
STEl'I VOUlllE : o.nzo-.. llUClJllY OEHSlT'I' : 
it.ull'Mt HUD PltESSUU : 4 . 6800 pa i 
'VIETltoi.ETU VOUllE : l . S4'J ._ 
SAll"-f llflGHT : 
LOW "tESSUll:E: 
lllUCUllY FILllNG PllUSUltf : 0 .6190 p1il 
U.st LOW 'llESSUl.E P'OlHT : 25 . 907'9 ptl • 
HIGH ,ltESSIJllE : 
AUTOMTtC 
11Ut1 ,.ETMOO : EGUlllWTEO 
EQIJ1LIBUTIOt4 TllllE: 
IHTlllJS10H DATA Sl.lf•.UY 
TOTAL IHTlllJSlOM VOllll'E • 0.4170 lll /9 
TOTALl'OllE AllE.l • ]9.SSl sq-•/9 
lllEDl"'4 l'Olf DUJlfTU <VOUMEl • 0.048'1 , . 
lllEOIAH ~E OIAl'ETU (.UO. l • 0.0422 .J• 
AVEIUGE l'OllE 01.ulETU (4V/A) 11 0 .042.2 JI• 
llUUC DENSITY • 0.IU69 9/111.. 
"''U.EMT (SICELETJ.L) OEHSlTY • 1.2SSS 9 / ._ 
"°"°SITY • Y..90 ::r; 
STE" VOLIME USED 11 
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Drug Load: 10.0 % w/w, Spheronization Time: 20.0 minutes. Run# l 
l'OUSIZU 9320 V2 .07 
SAMPLE 01UCTOllY/HU"8Ell : OATA 1 128 
°'UATOI : ket.,, wf\U 
WPLE 10: 10U0.11'\2- llUN1 
SUlll'l lTTEll: ketMI lleflU 
03 :09 : 15 12/02/96 
HP 04 : 41 :16 12/02/ 96 
IEP 04 : 41 :17 12102/ 96 
PEHETllOflETEll Nll"8Ell : 1]-0131 
PENETllOflfTU COHST.tHT : 10. 7'9 •Llpl 
AOVAllC l HG COHTACT AHGLE : no.a d .... 
U CEO IHG CONTACT AHCiU : 130 . 0 d~ 
ltEll CUAY SUlilfACE TOfSIOH: 48S . O ~le• PfHETltOf!ETEll llUCOHT : 6a .6.ll8 g 
STEJll VOlt.l'IE : 0 . 4120 ._ ltEllCURT OVISlTY: 1l . S41l gt-. 
ltAlllU'I lfEAO PIUSUl:E : 4 . 6800 p•1 
PVIETltOPIETU 'IOl.Uf!E : 3.6417 111.. 
SA.l'"LE WEIGHT : 0 .~ g 
SAlll'lf•PE.N<-Hg llUGHT ; 111 . 8144 1J 
LOW,1£S5Ull.E : 
llEllCUllY '1U.JHG Pl:ESSUllE : 0 .6790 p1h 
LAST LOW ntESSUllE 'OUIT : 2S .9'1"'9 p1 i • 
HJGH "ll:ESSUllE : 
ll:IJHT'YPE : AUTOflATtC 
EQIJlLlllUTEO 
10 uconcls 
llUN llETMOO : 
fQIJILlllU.TlOH TIPIE : 
TOTAL IHTltUSlOH 'fOt..lME • 0.4094 -.19 
TOTAL l'Oltf All:U • 3a . 662 lq-•/g 
llEOtNI POfl:E OlAAETU ('IOl.Uftf) • 0.°'41 JI• 
llEOl.t.11 l'OllE OIAAETU CAllU) • 0.0f.26 1• 
AVEIUGE l'Oll:E 01.utETEl C4V/ A) • O.Ot.24 JI• 
9JUC OEHSITY • 0.&l'oO g/ ._ 
"'''4UMT CSX.ELETAl) Of:MSITY • 1.2664 g / 91.. 
l'OlllOSlTY • 34.14 l 
STEii VOUJfltE USEO • 4oO I 
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Drug Load: I 0.0 % w!w. Spheronization Time: 20.0 minutes. Run # 2 
SJJll'U OIUCTO.Y/HLNER : OATA1 11.9 
OPEIUTOll : k•Un ..nu 06: ,9 :22 12/02/ 96 
1CIX20iiin2.-tuie2 HI' 07: 35 : 4' 12/02/ 96 
SUllllHTTU : ktt*"' eetita llEt 09 : 19 :21 12102/ 96 
l'EHETllCflfTH -....Ell : 13-0131 AOVAHCIHG CONTACT A.NGLE : 130.0 deg 
l'EHET.ctlETU CONSTAHT: 10 . 7'9 'LIP' lECUIMG CONTACT A.MGU: : 130 . 0 cM'Q 
l'EHET~TU llEl!OMT ; 67 . 6SSO 9 lllEllC\JllY stJU.lCE TV4S1t.ft : 485 . 0 ~It• 
STEii VOlt.llE : 0.4120 ._ llUC~Y OEHSIT'l : 13 . S41] 9 / .._ 
llAXI"'-'" HOO l'llUSUIE : 4.6800 pt, i SM~ llElGHT: 0 . '°10 9 
l'EHETllOflETU VOLIJllE ; ] . 6417 .._ s..utl"l.f•l'V..+41; \IElGHT: 110.&876 9 
LOW l'ltUSIJIE : 
llUCUll:Y 'ILL.ING l'ltESSIJllE : 0 . ma pa l • 
l.AST LOW l'ltESSURE '°INT: ~ . 1911 paia 
Hl!OMl'ltESSUltE : 
1U1 mt: : AUTI'lflATJC 
!Ml llETMOO : EQU1L18U.TEO 
E<ILllLIHATIOlf TUE : 10 a..:onda 
.,.,. l HTltUSlait OATA SUIMAJIT 
TOTAL umruSJOM VOLUltE • 0 . 4059 .. ,9 
TOTAL P'O«E .U£A • le.266 tq-•/9 
llEOIAN l"OlE OIAllETU (VOU#tf) • 0.04&1 ... 
llEOIAH l'OllE DIAIUTElt UltfA) • 0.0Q6 .11• 
Al/HAGE l'OllE DIAlfETEll: (41//Al • 0 . 0'.24 ,. 
8lJU( OU4SITY • o.cn ,, .. 
.ll'PAIEMT (Sl(f:UTAI...) OE>tSITY • 1 . 2695 9 / W. 
"°"°11TY • 34 .01 I 
STOI VOllll'tf USED • l.O % 
._ 
204 
Drug Load: I 0.0 % w/w, Spheronization Time: 20.0 minutes. Run # 3 
l>OIESllU 9120 V2 .07 HGE 1 
UJll'Lf OUECTOll:Y/ M.1'8£11 : OAU.1 / 30 
O'EIUTOlt : ltetan 91tt\U 
10"'..2Cla1n2~ 
SU&llnut : keun -.eflu 
L' 06 : 49 : U 12/0Z/96 
HI' 10 :00 : 45 lZ/02196 
t:EI' 10:00: 46 12102/96 
l'OIETIKlflUU IUISElt : 1l--OZ41 AOVAllCl/llG CONTACT AltGlf : 130 . 0 d<f9 
l'DIETllOl'IETU COfilSUJIT : 10 . 7'9 11L/ p, tECEDUCi ctlHTACT AHGU : 130 . 0 dotg 
l'VIETIOPIETU VUGHT : 69 . 1096 9 llUCUU SUWfACE TVtSIOM : '85 . 0 etyn / e• 
STVI YOUME : 0 . 4120 .. "UC\llT004SITY : 
Ultl'lE WEIGHT : 
13 . 541]9/ eL 
O.t.022 9 IV.XI,._.. HUD l'ltESSIJlf: : 4 . 68CXI pa; 
nHETltOflETU: VOlUftE : l . S44] llll.. SA.M'lf•I'~ llEIQtT : 110 .80!0 9 
LOlill'llESSUltE : 
flUCUltT flLllHG l'ltfSSUlf: : 0 . 1"95a pt i • 
U.STl.OW"l:ESSUltfl'OIHT : 25 . 8911ptle 
HIGH l'lfSSUU : 
AUN nn: : 
ltlJN llETHOO : 
EQUILUIAATION TlllE : 
ECIU1llWT£0 
10 1K.Ord• 
TOTAL ll'lftuSlON YOU.t!E • 0 . l.OS6 ._/ g 
TOTAL '°"E AUA • 34 .603 .q_./ 9 
llEDIAM l'OIE OlAltETUI ('tOl,..IM() • 0 .°'80 ,,_ 
llEOIAll '°'E OIAllETUI ( AltU) • 0 .04l1 ,. 
AVEllAGf l'OltE OlAAETt~ { 4V/A) • 0 .°"'20 ,. 
8UUC OOStTY • 0 . 1111 9 / ._ 
A,,UOO (SULlTALl OUISITY • 1 .2H1 g/ ._ 
l'OltOSITY • 32 . 98 X 
STOIV'OU.MEUSED • 40% 
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Drug Load: 20.0 % w/w, Spheronization Time: 2.0 minutes. Run# I 
"°RESllER 9]20 V2 . 07 
SAllPLf OlRECTORY/HONIU : OAU.1 Ill 
OPEU.TOlt : (nan ~t• 
UJtl'LE 10 : 20X.2• 1n2.itUH1 
SU&llTTU : .::etan Plel'IU 
LI' OS :2J : '6 12101196 
06 :08 :29 12/03/ 96 
UI' 06 :08 :30 12101196 
AOVAllC.lNG C.ONTACT ANGLE : 130. 0 cl..; 
l'EMETltOllETU CONSTAHT ; 10 . 7'9 JL / pf t:ECEDING CONTACT AHl>LE : 130 . 0 4cg 
l'fHETllOMETEl WEIGHT : 67.80l6; llUCUllT SIJllFACE TEMSIOM : '&S . 0 tlyn / u 
0 . 4120 ... llUCUIY 0£/llSITI : 
KA.I I"°" HEAD 'IESSUltf ; , .. 68CXI p•i 
l'fNETltOllETU VOLUPIE : J . 544] 9l. 
SAlll'LE WEIGHT : 
LOW "tESSUltf: 
llUCUll:T FILLUllG l'RESSUllE : 0 .5768 psia 
LAST LOW ,ll:ESSUt:E ,-OINT: 26 .0094 ps 1a 
HIGH l'IESSURE : 
ltl.INTYPE : 
ltlJH llff'MOll : 




IHTll:USIOH OAT.I. SUMAltY 
TO TAL l NTl:USION VOLl.lflf • 0.31114 -..l g 
1l . 5"64g/ .. 
0 . 4022 g 
TOTAL '°'9:£ AREA " 32 .887 ~-a/g 
llEDIAM l'Of!E DIAl'IETU (VOLIJflE> " 0.0580 11• 
!tEOlAM l'OllE OlAltETU UREA) • 0 . 0414 .n 
AVERAGE il'ORE O!AllETU ( 4V/ A> • 0 . °"6411• 
8ULX DOISITY • 0.85'7 g/ ._ 
Al'l' .O:EMT ( Sl(flETAU Oft4SITY • 1 . 267'9 g / .._ 
POflOSlTY • l2 .S9 1 
STE" VOlLME USEO • 37 t 
206 
Drug Load: 20.0 % wlw. Spheronization Time: 2.0 minute. 
l'OllESUEt 9l20 V2 .07 
SAl!PLf OIIECTOllTllU'tSU : 0ATA1 /Jl 
Of'UATOll ; KttM llet\U 05 :21:46 12103/'96 
HP 06: 49 : 20 12/0J/96 
IEP 06 : ,9 : 21 12/0l/96 
SA.llPlf. 10: 20%2a1"2.-n.ti2 
SUMlnn : K•tll'I llef'lt• 
AOVAltCllllG COftT"ACT AICOLE : 130 . 0 deog 
PEHETltOf!ETEI CC»ISTAMT: 10.79 1tL/pf aECEOUIG COMTAU .u«ilf : 130 . 0 "9 
PEllHJIOflmJ \/EIGHT : 68 . 7225 9 ltUCUlY SUUACE TEHSIOM : "" -0 rtyn /c• 
sro 'tOllME : 0 . 4120 .... llUClllY OOISITY: 
Kill ..... HE.AD PllESSUl:E : 4 ,6800 pt i s.utf'lf VEJCOHT : 
UIU'lE+PVt+Hg VEIGHT : 112 . 0378 g 
Ulli/PIESSUllE : 
llUCUll:Y fll.1.U«i ,.ESSUll:E : 0 . 5768 P•h1 
un LOW PllUSUllf. l'OlllT : l6 . t::c94 P• i • 
Hl~ Pltf.Ssutlf.: 
IMIT't'Pt: : AUTOAATlC 
IMI MTMOO ; 
f.QJll18lATIOM TIHE : 
EQUJllUAT£0 
10 1eccrci& 
TOTAl IMTltlJSlOM VOLUl'IE • 0 . 34.lS "'-19 
TOTAL. l'OllE .UEA • ll . 729 11iq-a/9 
llEDIAH ~E 01.u!ETU (YOl.1.1110 • O.OS45 Jf9 
llfOtM l'OllE DllJIETU (Allf.A) • 0.°'"20 119 
AVEl!MiE l'Oll:E OIAl!ml {4V/A> • 0.0455 ~ 
1!1UUt OOISlTY • 0 .9606 91111. 
APP.lllEHT (Uflf:TAl) OOISITY • 1.5210 9 / 111.. 
l'OltO$ITT • 36 . M % 
STEii 'ICl.Ul'IE vn:o . l7 J; 
207 
Drug Load: 20.0 % w!w . Spheronization Time: 2.0 minutes. Run # 3 
l"ORESIZEll 9320 V2 .07 .... 1 
SAlll'lE OllUC TOltY / HUtBU : OAT.1.1 / JJ 
Ol'flt.A TOll : btan ~ta U' 01 : 27:1 6 12/09196 
S.l.ftl'Lf ID: 20X.2a 1n.Z..it\.IJIO 141' 02 :09 : 50 12/09196 
SUMITTU : r:.et#'I AconU ltEI' 02 :09 : 51 12/09196 
l'f/rlETllOftETU HlNU : U-0131 AOVA/llCll«i CONTACT ANGLE : 130. 0 d199 
l'fHETllCflETU CONST AMT : 10 . 79 l'Ll pf lfClOIMG CONTACT .uGl.f : 130. 0 d99 
l'fHETIOltETU WEIGHT : 68 . 1041 Q ltUCVllT Sl.lltfA(f T£NSICH : 4aS . 0 dyfl / ea 
0 . 4120 ._ l'IUCUIY OEHSITT : 13 . S36l ;I-. 
IU.XI~ KU.D l'ltESSUU : 4 . 6800 P•i S.UWU WElGHT: 0 . '015 9 
l'EMETJIOl'IETU YOllMf : l . SMS Iii.. s.ull'Lf•l'Vt+ttg WEIGHT : 111 . 20Za 9 
LOW l'llESSUltf : 
llEllCUIY flLLll«> l'llESSUlf ; 0 . 6&23 pa i l 
UST LOW PltESSUH l'OINT : 2'.7'69 paia 
HIGH l'llESSIJll.f : 
RUN mE : AUTOftATtC 
EOJ1LISA.t.n:o 
10 •KO"ld• 
IUN ltfll«)O ; 
ECl.llLIWTJOH TUtf : 
IHTR\JSIOM DATA SIMU.lT 
TOTAL IHUtJSIOH YOlLME • 0 . 3a2S ._/ 9 
TOTAL l'Oltf AIU • :SJ .54) tq-1/ 9 
!1£01.&M l'OltE OIAl'IETU ('+'OIJ.lllU • 0 .0558 ,. 
llEDIAlil l'Oltf OJAJ'IETU (HEAi • 0.0412 • • 
AVEIUGE POll:E OINIETU ( 4V/ A} • 0.0452 Jtl 
auut OENSlTY • 0 .92'6 9 / .._ 
A"All:EHT (SICELflAl) OEHStn • 1.4304 g/ ._ 
f'OIOSlTY • JS.J6 t 
STEJll VOlUJllE USEO • J7 t 
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Drug Load: 20.0 % w/w, Spheronization Time: 10.0 minutes. Run# I 
'1)1tESIZU 9320 V2 .07 
SAl!PU: OlllECTCHIT I NOM8U : OATA1 / }4 
Ol'fltATOll : IC•tM1'ent • 
S.U.l'U ID : 20%10.in2-"\IH1 
SU81'HTTU : IC1tan l'l«lu 
l'EHETllOMETU "'-"M:I : U~41 
l'EHETllOltt:TEI COMSTAHT : 10 , 79 •L/ pl 
l'EMETIKlftETD '11£1GHT ; 68. 6317 g 
0 .4120 .. 
MAXI ..... HEAO l'l!:USUIE : 4 ,6800 p1 i 
l'EHETltOltETU vot.LWIE : l . 5443 Ill 
LOI.I l'll:ESSUU : 
01 : 27 : 16 12/09/96 
03 : Z3 :3a 12/09196 
UP 03 : 2J : ]9 12/09196 
AOVolHClNG COITACT All:illE : 1JO. O deg 
llECEOIHG CONTACT NGU : 130 .0 ~ 
llUCUllT SUUACE TEHstOH : 44S . 0 dyn/ t • 
MUC\llT OEJilstTY: 1l . 5l64 i / 9l 
s.utrU WEIGHT : 0 . 4031 g 
SAIU'U•I'~ V!JGMT : 110. 1447 g 
llUtulY 11Lll/llG l'IUSUllE : 0 . 6323 p1 i 1 
LAST LOW l'ltUSUU l'OIHT : 2S . 7469pa i e 
Hl~l'llESSUllE : 
NH TYl'E : 
~ 11Ell400 : 
AUTOPU.TI C 
EQIJILlSAATEO 
10 Ueondl EOJIUUATJOM TUI( : 
TOTAL JMTlttJSION YCU.lfllE • 0 . 3522 -.Jg 
TOTAL l"OlE AltEA • D . 215 sq-. / 'il 
ltfDUH l'OllE DIAllETU \ \IOl.UJIEl • 0 . 0497 ,_ 
llEDUM POJE DIMETU (AJIEA ) • 0 . 0419 1• 
AVUAGE '°'9:E OIMETU ( 4V/ A) • 0 . 0424 ,_ 
u.JC OEMSlTY • 0 .8707 9 / 9'. 
Al'l'U:EHT ( SKILETALJ DENSITY • 1.2557 g/ ._ 
FOltOSITY • 30 .66 I 
STEii VOLIJl'IE USED • Y. I 
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Drug Load: 20.0 % w/w, Spheronization Time: 10.0 minutes, Run# 2 
"<>ti!ESUU 9]20 V2 . 07 
SAllPLE OUECTOSY/!UttlEll ; OATA1 f lS 
OPERA TOlt : l(nan lletltl 
SAllPLE 10: 20X10.11'1l9dl.IM2 
SOMITTU : .:.n_, llel'IU 
l'ENETllOflETU HI.NEii : U-0131 
PEHETllOflETU «*STA.MT : 10.7'9 11L/pf 
l'ENETllOltETU \/EIGHT : 64. 1160 g 
STEii VOl.UftE: 0 . 4120 fll. 
AAXI~ HEAD l'llESSUl.E : 4 . 6eOJ p1i 
l'EHETROflETU 'IOll.llE: l.SMS fll. 
LOlill'llESSUllE: 
v 05:47 : 56 12/09/96 
HP 06 : 3.2:51 12/09/96 
IEP 06:57:21 12/09196 
ADVAHClNG CCfllTACT AJIGU : 130.0 ~ 
ltfCEOlHG CCfllTACT AHGU : 130.0 deg 
llUCUllY SUllFACE ftHSICfll: 485 . 0 ctyn/u 
MllCUIY OVISlTY : 13 . 5364 g/ .._ 
SAl'll'U llftGHT : 0.t.OZJ g 
SAAPLf.,.pflt+~ \/EIGHT : 111 .6Jl0 g 
llUCUltY FILLUCi l'llESSUllE: 0.6992 p1i1 
UST LOW PRESSURE JOINT: 25.7719p.a11 
HIGH l'IU:SSUllE : 
inMT'Yl'E : AUTOMTJC 




UHllUSION OATA SUlf'IAll'r 
TOTAL IHTltUSION "'ot.1.11£ • 0.3551 1111../ g 
TOTAL l'OllE UU • lJ .578 aq-1/g 
llEDIAM l'OllE OIAl'IETU ('t'Ol.UflEl • 0.0496 ,_ 
llEDIAH H>llE OUJIETH (UEA) • 0.0419 11• 
AVERAGE l'OllE DIAl!ETUI (4V/A) • 0.0423 11• 
IM.JC DENSITY • 0 .9973 9/ lll 
'"'AllEMT (SICELETAL) OEHSITY • 1 .5440 9/ml 
"°"°SITY • 35.41 X 
STVl'IOl.UltEUSEO• l5X 
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Drug Load: 20.0 % wlw. Spheronization Time: 10.0 minutes. Run# 3 
~ESllfll 9J20 '12 .07 'AGE 1 
SAN'LE OlltECTOflY/NlNU: OATA1 /J6 
Ol"EUTOfl ; IC.ttMt lt.+IU t..r 05 : 47 : 56 12/09/ 96 
SNll'LE 10 : 21lZ10.1n2-"UK3 Hr 07:39:58 12/09/96 
Sllel!ITTU: IC.•tM llehU U:, 07:]9:SI 12/09/96 
,VtETtlOflf.TU ,.,..0 : 1]-GZ.41 AOVAJK: I HG COHTACT AllGLE : no.o d99 
l'EMETllOMTH COMST.MT : 10 . 79 11\../pf IUCEOIHG COfilTACT ,.,,..U : 110. 0 Mo; 
POiHJIOllETU llEIGHT : 65 . m4 !1 ltUCVltY SUll:FACE TUSl<ll ; 445 . 0 dytl/~ 
STEii \IOLtME : 0 . 4120 ._ llUCUltY O~SUY: 13 . 5364 9 / lli. 
IWl:UUI HEAO l'IESSUU : 4 . 65X> p11 S.lftl'U VEIGHT : 0 . 4019 g 
l'fMETllORfTU 't'OllME : ] .54"] ._ SA.11,U•l'Ef"Ho; VEIGHT : 110 .9042 g 
t..Olil,.ESSUl:E : 
llUC\lltY fILLIHG "IESSUU: : 0 . 6992 p11• 
usr LOW "IESSUltE KllMT : 25 .n19 P•,. 
HlGH l'ltESSUll:E : 
M.INT'f'l'E : AUT~TI C 
lttM llEnt:>O : EQU:LIBAATEO 
EOUILl8UT10N TUIE : 10 Hccn;l1 
TOTAL UtTlt\JSICI( VOllME • 0 . ]516 ._1';! 
TOTAL l'OlE AJ:f.l • l2 . ti77 aq-• l !I 
llEOl,l,111 POltE OIMETU ( \IOLIMEl • 0 . 049S p 
PIEIHAH PORE 01.t.llETU <AIU) • 0.0425 ,_ 
A.VU.AGE l'OllE OIAltETU U oV/ 0 • O. Ol.28 JI• 
i!lllJUC OatSlTY • 0 .8701 g/ "-
Al'l'.U:EHT ($KILETAL) DUISlTY • 1 . 2'37 gt -.. 
:5C>.S9I 
STEllvot.UftEUSED • :54I 
2 11 
Drug Load: 20.0 % w/w, Spheronization Time: 20.0 minutes. Run # l 
l'Oll:ESIZU 9l20 Y2 .07 
'.I.GE 1 
SAllPLE OlltECTOIY/ ff.MBU: m 
Of'ERAtol: KetWlfl.ehta 
SUMITTER : ICetWI llehu 
OJ :07:26 12/10/96 
H' Ol : S7 : 40 12110/ 96 
ltEI' 0J : 57 : 41 12/10/ 96 
AOVAHClH!i tOfilTACT AHGlE : ll0.0 d"'iJ 
PENETllOfllETU COHSTA.HT: 10. 79 11L/ pf lfCEDlWO OONTACT AllGU : 130 . 0 d"'iJ 
'fKETltelf'ETElt VflGt4T : 67 . ao50 g PIEltCUIY ~fACE TUISlOH: 4aS . O dyn l c• 
llEltCUltY DDISlTY: 
IU.XI*'" HU.0 'ltESSUltE ; 4 . 6l!OO psi 
'fHETltOfllETEll VOll..lftE: l . 544] ..._ 
SAl'll'U WEIGHT: 
LOW PllESSUllE : 
llERCU«T IIUIHG PllESSUltE : 0.8010 pti • 
L.lSf LOii PltESSUltE fl'OUtT: lS.8091 pai a 
HlGHPllESSUll:E : 
NM T'"E : AUTOfllATIC 
ECIUlLISAATED 
EQUILIMATIOH Tll'tE : 10 Heondt 
IHTltUS!OH DATA SllflllU.ltY 
TOTAL lNTltUSlOH YOUME • 0.3259 .C../g 
1l.s:564 gf lt. 
O.lo021 'ii 
TOTAL l'Ot!E UEA • 30. 785 sq-• / 9 
llEOIAH ~E OIIJllETU (YOl.UltU • 0 . 0495 119 
MEDIIJf lf'OltE DUJIETU CAllEA) • 0 .0411 1• 
AVEltAGE P'OIE 01.U.ETU. (4V/0 • 0. 0423 ~ 
8UlJC DENSITY • 0.89SO -;i/lli. 
A'l'UEJIT ( SkELETAll DEHSITY • 1.2635 g/ ._ 
POlllOSITY • 1.9 . 16 X 
STEii YOUME USED• 32 X 
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Drug Load: 20.0 % w/w, Spheronization Time: 20.0 minutes. Run # 2 
POllESUEll 9320 "2 . 07 
SAl'.,LfDIUCTOltY/~11: 
Ol'ElATOlt : ICn .... ..-.u 
S.ut,LE U : 20%20ainl..itll'l2 
sua1unu : «•t"" ...nu 
,,. 
lJ OJ :07 :26 12/10196 
05 :10:S2 12110196 
UP OS : 10 : 5J 12110/ 96 
'lNET~ETU Ml.IW:ll : 13-0'131 
PVIETllOflttU toHST.tJIT : 10. 1'9 ,iL / pf 
AOVA.llClHG CONTACT AHGLE : 130 . 0 OeQ 
ltECEOIHG CONTACT AHGLE : 130 . 0 0.,.. 
llHCutY SUllUCE TENSIOH : 4aS . 0 ttyri/u PEMETllOflETU VElGHT : 68 . n74 9 
STE PI YOlUflE : 0 .4120 .. llUC\Jl'f OENS1TY: 13 . 5364 g/M. 
l'All,... HIEAD PllESSUlf : 4 .68CXI pa l 
PEHETllOIUTH 'IOl.UflE : J.SMS M. 
S.vlflf WEIGHT : 0 . l.008 9 
SAlll't.(•P~llEIGHT : 112. 13'09 
LOW PllESSUlf : 
llUCVllY fJLLIN:i PllESSUU : 0 .8010 pa 1• 
U.S1' LOW PllESSUllE l'OINT : 25 . 8091 pa,. 
HUiH PllESSUllE: 
ltllHTYPE : 
EQUILIBAATlOH TUIE : 
AIJTCAATIC 
EQUllllltATU 
10 u concll 
llHltUSU::W DATA Sl,JfMAA1' 
TOTAL INTIUSICN YOt.UflE • O.JD9 .._, , 
TOTAL l'OllE AIU. • ]1 . 783 ~-•/g 
PIEO I A.H ..oll:E DlAl'IETU (\IOLUflD • 0.0495 ,_ 
NEOIJJt l'OllE OINIETU (AllLO • 0 . 0411 11• 
A\IU.AGE P'Ollf OIMETU (4\1/A) • 0 . 0420 11• 
BtJU( OVISITY • 1.0104 g/ tll.. 
IJIPAUMT ( SIC!UTAL) ~"JtSITT • 1.52"3 9 / ._ 
l"l*)SITT . n .n I 
STEJlt'IOl...UflfUSU • l2 I 
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Drug Load: 20.0 % wlw . Spheronization Time: 20.0 minutes Run # 3 
'°41£SJZU 9320 V2 .07 , AGE 1 
I.I 02 :2S : 4S 12116/ 96 
H, 03 :05 :51 12/1 6196 
llEI' 03 :09 : 58 1211 6196 
l'EHETJIOl'IETU NUNSO : U--0241 
l'EHETJIOl'IETU COHSTAHT: 10. 79 11L/ pJ 
ADYA.MCl/llG COHTACT AHGLE : 130 . 0 d99 
UCEOIHCi CONTACT Afi!Glf : 130 . 0 dev 
llEICUllY SURFACE TEMStOM : 481 . 0 ftyn/~• l'EHETl!OflETU llEIGflT : 67 . 6SJO 'ii 
STEA vot..Uf!E : 0.4120 .. llEICVltY OEHS11'Y : U . Sl64 gt -. 
AAJINUfl HEAD l'llESSUllE : 4 . 6800 pti 
l'EHt:TJIOl'IETU 'IOll.l'IE : l . S44J ._ 
SIJl,U WEIGHT : 0. 'IXX> 'ii 
SAN'U•l'E~ VUGHT : 109 . 9712 g 
LOW "IUSIJllE : 
llUCUltY '1LLIHG l'llESSUllE : 0 . 6843 p .. h 








lNTlt\JSIOM DATA Sl.11'1..UY 
TOTAL UtTlt!JSlClt VOLL.ME • O.Jln llL/9 
TOTAL l'Of!E AllU • 31.498 tq-• / g 
11£01.fJll '°41£ OINIETU (V'Ot,.IJllE) • 0.0l.95,,. 
ltEOIAH "°4tE OlM£TEL (Al.EA ) • 0.°"20 ,. 
AVEIUGE "°41.E OllJIETU (4V/ A> • 0.0429 _. 
11UU: OfHSITY • 0 .1937 g/ lli. 
Al'l'HOfT ( SXlLETAl) DENSITY • 1.2Sl) gJ-.. 
"<>llOSITY • JO. 18 1 
STEJlvot..Ul'IEUSEO• ]]% 
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Drug Load: 30.0 % wlw. Spheronization Time: 2.0 minutes. Run # I 
SAllPU: OUECTOllY/.......U:R : OATA1 /40 
Of'EU.To« : l(.et..,llmu 
SAMLE 10: 30X.2•1n2..aurn 
SIJ6fllnU : ICRtWll'l«lt• 
02 : 2S :4S 12116/ 96 
HP 01 : 49 : 28 12116/ 96 
llH03 : 49 : 21112116196 
AOVMCING (OflUCT AHGLE : U0 . 0 d~ 
PEMETllCflETU CONSTANT : 10. 7'9 11t../pF l:ECEDtHG CONTACT AHGlf : 130. 0 de; 
PEHETICll£TU WEIGHT : 611.5499; ltUC\lllY SUUACE TEJISJOll : '4S.0 ltyrl/u 
0 . 4120 .... "ucun OEMStTY : 13 . Sl64 OlllL 
ltAXllU'I HOO PllESSUU: : 4 . UOJ p1i 
PVIETAOllETU V'Ollll'lf : ] . ~5 Ill 
SAllPU VUGHT ; 0 .~ 0 
SAlll'Lf+P£1+4-H; llUGHT : 111 . 9406 O 
LOlril PltESSUll:E : 
llUC1JltY 'ILLJHG PlESSUH : 0 .6841 p1i• 
LAST LOW l'ltESSUllE '°!NT: ZS . o.544 p11• 
HIGH PllESSUllE : 




fQUILlMATIOH TlllE : 
TOTAL lKTlVSION VOlUfllf • O.J6Z8 111... / ; 
TOTAL '°llE UU • ]1 . 031 .q-•/O 
JltEOIAH l'Ollf OIMETU (\'OU#lf) • 0.0644 11• 
llEOLUI l'OllE DIAltfT!l (.UEA) • 0 .°"-0 #• 
AVEAAGE l'Olf OIAltfTU ( 4\1/A) • 0.°'68 11 • 
1!1UUt DENSITY• 0 .9TH ; I -. 
.VP.O:DfT (SICELfTALl ioEHSITY • 1.4999 ; / Ill 
'°"°SITY• JS . 24% 
STEllV'Olll'IEUSEO• lSX 
2 15 
Drug Load: 30.0 % wlw. Spheronization Time: 2.0 minutes, Run # 2 
SAll,LE Dl ltECTOU / HUMEll : OATA1 / 4 1 
OPEUTOlt: ICeten"ft\U 
SJ.Jlt'LE 10 : XJ12• o'2-'IUMZ 
SU81UTIU : ICeten ""'1U 
07 : 15:40 12116/% 
"' 07 : S8 : l4 12116/% 
ltEP 07 : Sl : 34 12/16/ 96 
AD'IAMCIHG CONTACT AHGU : 130 . 0 deoa 
'ENETJIOftETU COMSTAIH : 10 . 1'9 t1L / pf IECUlNG CONTACT AMGLf : 1l0 . 0 d eog 
'ENfTJlOftETU llUGHT : 67 . 89}(. g llUCUllY SUltfACE TPISIOJt : "3S . O dyn lt• 
STlllYOLl.flE : 0 . 4120 .... llUCUllY OUISITY: 
IU.IUUI HEAO jl'ltESSUltE : 4 . 6SXI p1 i 
l"EHETl!Of!ETEll YOt..Uf!E : l . 541.] .._ 
SIJll'l.E \lflGHT : 
LOW PllESSIJllE : 
"UCUllT '1LLING PltESSUltE : 0 . 69]] p1il 
LAST LOW 'ltESSUltE l'OlHT : ZS . &376 p 1 i a 
HIGH "IESSUltE : 
ltUH TY,E: 
ltUH llEnc>o : 
EOJlUUATION TUtE : 
AUTOIU.TlC 
EOJlLIUATEO 
10 H Condl 
lHUUSlON DATA SUMAAT 
TOTAL INTll'\JSIOH 'tOLLl'IE • O. Jseo .C./ 9 
ll . Sl64 " ' .._ 
0."°6g 
TOTAL f'OllE .lll: E.A • 30 .147 tq-.Jg 
llEDIAH l'Oll:E OIAltETU ( Y'OLUl'IE> • 0 .06Ja .-
llfDIA.lt f'OllE OlAllETU CAAU.) • 0.0406 11• 
AVUAGE !'ORE OIAllETU (4Vf A) • 0.0475 , . 
8lllJ( GDISITY • 0.87'S4 g/ ._ 
... ,,.U!JolT (SIU:..EUL) OO!SITY . 1.zn;; ~/ 91. 
"°~SIT'!' • ]1 . 34I 
STE,. VOLLltlE USED • 35 I 
216 
Drug Load: 30.0 % w/w, Spheronization Time: 2.0 minutes. Run # 3 
PO AESllEit 9 320 V2.07 
SAMPLE OUECTOltT/ HUl'!BElt ; OATA1 I Q 
Of'UATOll : (ttan l'let!tl 07 : 15 : 40 12116 / 96 
SAllPLE 10 : J.J%2••n2~ HI' 08 : 55 : 59 12 / 16/ 96 
SU8" 1TTER : (etan lletlt • ltEP OIS : S6 :00 12/16/ 96 
PEHET"°"ETU !U18U: 13--0131 AOVMICU«'.i COtHACT AHGLE : 130 . 0 d119 
l'EHETROl'IETU COHSTAHT; 10 . 7'9 11L/pf UCEOIHG COllUCT ANGLE : 110 .0 d~ 
PEHETllOflETU llEJGHT : 68 .6191 g llUCURT SUllFACE TENSION : 435 .0 dytl / c• 
STEii VOLUltE : 0 . 4120 Ill.. llUCU«T OEJISITY : tl . 5364 9 / 9L 
llAXUtlfl HEAO f'RESSUllE : 4 . 6800 p11 5.ull'LE I/EIGHT ; 0 . 4006 'i 
PENETllOflETU 'tOl.llftE : l . SMS 11t. SAlll'LE•f'Elt*"Q llEl~T ; 112 . 0IS18 g 
LOW f'USSUU : 
llEllCUll'I' FlLLJHG f'llESSURIE : 0.6933 p1 i • 
LAST LOW PllESSURE '°lNT : 2S.8J (6 ps i • 
HIG!ol PIESSUU : 
111.#!Tll'E : 
~/11£nil00: 
EQUILIBlATJOH TU•E : 
fQUOLIWTEO 
10 1-=r>d1 
UITJIUSlOH DATA Sllf!MlT 
TOTAL. llHRUSJOH YOlLlllE • 0.]595 lll,. / g 
TOTAL P'OttE HEA • 30 . 107 sq-•/g 
llEOIAH l'OlllE OIAAETElt (VO!.Uf'lf) • 0 .0640 11• 
llEOIA.I( 'ORE OIAllUElt (AREA) • 0 .0410 11• 
AVEltAGE l'Otl:f OtMETElt (4VI AJ • 0.0478 11• 
A,,UENT CSICELETAl l OENSITY • 1 . 52169/ 111.. 
l'OROSITY• JS . 36: 
STEKV'Ol~'lUSEO• 3S X: 
2 17 
Drug Load: 30.0 % w/w, Spheron.ization Time: 10.0 minutes. Run# 1 
POllESIZU 9320 V2 . 07 
SAll,LE OlllECTOflT/ HtJ"8EJI : 
MEUTOft : IC•U .. 'I l'lenu 
SAJllPLE lO : }(JX10111n2-.AUK1 
SIJBIUTTEI : ltetenllehU 
00: 4]:22 12117/96 
HI' 01:44:25 12117196 
llEI' 01:44:26 12/17196 
PEHETROftETU l«JM&EJI : 1J-01l1 AO¥Al'IC1HG COtlTACT AHGLE: 130.0 ffo;I 
PEHETllOflETEJI COHSTAllT : 10. 79 1L/ pF llECUlHG COtlTACT AHGLE: 130.0 ~ 
PEMETllOflETEll WEIGHT : 67 . 7465 <J llUCUU SUll:fACE TENSION; 485 .0 dytl/c• 
STEI' VOUJflE : 0 . 41<!0 el. llEJICURT OVISJn: 13.5364 g/._ 
ltAI1Pl.ll'IHEAOPllESSUll:E : 4 . 61JCOps i 
PEHETltOflETU V'Ol.UIU : l . 5885 el. 
SAll'LE WEIGHT: 
LOli/PRESSUAE : 
llEJIC\JR'I" FILLIHG. PllESSUtllf : 0 . 6858 psi1 
UST LOW PllESSURE il'OlNT : 25 . 718'9 psi1 







TOTAL UITRIJSlOtl VOLUl'IE • 0.]41.Q Ill.lg 
TOTAL POllE AREA • 30.610 -.q-• /g 
11£01.ul !'ORE OIMETU ;'t'Ot..UftE> • 0.0593 .. 
llEOUH l'OllE IHA.llETU ;.ue.o • 0.041] .. 
AVUAGE POftE DlAl'IETER (4V/Al • 0.0449 11• 
llUU:: OEJISJTY • 1.0COS g/._ 
A,,AllEHT (SULETAL) DOISJn ~ 1.S261 g/11i. 
34.42 x 




Drug Load : 30.0 % wlw, Spheronization Time: 10.0 minutes, Run# 2 
IOOllESIZEI 9320 Vl . 07 
S.utl'LE OlllECTOllY/,._U : OAU.1 JU. 
OPEil.i. TOii: C:~tWI llef'IU 
S.t.l'l,L£10:30%10. in2~ 
SU8fHnn : (UM! lleht• 
l'EMETIK»'IETU NUIBU : 1]..Q241 
l'fHETltOf!ETU COHSUMT ; 10 . 19 ,Up# 
l'EHETllOf!ETElt YEtGHT : 68 . llOO g 
0 . 4120 ... 
M.XIIUI HEAD l'llESSUU: 4 . 6800 ps i 
l'ENETll<WIETU YOlUllE : l . 541.J L 
LOW ,.ES$UJIE: 
LI' 00 : 43 : 22 12117196 
Ol :l2 : 44 12/17196 
llEI' 03 : l2 : 45 12/17/96 
ADVA.llClNG COHTACT Af!CiU : 110.0 d119 
u:ct:ou«; COHTACT AJIGU : 1l0.0 o...i 
!IEllCUttT SIJIFACIE TENSIOH : 41S . 0 tlyft / u 
!IEllCUU OEHSITY: 11 . 5364 g/ ..._ 
0 . 4COJ g 
SIJll'lE+l'E~Hg llEtGHT : 11l .Q81.0 'ii 
llEllCVlT FllllMCi "IESSUllE : 0 . 68S& pti1 
UST LOW l'ltESSUAE l'OIMT : lS . 7189 ps i • 
HIGH l'ltESSUU: 
.-UHTYl'E : AUTOIU.TIC 
EQU ILl lllATEO 
EQUILIP.ATlOH TUIE : 10 s-=nds 
IHTRIJSIOH OATA $UM.UY 
TOTAL IMTa!JSIOH VOUlf!E • O. l4J9 .t./ g 
TOTAl. l'OltE AllEA • 29 . 707 sq-sf g 
llEDlA.N l"O«E OIAMETtl ('tOUMEl • 0 .0623 • • 
ltEOIA.11 l'OIE 01.u!ETU CUE.A ) • 0 . °'24 11• 
.l\lfllAGE l'OAE OIAK(T'EI {4Y/ .l ) • O. Ot.63 11• 
auu:: OOISlTY • O. M43 g/ 111.. 
A,,AUHT Cst:ELETAL) DENSITY • 1.2707 g/ ml 
l'OftOSlTY • ](). 41 l 
STEii VOl~E USEO • ll l 
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Drug Load: 30.0 % wlw. Spheronization Time: 10.0 minutes. Run# 3 
POllESIZER 9320 Y2 .07 'AGE 1 
SAl'l'LE l>t•ECTOllY/N.NElt : OATA1 145 
OPEUTOl : IC<tUt'I Jl<ttlt• U' 10: 4l : 17 12/17/ 96 
SA.11,LE 10: JOt10.1nZ-.ltUM3 11 : 26 :31 12/17/ 96 
SU81'1InU: ICH.n Jleht• RE' 11 : 26 :12 12/17/96 
'fKETIOflETElt -...Ell : 13-0Z41 AOVAHClMG CONTACT .fJllOLE : 130.0 ~ 
'EHETllOf!ETU CONSTAHT: 10. 79 111...lp, llECEOIHG COHTACT" AMGLE : 130. 0 deojl 
'fMETltOf!ETU llUGKT: 68 . oeo9 g llUC\JRY SURFACE TEMSIOH : 485 . 0 rtyn / u 
STEii VOl.t.l'lE : 0.4120 ._ ltEltCUll1' OEHSITY: 13 . 5364 g/ .. 
1wmut HEAD ,.ESSUltE : 4.6800 pa i SAll,LE llEIGHT : 0.4007 9 
'EHETAOl!ETU YOLLll'E : 3.5443 ._ S.u!PLE .. ,V..Hg llEJGHT : 110. l'J1 g 
LOW 'RESSUllE : 
ltfltCUJIY flUlHG 'RESSUllE : 0.6758 pti 1 
UST LOW PllESSURE l'O l NT ; ZS.~961 pa; • 
HIGH PJIESSURE: 
111.M TYP'E : AUTO.....TtC 
1tUN llETHOO : EOUlllHATtD 
EOUlLl!M.TlON TJJIE: 10 1KOl"d1 
,,. • ..- l HTRUS JON OA U. SUMARY 
TOTAL JHT.VSIOM VOLUPIE • 0. 1'-87 Ill. l g 
TOTAL l'OIE AlllEA • l0 . 897 aq-1 / g 
llEOlAK l'OIE 01.U.ETU (\l'OC.1.111 £ ) • 0. 0605 111 
llfOIAH l'OlE 01.u!ETEJI ~AREA ) " 0.0414 111 
AVEiv.GE PORE 01.U.ETU {411/A) • 0.()l.51 11• 
llUUC OOISlTY • 0.8869 9/91. 
.l1PAllEMT ( SltELETAll OOS ITY • 1 . 2840 g/.t. 
~-:OSITY • 30.92 X 
STEM VOlUflE USEO • Y. t 
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Drug Load: 30.0 % w/w, Spheronization Time: 20.0 minutes Run # l 
PORESIZER 9320 '12 .07 
SAl.,LE OI RECT0Rl' / IMl8ER : OATAl / 40 
Ol'EllATOR : .:.un...nu 
3CX2CM1n2-"'-"11 
SUSlll nU: ICet.,,llet>t• 
'UIETllOllETUNl..IMMR : 1]-Q131 
'ENETllOllETU CONSTANT : 10. 1'9 jri./pF 
l"EllETltalETU WEIGHT ; 64.3199 i 
STEii VOl.IJllE : 0 . 4120 llL 
ltUlllUfl HEAD 'ltfSSURE : 4 .6e00 p• i 
'EHETllOllETElt VOLLl'IE: l . SMS 11L 
LOV PllESSUll:f: 
10 : 43 :17 12/17/96 
H, 00: 20 : 4a 1Z/18/ 96 
IEI" 00 :20 : 4a 1Z/18/ 96 
AO'IA.ltCIMG COHTACT NIGLE : 110 .0 deog 
RECEDING CONTACT AHGLf : 130.0 dev 
"UCUltY SURFACE T£HSIOflt : 43'5.0 dynlc• 
"UCURT OEHSlTY: 1J . S36' g/ 111.. 
SM,LE VUGHT : 0.4014 g 
S.u!'1.f+'ff'f+f49 WEIGHT : 112 .0143 g 
llEllC\IU HLLl NG l'RUSUllllE : 0 . 6'758 p1 i1 
LAST LOW l'RUSUllE l'CHNT ; 2S . S961 p1i1 
ltUHllETI<IO : 
fOUlLISltATION THIE : 
EQJILl!ltAT!O 
10 11condt 
TOTAL INTltUSlON VOL\#lf • 0.J19S llL/ g 
TOTAL l'Ol:E Al:EA • 28. 143 sq-• / g 
llfOlAll il'OtE OUJtETU (VOlL.1'1£> • 0 . 0584 JI• 
llEOIM '°llE DIMETEll: (AllEA) • O.Ql.06 JI• 
AYfllAGE il'Otf OIAllETU (4Y/A) • 0.04$4 111 
&IJU: DENSITY • 1.0289 gt -. 
APPAAENT (SKELETAL) OEHSITY • 1 . Sll7 g/ .i.. 
l'OllOSITY • ll .87 X 
STUI 'IOll.lllE USEO • 31 X 
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Drug Load: 30.0 % w/w, Spheronization Time: 20.0 minutes. Run # 2 
l"OllESUU 9]20 V2 .07 
SAllPU OUtECTOllY/IQIBElt : OATo\1 / Sl 
OPEIU.TOW : ICETAH llEHTA 
SAlll'Lf 10 : 10%20.1~.-lt\JK2 
SUM1nu : UTAH llatTA 
04 :20 : 19 Q2/ 18/97 
04 : Sl : '-O QU18197 
IE' 04 : 58: 1.ll 02 / 18/ 97 
PEHETllCJllETUllJNU:ll : 1l-<Ml1 AOV.+JIClHG CONTACT AHGU : 1l0. 0 d9Q 
PENUllOl'IETU ((INSTAllT: 10. 79 •I. I P' IECEOlHG COl'ITACT AHGU : 1l0.0 Mg 
'EMETJIOltETU \IUGHT: 68. 0736 g "UCUIT SUllFACE TENSION : 485 . 0 ityn/ e-
STElt VOUME : 0 . 4120 111.. PIEllCUllY DENSITY : 1l . SllS g / ..._ 
11.Ul!U' KOO ,llESSUllE : 4.68CX> pai 
'EHETltOltfTH YOL.UflE : l . SMS -.. 
SNU'U llEIGHT: 
LOW,lESSUltE : 
1tncu11r ftLLIHG "tusuu: a.sass pa i• 
LAST LCN l'llESSUltE l'OIMT : 25 . 4901 psh 
HIGH "IESSUllE: 
1'1.JHTYPE : AUTOftATIC 
1'1.14 llEntOO : EQUIL18AATEO 
EQUlllBlt.l.TIOH r:11E : 10 uecnd• 
_.. • ..- IHTlt\JSlOH OATA SUNUllY 
TOTAL l MTlt\JSlOfl \IOLl.lltE • 0 . ]352 -.. l g 
TOTAL l'OllE .U:U. • ZB.67'0 1<1-• / g 
ltEOlAM P'OflE 01.lllETElt (YOLUllEJ • 0 . 041l i • 
llEO lAN l'OllE OlAllETElt ( .U:(A) • 0.0411 JI• 
AVfltAGE l'OllE OlAllETElt ( 4V/ A) • O.Ot.65 JI• 
flUU( OEHStTY • 1 . 0127 g / 9l 
A,,AAEHT (~LfT.t.U O~.HSlTY • l.53l0 g/91. 
~SITY• 33.94% 
STD! VOt.t.lltE useo • 33 :i: 
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0. '°36 g 
Drug Load: 30.0 % w/w, Spheronization Time: 20.0 minutes, Run# 3 
POllESllEll 9320 '12.07 
SAM,LfDlllECTORY/NU .. 8£11 : DATA1 /S4 
0'ERATOll : 11'.ETAH llEHTA L' Qt, : 20 :1 9 02118/'17 
S.Ull'l.E IO; 3CJX20,. ; f'29dUK) H, OS : S9 : ]1 02/ 18 / 97 
SU81UHER : KETA.11 llEHTA RE' OS : S9 : ]1 02/1 11 / 97 
'fHETllOf!ETEll /lllllt8EJI; 13-0241 AOVAHCIHG COMTACT AHGLE : 130.0 de\) 
'fMETKlf!ETEll COMSfA.llT: 10. 79 .. lip, ltECEOING CONTACT Af!IGU : 130 . 0 d.g 
'EIOETllOf!ETEll \!EIGHT : 68.6578 'ii llEllCUllT SUUACE TVISlo.I: 48S .0 ayn/c.• 
STEl'I VOLUftE: 0.4120 Ill ,.EllCUltY DENSITY: 13 .5)35 g / lll 
PIAXll'Ul'I HE.AO PUSSURE : 4 . 68(1) p 1 i SAl'l'Lf VElGHT: 0 . '°22 9 
PEHETROPIETER VOLUllE; l .5443 Ill SAl'IPLE+'E'"'Hi; WEIGHT : 110 .9184 'ii 
LOW PltESSUllE : 
MUCUAY FILLING ,,IESSUAE : a.sass p• i • 
U.ST LOW PRESSURE l'OIHT ; 25 . 4901 p1i • 
HIGHPRESSUllE ; 
ltl.llTY": : 
~UH llEThOO : 




TO TAL tNTRIJSIC»I VOl.Ul'!E • 0.3263 lll / g 
TOTAL l'OlE AllEA • l7 .170 aq-• /g 
"ED!AH l'OllE OIAJIETU ('IOt.UflE> • 0.0480 11• 
llED l A.11 '°41£ OUJIETER CAlEAJ • 0 .045] 11• 
AVEIUGE P'O«E OIAllETU (4V/Al • 0 .04«> 11• 
9UUC. D~SITl • 0 .8911 g/..._ 
Al'l'Alt [HT (SKfUTALl DEHSlTY • 1 .2S64 ;/..._ 
l'OltOSlTY • 29.07 1 
STEll\IOLl.1't[USEO• 321 
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Drug Load: 40.0 % w/w, Spheronization Time: 2.0 minutes, Run# l 
POllESIZEll 9320 V2.07 
SA"PLE OIRECTOl:T / NUfl8Elt : OATA1 155 
OPEl\ATOll : KETAH llEHTA 
S.u!Plfl0 : @2•in2~1 
SUEll!lTTU: UTAH llEHTA 
l'EHETllOPIETEl NUfl8U: 13--0131 
PENETllOPIETU COHSTAHT: 10 . 19 •L/ pf 
PENETllOltETU WEIGHT : 67 .9958 g 
STEii \'OlUflf; 0 . 4120 Ill. 
IV.X{PU'I HOO PRESSURE : 4 .6e00 pi i 
PEHETllOltETElt YOLUflE : ] . sass el. 
LOW PRESSURE : 
00 : 44 : 16 02 / 19/97 
01 :2J :OJ 02 / 19tn 
11£1' 01 : 23 :04 02/ 19/97 
AOY.u!CIHG CONTACT AHGLE : 130.0 c!Of9 
tECEOIHG CONTACT Al«ilE : 130 . 0 °"9 
llEllCUIY SUllfACE TUISlOft : 435 . 0 dyn/ea 
.llEltCUllYOENSlTY : 1l . SllS9/ 11L 
SAAPLE WEIGHT : 0 . 4011 g 
S.utl'lf•l'EH+ltg WEIGHT : 111.)61.a g 
llUC\JIY '1LLIHG PllESSUAf: O.S30tl p1i a 
LAST ll"" PllESSUllE l"OIHT : 25 . ~]J.4 p1 i a 
Hl<il'l"llESSVllE: 
ltt.INTil'E : AUTOAAT1C 
ltUN 11.ETHOO: 
EQIJILIBltATJOH TUIE ; 10 Heond1 
.,../ INTRUSION OAU. S.UPlf\AllT 
TOTAL lHTlt\JSIOH VQllJfllf " 0 . 3713 .t./ g 
TOTAL il'Olt f .UU • 25 .80' sq-a/ 9 
llEDIAH l'Oll:E OUJtETElt (VOLi.ME> • 0.(l191.9 • • 
llEOI.u4 l'Oll:E OJAAETU (AllU) ., O . Ol64 11• 
A\IU.AGE l'OAE 01.u!ETEll ( 4V/A) • 0 .0586 11• 
auu: JEHStTY • 0 . 9716 g/9l 
... ,,AllEIH (SKELETAL) OEMSlTY • 1.SlSO g/9l 
POROSITY • 36 . 71 t 
STEii VOlUlk USED• l7 % 
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Drug Load: 40.0 % w/ w, Spheronization Time: 2.0 minutes Run# 2 
l'OUS!Hll 9320 \12 .07 
SAllPLE OUECTOIY/ JrCJf'l8Ell : 156 
O'UATOI : (fTIJll llEMTA 00: 44 : 16 02/ 19/ 97 
SAllPU 10 : q..2• in2~2 HP 03 :00 : 44 02119/ 97 
SU81HTTU : UT.lit llEHTA lllEP OJ :00 : 4S 02119/ 97 
PEJIETllOflETU ~II; 13--0241 AOVAH<U«:i CONTACT ANGLE : 130.0 d~ 
PEllETIOIETU: COHSTNIT: 10 . 7'1 11L/p' llECEDIN6 CONTACT AHGLE : 130 . 0 d<t!J 
PEJIETltOflETU \/ElGtH : 68.7471 9 llUCUllY SUllfACE TUISIOH : ~s . o lfyfl / U 
STUI VOLUMt: : 0 . 4120 ._ llUCUllT OUISITY ; 13 . SJ)S g/.i_. 
IU.J:llUI llU.O "llESSUllE : 4 . 6800 psi S-'"'1.f llEIGMT : 0 . 40:19 g 
PEHETM)flfTU VOLUME : l . 5443 -.. SAllPLE•PEM+iti llElGMT : 110 . TJT] 9 
LOW PUSSUltE : 
llUCUll:T FILLI NG PllESSUllE: 0 . 5JOl5 p• i • 
UST LOW PUSSUllE l'OlllT ; 2S . Sll4 psi • 
Hl!OHPRESSUU : 
lt!JNTYl'E : 
avH ltETl400 : 




TOTAL lHTtuSIOH 'IOLLllE • 0.31'91 -..19 
TOTAL '°41:£ AlEA • 26.0!IO sq-e/g 
llEDIAH l'OllE OIAllETH CVl"IU.lltE> • 0.0952 11 • 
llEOlAH '°*E OIAllETH ( AllE.O • 0.0385 JI• 
AVERAGE l'OllE OJAl'IETIElt (4¥/A) • 0.0S81 JI• 
BUU: OEMSlTY • 0.8S07 g / 9L 
-"'UUfT CSKfLfTAU DENSlTY • 1 . 2557 g/9L 
l'OltOSlT'Y • 32.25 X 
STEJI V'OUMc:: USED • r7 X 
225 
Drug Load: 40.0 % w/w, Soheronization Time: 2.0 minutes. Run# 3 
l'OlESUU 9320 '12 .07 
SAll,Lf OUECTOIU' / HUMU : 
0'EA.lTOlt : C.etan ,..,..u 
SAl\l'U ID: 4CT.t2-.2•1nltU"'3 
SIJBIH nU: (.et8"1\eflU 
"' 
P(HETllOltHtlt 111..11180 : 1]-01]1 
PVIETllOflUU CCNST.un : 10 . 79 JL/ pr 
PEHETIKIMETU t.IElGHT : 68 .917& 9 
U' OO : l'il : 33 0212.Co/97 
"' 01 : 16:09 f12f2"97 
REP01 : 16 : 1002./ 21.ffl 
.t.0\1.f.llCIHG CONTACT AHGLE : 1l0 . 0 ffg 
RECEOIHG CONTACT .......,LE : 130 .0 ~ 
llEltCUllT SIJl:FACE TVISI OM : 485 . 0 dyr!. / u 
STE.II YOl.Ul'IE : 0 . 4120 ... llUCUU OOISITY : 13 . UlS 9 / 1111.. 
!V.XlU H[AO PltESSUllf ; 4 . 6800 psi 
PEHETllCMETU YOLUllE : ] • 5&55 111L. 
s.utl'lf llElGKT : 0 . 4029 9 
SAl\Plf•POf<-MQ llEIGHT : 112 . 2T'il0 9 
LOW PllESSUllE : 
llUCUll:Y 'ILLJHG PllESSUllE : 0.8&6] p1 i • 
UST LOW PltESSUU "'°lllT : 25 . 7454 p1 i1 
HlGlt"IESSUltf : 
ltUH TYPE : 




l/HltUS !OH DA TA SVflfl.UY 
TOTAL ! KTl:USIOH YOLUl'lf • 0 . 1736 lllL. / 9 
TOTAL l'Olf AltU • lS . 762 ~-./9 
llfDIAH P'Oltf 01.IJIETEI ( YOLUl'lU • 0 . 09JJ 11• 
l'lfOIAM l'Olf OUJIETEI ( .U:U l • 0.0361 J• 
.\VU.AGE ~f OIAllETU ( 4V/A ) " 0 .0580 1• 
lllJUC. OEHStTY • 0 .9723 9f lll 
""AAEHT (SKELETAL> OEMSITY • 1.5270 9 / .._ 
l'OtlOSITY • 36 . ]] t 
STEJll\'Ol:.ltEUSEO• 37% 
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( Drug Load: 40.0 % wlw. Spheronization Time: 10.0 minutes. Run# 1 
'°RESIZEll 'H20 V2.07 
S.llt,LE Ol llECTOll'r/NUl'l8U:: 0ATA1 / S.S 
MfllATOll: ic.tan ~U 
SAll,LE 10: lo0%2• 10.1nlt\JIK.f1 
SUMlTTEll : !Catan lleflU 
00 : ]9 : ]] 02124/ 97 
H' 01 : S0 :09 r:R.12,.4191 
RE' 02 : lS :47 02124197 
'EHETl!OftETfll Ht.NU : 13--0241 
'EHETJIONETfll COHSTAllT; 10 . 1'9 iL / p' 
'EHET"°"ETU 11El<>HT : 67 . 7971 g 
ADYIJICIHG CONTACT AICilf : 130 .0 4ltQ 
IUCEOlHG CONTACT AHGU : 130.0 d.; 
llfllCUllY SUllfACE TEMSlOH : "85 . 0 dy"'c• 
STE.II VOllllE : 0 . 4120 Ill.. 11.UCUllY DEHSlTY : 1l . Sll5 g / W.. 
"4.lllllJfl HE.lO ,llESSUllE : 4 . 68QJ pi t 
'fNE~ETU VOlUflE: l . 544] ml. 
LOW"tESSUllE : 
ltUCU IY llLLIHG PllUSUllE : 0 . M6J p1 i a 
U.ST LOW "l:fSSUllE il'OUtT : 2' . 7454. p1 i a 
HlCiHl"llESSUlf ; 
l:UNTYl'E ; AUTOP\ATI C 
in.N 11£'0400 : fQJILtlSUTU 
fQIJILllU. TIOH TlllE : 10 sec:oncl1 
TOTAL JllT~StON YOUME • 0.]]9;? .i.t ; 
TOT.ll. l'OllE UU. • 2S . 045 tq-a / g 
llEDUH l'OllE DUJIITTI (VCUJftE) • 0 . 068S JI• 
ltEDI Al'I l'Ol:E 01.utETU OAE.O • 0.0452 JI• 
AYEIUGE il'OllE OUJUTU ( 4V / 0 • 0.0542 11• 
lllJlX nOISITY • 0 .&&61 9/ 9l. 
.t.1',UEJfT ( S«'.£L£T.ll) OVfSITY • 1.Z661 ia / 91.. 
l'OAOSITY• l0 .051: 
STt:ll 'IOll.ll'IE USEO • ]3 I 
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Drug Load: 40.0 % w/w. Spheronization Time: 10.0 minutes. Run# 2 
"°ll:ESllU 9320 V2 .07 
S.tJ!PLE OlAECTOltT/ Nl.1"8.U : OAU.l / 61 
Of'ElATOll: : Ket*" ltti'tt• 
SAllPLE tO : i.ou- 10.i"a!.lllZ 
SU9111TTU : ICet.,,NetlU 
LI' 05 : 18 : 4902. / 24197 
HP OS :SS : S9 02. / 24/ 97 
•EP 05 :56 :00 02./24/97 
PEMIETAOftETElt MUNEI : tl~ll 
PENUAOMETD COHSTAMT: 10 . 79 •l/ pF 
PEH£TIKl'l£TU llEI<iHT: 67 . 8911 Q 
AO'OJICIHG COfllTACT A'!GLE : ll0. 0 d"Q 
lEUOING CONTACT oUIGU : ll0.0 deg 
llEJICUllY SIJIHACE TUISlOH : 485 . 0 dyn/u 
STEii YCUllE : 0 . 4120 9l.. 
l'IUlNJllHEAOPllfSSUIE : 4 . 6llOOp1i 
PEHEUOl'IETU VOl.LlllE : l .Saas .... 
LOllPllESSIJIE : 
llUCUIY OOSlTY: 
SAJlll'LE l/UGHT : 
llfRCUllY fllllMG "IESSU•E : 0 . 6190 p1 i1 
LAST LOW PftfSSUllE l'OINT : 25 . 6197 pa i l 
HlGH PltfSSUllE : 
NII TYPE : AUTOf'IATIC 
fQUILllUATlOH TlllE : 11) H«W'lds 
,.. • .,. INTltUStOH OAU. SUM .. O:T 
TOTAL INTlllJSlOH YOU#IE • 0 . 3462 -..19 
1l. 5ll5g/ .. 
O.t.0019 
TOU.L l'Oi!E .U£A • 26 . 27'0 M1-1/9 
llEDIAH l'OllE OIAllETU (VOl.Uf!E) • 0 .06J9 11• 
AED1AM ~E OIAllETU OIU.) • 0 .0453 111 
AVUAGE l'OitE 01.METU (4V/ A) • 0 . 0527 11• 
llJL( DEHSITT • 0 .9718 QI ._ 
A,,UfHT (SKELETAL.) OEICStTY • 1 . "644 ;I._ 
'<>f!OstTY • Il . 64 t 
STEllYOUlllEUSEO• 341 
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Drug Load: 40.0 % w/w, Spheronization Time: 10.0 minutes. Run # 3 
~ESIZEi 9320 V2 .07 
SMPLEOlllECTOltTI NUl't!IU : OAU.1 I~ 
Of'EllATOfl:!Ceun~u Ll' OS :15:49 02/24/ 97 
HI" 06 :31 :09 02.124197 
llEI" 10: 1ii! :20 02124/ 97 
SMPLE IO ; l,Q%.2-10. ;111WN'] 
SUBIUTTU : Ketan ll~U 
.lOVMClHG COHTACT AHGL.f : 130 . 0 d.g 
PEHETllOf!ETU COHSTAHT ; 10 . 79 11L/ p, IECEOIMG CONTACT ANGLE : 130.0 d.g 
l"UIETllOllETU llUIOHT : 68 . 9310 !1 llUCUIY SIJllfACE TEHSIOH : t.aS.O dyn / o:• 
0 . 4120 111.. llUC1JltY DENSITY : 13 . 53]5 !1/9l 
IV.XllUI HE.AO PRESSOllE ; 4 . 6800 p1 ; SAMl't.E I/EIGHT : 0.'0X> g 
l"EHETllOllETU 't'OLLME : 3 . 544] Ill.. SAAl"U•l"Vt+ttg llEIGHT ; 111 . 11'0l5 g 
LOW PIESSUIE : 
llEltCUllV flllif'IG PllESSlJltE : 0 . 6190 p1ie 






EQUlllBAATIOfll TUtE : 10 1econd1 
IHTRUSIOICOATASUl!MltY 
TOTAL llilfltUSION YOlUflE • 0 . 1414 .Ug 
TOTAL l'OflE AUA • lS . 649 1<1-•/ g 
llED ! AM l'O•E OIAMETU ('IOLU!fl • 0 . 0682 ,_ 
llEOIAH l'OltE OlA.ltETU UREA) • 0 . 0453 11• 
AVE!WiE l'OIE 01.\lllETU (411/A) • 0.0532 118 
9Ut.X OU4SITY • O.Ml5 gt.i.. 
Af',.UEIH (Sl(fLETAL) OfHSlT'J • 1.2651 gt .._ 
30 . 161 
ST'E,.V'OLUftfU5fO• lll 
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Drug Load: 40.0 % wlw. Spheronization Time: 20.0 minutes. Run# I 
l"ORUIZEI 9320 V2.07 
SAltPU OUECTOlt'r/NUMU : OAT.ll / fl] 
°"U .. UOlt : IC•tan ill«'IU 00:02 :0] 02/25197 
SAlll"LE 10 : "°12-.20mo inltl.N1 HI" 00: 49 :07 02/ 2j / 97 
SUMITIU : Ket81'1 !Wit• llEP 00: 49 :09 02. / l51'7 
'EllETllOMTU NUMU: U~54 AOVAHCIHG CONTACT ANGLE : 130 .0 cl..; 
l"EMETllONETO ct*STAKT: 10.19 n,Jpl lECUIHG CONTACT ANGLE : 130 . 0 d"'i1 
'EllETllOflETtll llflGHT: 61 . 99\l:l g "EltCUltT SUllfACE TENSION : "5$ . 0 Jto/fl/c• 
STVI \IOl..Ultt: : 0 . 4120 ._ llEll:CUllY OUISITY : 13 . Sns g/ .. 
IUJ:llUt HEAD "ESSUIE : 4 . 61!CO ps i 
l"EJrjfT.otlETElt \IOl.LME : 3 . 5541 .i. 
lOlill"lltESSUllE ; 
MEll:CUltY FILLING ,.ESME: 0 . 6073 ps i a 
L..UT ~ l"ltfSSllllE l'OINT : 2S . 7l27 psb 
HIGH "IESSUllE : 
11:1.M NETltOO : 
AUTOIUTIC 
ECIUILIHATt:D 
10 Heondl EQIJILlllAATlOH TlME : 
TOTAL JNTlt\JSIOH 'IOLUl'IE • 0 . 3615 111../ g 
TOTAl l'OllE .UU • 21 . 265 ..:,-a/ g 
llEDIAH l'OllE 01All£TEll: (YQ.J..91£) • o.osn ,,. 
llEDIAfll l'Ot!E OUl'IETEil (.lllfA) • 0 . 0453 ¥ • 
AVOAGE l'OllE OIAllET£1t (4'U.l) • 0 . 0S12 11• 
euu:: OEMSITY • 0 . 866' g/ lll. 
.UOl'.UENT ( SU:UTAL) OVtSIT'I' • , . 2614 g / 111. 
l'O'tOSlTY • 31 . 32 :C 
SfVIYOU.ll'IEUSEO• lSI 
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Drug Load: 40.0 % wlw. Spheronization Time: 20.0 minutes Run # 2 
l'OllESIZU 9320 V2 .07 'AGE 1 
S.vlPLE Ol llECTOC'f/HUll!IU : OAT.1.1 / 64 
O'EU.Tott : !Cetan llehU 
S>JIPL£ 10 : i.o:t:2..Z0.1t11tl!M12 
SUl!l\I TT Ell : Ko:un lleftt• 
00 :02 :03 02/25 / 97 
01 :25 :12 02/25 /97 
REP OZ : JJ : t.2 0212'5/97 
.OVAHCUIG CONTACT AllGU: : 130.0 d91jl 
'EHIETltOftETElt COHst.un: 10. 79 /IL/ pf IECEOUIG CCfllTAC:T AIGU : 130.0 ~ 
PEMETIIOl'tETElt VUGHT : 68 . 4436 g llUIC\ll'f SUUACIE TENSIOft : 485 . 0 tlyn / c• 
STEii VOUME ; 0 . 4120 9'. llEll:CUllY DEllSITY : 1].5]JS g/111. 
IWtl""'" HEAD ,llESSUllE : 4 .6800 p1 i SM'U llEIGHT: 0 . 4005 g 
'ENETllOl'IETU \IOLL.111£ : J . 699'1 ._ SMM..E•'~ VUGHT : 112 . 6359 g 
LOW 'l:ESSUllE: 
llEltCUAT '1LLIH6 PlllESSUlllE : 0 . 6073 psi• 
UST LOii ,llESSUU l'Ol llT: 25 . 7l27 p1ie 
HIGH PllESSUU : 
NH llETHOO : 
AUTOfU.TIC 
EClllLIWTt:D 
10 •e«ind• EQIJlLIWTIOH TUtE : 
IHTllUSICH D"TA Sl.IMAAT 
TOTAL umtustON YOU.IP!£ • 0. 3645 111./ g 
TOTAL l'Ol:E AltE.& • 29.09lfl aq-• / g 
llEDUJI il'OAE OIJJIETEll CYOU#!El • 0 .0574 ,_ 
llEDIM l'04lE DIAl'IETEll '.tJtU.) • 0 . 0452 lf9 
AVEAAGE IJOlE 01.YIETU (4V/A) • 0 .050'! p 
llUl.l'. OOISITY • 0 .86'5 g/ 9L 
.t.P,,.llVIT CSKILETAU OVtSlTl' • 1 . 2621 g/ ._ 
l'OllOSlTl'• 31.51 l 
STVt'tOLl"'£US£0 • 351 
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Drug Load: 40.0 % w/w, Spheronization Time: 20.0 minutes, Run# 3 
~ESIZU 9320 VZ .07 
SAl"LE 0111E CTCM11' / Nl,"9U : 0ATA1 / 65 
O,Elt.UOll. : l(eten IMt'IU 
SAll,LE 10 : t.0%2-20a1nflUHl] 0 
SU9'11TTElt ; l:•tWll'l<tf'tU 
L' OJ : io] ; 43 02.f'ZS / 97 
04 : 11! : 43 02. / lS / 97 
U' 04 :1 5 :49 OUZS/97 
AOVAHClHG COHTACT .oc;U : 1l0 . 0 deg 
'EllETllOfllETU COHSTAHT: 10.1'9 11L/pf llECUUG COMTACT .t.llGU : no.o deog 
'EHETIOl'IETH I/EIGHT : 67.tl174 g llEUUIT SUll,ACE TEHSIOfl : c.as .o cfyfo / c• 
STEtl 'IOLLlltE : 0 . 4120 ._ llEICUllY DENSI TY : 13 . 5]]5 9 / 91.. 
MlUILllt HUD 'llESSUltE : 4 . 6800 p.1 
'EllETIOl'lffU 'IOLUltE : ] . seas .... 
S'-"'U 11£1GHT: 
LOW "l:ESSUll:E : 
llflcutlY flllUG 'llESSUllE : 0 . 7903 p• i • 
U.STLOW'llE5SUllEP'OIMT; 2' . 519'1ps i 1 
HlGH 'llESSUAE : 
llUH TYPE: AUTOMTIC 
ltUN llETMOO : EOJIL181UT£D 
EQIJlLlllU.TlOH TlllE ; 10 Heo:"ldl 
TOTAL IHTltUSIOH VOi.Uit£ • 0 . ] 578 111.. / 9 
fOT4L l'OIE UfA • 28 . lSI! ~-1/9 
llEDUll PORE 01.tJIETElt (VOl..Ultf) • 0 .0580 1 • 
llEOlAH ~E OlAllETEll ( .U:EA) • 0.045] 11• 
.I.VU.AGE l'OllE ldAltETEll (4V/.l) • O. OS07 11• 
9UlJC O!MSlTY • 0 . 97JS 9191. 
... ,,uor CSICEUTAL) 0£.ltSITY. 1 .49399/ 111.. 
l'OIOSITY • l4 .8J : 
STEii YOt.l.ME USEO • 35 X 
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O. l.002 g 
Appendix 3b 
Determination of porosity parameters by mercury intrusion porosimetry. Pellets 
formulated with different granulation water levels. 
,... ..... · 
Granulation water level: 60 % w/w Run# l 
"°llfSlZER 9120 V2 .07 
SAl!,U OIRECTOUll•.MU : OATA1 n3 
Ol"EIUiTOll: !C:tt«'I ~t• Lt 06 : 21 : l0 OJ/ 04/ '17 
10U0.1n6Q:~urlll.Ml1 Kt 09 : 0 :04 03/04197 
SUBIUnU: htan fllettta UP 09 : "3 :05 Q] / 04/ 97 
,EHET'°"ETU 1ueu: ll--OeS4 .t.OVAHC1NG CONTACT NIGU : 1l0.0 deg 
PEMUltOl'tHU COMSTAAT : 10. 79 #Llpf ltfCHIMG COlfTACT AHliU : 130. 0 d<IQ 
PEHETIKlflETU V£1GHT : 65 . 5228 'ii llUC\ltT StMUCE TVISION : 485 .0 ~I~ 
STEii 't'CUMf : 0 . 4120 ._ llUC\MT OEJISITY: 13 . SlJS 9 / 0ll. 
l'IAlUUI HEAD PlUSURf : 4 . 68CC p•i SANU WEHiHT: 0 . 4.024 'ii 
PEMETl!Of!fTU VOLL.It£ : }.5541 11t. SM,LE+'Vt+tl; WEIGHT : 111 . lOll.2 9 
LOW "tESWRf : 
l'IUCVlllT 'ILLIH& 'IESSUtl:f ; 1 • .0SO p1h 
UST LOW PltESSUlE "'3JlllT : lS . 6.'41 p•i• 
IUM llfTHOO : 




JMUUSIOM OATA SJ.M,U:T 
TOTAL IHTllUSIOH YOltMf • 0.2643 Oll. / 9 
TOTAi. f"Ollf AIU. • 24.&30 tq-e/ g 
.ltfOIAM f"Ollf OlMETH (YCUJll(} • 0 . 0453 ,w 
"EDIA.N l'OltE DlMETU (Al:E.l) • 0 .045) ,_ 
AVUAGE l'OltE DWlfTH (4V/A) • 0.0Q6 J1t1 
MJC OatSlTY • 0.95Z7 9/ -. 
A"UEKT CSK.ELETAL) 0£HSlTY • 1 . Z7ll g / ._ 
l'OflOSITY • 2'.18 l 
STD! \IOU.If!( USED• 26 X 
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Granulation water level: 60 % w/w Run# 2 
~ESUU 9l20 Vi!: . 07 
S.Ul'lf OlltECTOll:Yll•.llBU: D.l.TA1 m 
OfUATOI: : Kst.n Mf\U 01 :09 :06 03/05197 
SMl'lE 10 : 10X.ZO.i"6/J'Xw•t•rtuMl2 01 : 4S:44 03/05/"fl 
si.eunu: (•un Mhu AEP' 01:45;"' CD/05197 
POIETltOl'IETU Nl.'"8U : 1l--Oe54 ADVAHClNG CC»CTACT AHGLE : 130.0 ~ 
l'ENETllOl'IETU CONSTAHT: 10. 79 11Upf llECEDING CONTACT AllGLf: 130.0 ~ 
l'OIETltOl'IETU WEIGHT: 67.52S9 9 ltt:ltCUltY WltfACE TVISION: 415.0 dyn/c. 
STV. 't'Ol.IAIE: 0.4120 a. ltt:JICUllY DOISITY : 1l . SSJi5 g/.._ 
MXIIUI MEAD "l:ESSUll:E : 4 .6«0 p• i SUI"-! WEIGHT: 0 . 4007 Q 
l'VltTllOl'IETU YOlt.11'1.E : 3.5541 a. S.UrLE+l'EH+HQ WEIGHT: 110.6407 i 
LOW Pll:ESSUll.E : 
"UCUll:T' flUJHG "l:ESSUllE : 0 . 1'9M ~i • 







TOTAL IJllTltUUCfo YCU.l!E • 0.2619 -..!; 
TOTAL l'OltE AJIEl • 24. 981 sq ..... /; 
llf01AM l'OllE 01Alt£TU CYCU.l!E> • 0.0467 ,. 
llfDlA.K !'O«E OUllETU <AllEA) • 0.ID81 119 
AVUAGE l'Oltf OlAllETEI (4V/l) • 0.()1.19 ,n 
llUl.K DENSITY • 0. 9Sl8 g/111.. 
...,., ... llEHT ( SIC!.LET.l.L) DEHSlTY • , .2ns ,, .. 
l'O'IOSITY • 24.98 X 
STEJll 't'Oll.llE USED • 25 X 
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Granulation water level: 60 % w/w, Run # 3 
l'OllESUU 9320 V2 .07 
SAA'U OlltfCTOl:Y/ lt..N.Elt : OAT.f.1 / tlJ 
Of>ElATCMll : lt•tan ..tlta 
SAAl"LE ID ; 1at20ll i n60XwterlUllJ 
SUllfllTTElt : Ketan ..nt• 
l"atETllOf!ETH HlNH: l3..Qll68 
l"fHETllOf!ETIEI CONST MT : 10. 79 11L/pf 
l"OtETIICflETU llUGKT : 61. 92S9 g 
STE.II YOltME : 0.4120 .._ 
IU.XUUI HW l'ltlESSU1tE: 4 . 68((1 p• i 
PfMETIOMETU YOU.llE : " ].6991 ._ 
l.OW l"l:ESSIJtf : 
01 :09 :06 Ql/05197 
HI" 02:22:11 «1/05 /97 
ltEI" 02 : 22 :14 03/0S /97 
AOVAHCING C'OfllUCT AHIM..f : no.a d<IQ 
IECEOIM& COHTACT NtCOLE : no .a ... 
MEltCUltY SUl:fACE TDISIOH : 485 . 0 d'fn / c. 
ltf:ll:CUllY OOISITY : 1l . 5D5 g/ li.. 
SNIL'U I/EIGHT: 0.4003 'ii 
WU'U+l"Elf++t; 11£1GKT ; 11l.1'S79 g 
ltEllCUIY flUllG l'llESSUllE : O: 7988 ~11 
LAST LOW l"ltESSUltE l'OUfT : 25 . 6147 i>ai• 
HliH MIESSUlE : 
ltUJllTYPE : 
lltUM .llEn«:>O : 
EQJILIUATlOH TDIE : 
AUTOMTtC 
10 1.eondl 
IMTltUSlON OATA SlfftAllY 
TOTAl. l.llTll\ISIOf4 'tOt..tM£ • 0.2665 lllfg 
TOTAL il'OIE .UU • lS.547 tq-ti/ g 
MEOLUI l"OlE OIMETEJI : 'i'OllMU • 0.0476 ,,_ 
.llEDlM l'OllE DIAltETElt ( .lllf.A). o.mro.,. 
AVERAGf: P'OlE DINIETU C4V/A) • 0.0417 ,,. 
llUU( HMSJTY • 0 .9622 g/ lll. 
Al"PAllEMT { SICEUTA.Ll DOfSITY • l.2941 g/ lll. 
P'OllOSlTY • 2S.64 X 
STOI VOUME USED • 26 X 
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Granulation water level: 65 % wlw. Run# I 
l"OltESIIU 9120 Y2 .07 
SMPU OUECTOIYl lllNEI : OATAl /15 
ort:ltATOlll : ic.un "-"'t• 
SMl'U 1D : UJX20ll t n6SI-terlt\N1 
sa..llTID: ICU., "-"t• 
"'"' 
v Oll :1l :56 03/03/97 
°' :04 : 16 03/04197 
lEI' 04:05 : 31 03/04197 
'lM:Till:lMTfl IU'8U : 1l-<JIS68 
'fNETICflfffl CONST Alff : 10 . 79 •L./pf 
PU9ETIIOM:Ttl llUSHT: 67 . 9196 9 
ADYAHCJNli COKT.lCT AIQ.f : 130. 0 4eQ 
ltfC(OINli CDWTACT AIGU. : 130. 0 deQ 
MICUlY SUlfACf TtlfSIOll ; '-IS . 0 tiyfttlc. 
STDI WOl.Llltf: 0 . 4120 .... llfltCUllYDOIUn: 1l . 5DS9/._ 
MIUUI HEAD l'IESSUllE : 4 . 6800 ps i 
l'fMTll<ltETEI YCIU.9IE : l . 6991 Ill. 
SNll'U llUGHT: 0 ,""10 g 
S.U"Lf+I'~ Vf:tGHT: 112 . 0096 9 
LOW l'tESSllltE : 
llEla.T 'ILL.IN& ,.ESSUll:E : 0 . 1065 P• I• 




EQIJILIMATIC. flllf : 
EQIJlllUATED 
10 1ecorda 
INTltUSIOlll DATA Sl.MMIT 
TOTAL lMTIIUSJart YOU.ME • 
TOTAL P'OllE .U:O. • 
lff:OIAllll"OltEDlAAETf:l ( 'f'CIU.9!( ) • 
iq;ou.x l"OltE ownu u.u.u • 
.lYEIU6E l'Oltf OJNIETU (4Y/ A) • 
auuc :>SISHY • 
101tOS1n • 







0 . 8536 ,, .. 
1.2.&U ,, .. 




Granulation water level: 65 % w/w Run# 2 
l'OllESUU 9320 V2 .07 
Ulll'LEDIJIECTOllT/~l: OATA1 , n6 
OfEltATOll : Kott., Aef'tt• 09 : 1J : 56 03/03197 
SIJ"lf ID: 10X20ili "65XWl!terltl.N2 HP 04:51 : 31 aJ / 04197 
SUlli'llTTEI : K•t_, """'t• JIEI' 04 : 51:32 03 104/ 97 
'DETl!OflETEt .... eu: 1]-01]1 ADVAltCING COHTACT AHGLE : 130.0 ~ 
l'VIETltOPlffil COflSTAMT: 10.7'9 #l/pf IEC'EOlHG CONTACT AIGLE : 130.0 d4lg 
l'EHETllOflETU llEIGHT : 6& . 1962 g MllCUllY SIJllFACE TENSION : 4M . O flyn / c• 
STEii VOt..lME : 0.4120 a. MICURY DOISITY : 13 . S]JS <;1 / a. 
llAXUU• HEAD l'lfSSUll:E : 4 .6l!IXI psi SAM'1.E WEIGHT : 0 .4015 g 
PDIETJIOftfTU YOU.II.IE : ] . SISS ._ SM'1.E+l'e.++IQ WEIGHT: 1l2 . 0Z19 g 
l.DWl'llESSLlllf : 
llUC\llY 11LLING l'ltfSSUllE : 0 .1"'165 p•l.t 
UST LOW l'llESSl.UIE l'OINT : Z5 . 2189 P•il 
IUGl'i l'IESSIJltE : 
~TYPE : 
EClJILIBllAT JOH TJM: 
EilJ I LISAATEO 
1'JaKCll'lda 
UlntJSICll DATA SIM'UT 
TOTAL UfTllUS lOH YOU.11.E • 0 . J.!SO lllL/g 
TOTAi. l'Oll:E AlEA • 32 . 234 .ci-/ ; 
/If.DIA.IC l'Ol:E OLUIETU ( \IOl.1.11£) • 0 . 0481 ,_ 
llEOIA.11 l"OltE 0 1.tl'IETU ( AIEA ) • 0 . rnit9 ,_ 
AVERAGE l'Ol:E OLUIITTI (4V/ A) • 0.0473 111 
19UUC D£>fSlTY • 0. 9465 9/ a. 
A,,AIOIT CSICil.ETAl) DEXSITY • 1 . 4893 Q/ lll. 
f'OIOSlTY • 36 . 44 l: 
STIR vrou.N: USED • 38 l' 
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Granulation water level: 65 % w/w Run # 3 
POAESIZElt 9320 V2 .07 '4GE 1 
SAll'lf DllECTOCT/ MNEl: DAU.1 m 
Cf'H.lTOlt: JAt.,. ....,,. 
SAll'LE ID: 10120lin6SXwiur....wl 
SIJlllUTIU : Ket., lhtltl 
06 :21 :30 aJ/Olo/97 
07 :01 :01 aJ/04/'77 
ll:EI' 07 :01 :02 aJ/04/V1 
l'OIET~I 11..1•0 : 13--0241 
l'EKETil<l'ETU CCllSTAHT: 10 . 79 11Upf 
l'MTACMTD llUGHT : 68 . 9<&4 9 
.lOV,tJKl,.,; CCWTACT ANGU : 130 .0 O.g 
lECEDIHG COffTACT IJCiU : no.a o.q 
llEltCUltY SUllfACE TOISIC. : 415 .0 fl'fn/ea 
STEM VOUME : 0.4120 .. "'ICUl:T OOISITY: 
s.vtl'U WEIGHT : 
1l . 5DS91-.. 
0. 4003 9 llAJllUI MUO UESME : 4 . 61DJ p1 1 
l'VtETIIOMTtl '+'Ol.l.N : 3.544.l .. SAIU'U•l'Ot+ffl;l llUGHT : 110. 1945 9 
LOW l>USSUll£: 
IH;1cun '1U.1Mi l'ltESSUH : UJ350 p• i• 
LAST LOii nESsuttE l'OllH : 21 . 6.341 peh 
AUTCMTlC 
ltt.llltETMOO : fQJJLIUAftO 
ECUillUAfJCN TUtE : 10 second• 
TOTAL. IMTRUSICll 'l'Ol..Ul'tE • O. J&6J 91..19 
TOTAl ~E .U:U. • 34 . 682 e,q.-e/ 9 
PIEDIAH l'OIE DIN!t:TU (VOLUflE) • 0.0453 _. 
ltt:DJ.AM l'Ollf DlAllETH U.AEA) • 0 .0372 ,_ 
AVEIUiGE l'Otf DWt(TU (4V/A) • 0 .°"'6 ,. 
IUlJc: DOISITT • 0 . 8464 9/ L 
Ul'.U:EMT (SKf:UTAl) OEHSITY • 1 . 2175 9 / ._ 
3.2.691 
STEii YOU.l'!E USED • 38 1 
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Granulation water level: 70 % w/w, Run # I 
Ull".f ' l O:CTOIT f ......eEl : 
Ol'E U TCMI ; ll•t., ..,,ti 
UJVt.£ UI : 10U0.•n.2..it!M1 
~lrTU ; ll•t., .nu 
'0•£Tll011UU•ll.••U : 13-0111 
'01(fltO!t: Ttl CC*ST.Ult : 10 . 1'9 #1./ pf 
'fNfT~TU llf.lGMT : 61 . 6Jl8 1 
STEii VQ.LIU : 0 . ,120 Ill.. 
1'.UlllUltMUO ••USUlt: : 4 .6a1Xip• 1 
't:HUllOIUU VOl.IME : l . 6417 ._ 
LOW ,.fSSUtlf : 
03 :09 : 15 1l/QV96 
04 : 41 : 16 12102 196 
•t:, 04 : 41: 17 12/02/ 96 
AO'WAllCllG CORT.I. CT .uGU : 130. 0 ~ 
O:CHUG tcllTlCT .wil..f : 130.0 deo; 
llUCUIT SOllUC! TOSIC* : ""' .0 ~/ca 
lttl(IJIT HflSJTY; 13 . 541] gl -. 
s.t.#UWl l lOMT: O. liQl59 
SAMt.f•"~ lll lGMT : l11 . 1144 9 
llUCUIT 'IU.1111& 'ltUSUl( : 0 . 6790 ps 1• 
L.AST lOW•ffSSIJlll'OUtT : 2' . ~p•1 • 
"IGM ,.USUlf : 
It.MM! : 
~Mn«»: 




TOTAl IKTIIUS1C*~• 0 ."°"'-.19 
TOTAL. JOltt: .UU • 11 . Ml ~/9 
"'Ol.&ill IOI( OUMTH C~J • 0.0il.a'I ,. 
IW:OlA.11 ll'Oll:( OL&Mnl ( .UU.l • 0 .0426 ,_ 
4VEIMK li'Oll:f D!Mfl'tl 14V/AJ • 0.°"24 ,. 
au Ot>ISIT'r • O. UAO 91.._ 
A"HVIT ( SK!lfTAl) OOISITY • 1 . 2664 9 / 111. 
l'OIOSITY • 34 . 14 l 
sm ..o.J.N uso • '° i 
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Granulation water level: 70 % w/w, Run# 2 
"OIUIUI 9120 '12 . 0'7 .... ' 
l.UWLf OllfCTOIY/ll,,l•U : OAU.1 /~ 
QllU.Uot : tetM Wlt1 06 : 49 : 22 1i2/ QZ/96 
SAll'LI to: 1C:U0. 1~ a1' : JS : 44 12/Cl/ '6 
W.ITTll : tnmn ..t\U ~f' 09 : 19 :21 12/Ql/ 96 
'EMlr.:lMTtl lll.llRI : 1]...Q1]1 •O'+'.ut<:U .. CClllU.CT .UCLf : 1](1 . 0 dilllJ 
'fMfTllClllTll (QlllSTUIT : 10 . 1'9 •L/ pl llCHIMi CC-TACT Allil.I : no.o 0., 
'OllT...-Tll llfllHT : 67 . 6SSO t 1tUCUIT 1Ul'o\Cl l'VISlCM : 4e . O ~lc. 
UP Y'CUlll : 0 . 4120 ._ ..rtC\.lllY OQl1tn : 1] . S41] 9/ .. 
IU.Uiut MUI 'llU"-'11 : 4.6im0 1M1 UMU '1(18'1' : 0 . liO'IO 9 
'fJIET..-rEI 'l'OIJ,lll : J . 6417 ._ SAMU•'~ Wl lGHT : 110. M76 'ii 
UM "1S3llll : 
.._tc\WI' 'ILlt• fl'US11Af : 0 . ml p.1 \1 
l.lST LOii nt:SSUll POINT : a . ,,,1 fl'l i • 
f<IJILIMU IClll TIN : 
?OU.I.. llll'IUSIClll 'l'OUM • 0 . 4059 &It 
TOTAL. ~ AllA • )& . 266 ..-1; 
llOlNI l'Otf. DIArlllnl C\ICUlll l • O, OilolJ tf9 
lllDIM l'Qtt: OLUll'TH ( Alf.A) • O. or.26 ,_ 
AvtlAIOI l'Otf. IHAMl'tl UV/ A) • 0 .°'24 ,,. 
M.C OOSlT'T • 0 . 077 g/ ._ 
AHU.DfT ( SICIU'TA&.l teal TY • 1 .~ t / ._ 
~ITY• '4 .011 
STIR ¥QlJft U.I • ~ I 
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Granulation water level: 70 % w/w, Run# 3 
SAlll'L( O(l(C~Y /11t,1•U : 0AU1 130 
~'1tn~ : kn.,. _..u 
10t2Qlo 1"2.-t\llJ 
SUBl'll THI : uun _..u 
06 : 49 ; Z2 12102/ 96 
ltf' 10: (1): ,S 1ZIQZ/<Jr6 
If, 10 : (1) : '6 1Z/0Z f 96 
.l.D'tNtCIMli CCllUCT ""5l..l : ll0.0 44f 
''"(T'°""T(I CClllSf.l.llT : 10 . 7" IL / pl ucuu .. CClffACT .u.i;u: ; no.a ... 
'fJill~U VUGMT : 69 . 1096 I "UC\lllT SUlfACI fDl11Clfll : "-' · O ~/(JJ 
1TU•'fOU.ltl : 0 . 4120 .. "flCVIT OOtUTY : 1l . S4 1] 91-.. 
"-Ul"" ltl.AO "!SSUll : 4 . 681Xl I" ' 
l'(NUllQllETtt VOl.LlllE : l . )41.l ._ 
Ullll'll \lll&HT : 0. '°'2 1 
W.U•~ llfUiHT : 110.«BJ 9 
LOii 'IUSUltl : 
llllCVllT 'llllllli "Usutt : 0 . 7951 P9 l • 
LAST \DI! ,.fUUI( ,.gu1r : 2' . 19'11 P91• 
MlfOH "fSsut( ; 
l\.Mf'n't : 
It.II lllfn«lO : 




TOTlL l llUUSIOM ¥IJUM[ • 0 . 40S6 .. , , 
1'0TAl ,.... AaU • ll . 603 ~t 
lfD IM~ DLUl(T(l ( YOL..IN ) • 0 .0l.IO,. 
tllfDINI JIClt( OIAMTR ( AftA) • o.wr .. 
AVfltAIW JIClt( llAl'ln.1 (4V/ A) • 0 . °'20 ,. 
UJi:: teatTT • 0. 11]1 t i .. 
"''uorr <taUTAll oos1n • , .2131 , , .._ 
~ITT• 12 . 911 
S TUI ¥OlJN. ltlU • 40 S 
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Appendix 3c 
Determination of porosity parameters by mercury intrusion porosimetry. Nifedipine and 
nifedipine:pluronic® F-68 (!: l) solid dispersion pellets after different dissolution time 
intervals. 
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Nifedipine pellets, dissolution time: 0 hours 
PORES!ZER 9320 V2 . 07 PAGE 1 
SA/'1PLE OIRE CTOR Y/NU"BER : lh\TA1 / 81 
OPERATOR : Ke tan /1ehta 
SAMPLE IO: 20Y.nlfedipine beads 2u Ohours 
SUB/1ITIER : Ketan l"lehta 
LP 07 : 42 : 00 04 / 06 / 97 
HP 08 : 17 : 40 04 / 06 / 97 
REP 08:17 : 41 04 / 06 / 97 
PENETR°"ETER NUHBER : 13-()868 
PENETROl!ETER COHSTAHT : 10, 79 pl/ pf 
PENETROf1ETER WEIGHT: 68 . 1624 g 
ADVANCING CONTACT ANGLE: 130 . 0 deg 
RECEDING CONTACT ANGLE: 130 . 0 deg 
11ERCURY SURFACE TENSION : 485 . 0 dyn / c• 
STE" VOLU11E : 0 . 4120 •L 11ERCURY DENSITY: 13 . 5335 g/ •L 
"AXI"U/1 HEAD PRESSURE: 4 , 6800 psi 
PENETRO•ETER VOLU•E : 3. 6991 •L 
SAllPLE WEIGHT : 0 . 3010 g 
SAllPLE+PEN+Hg WEIGHT : 114.2917 g 
l°" PRESSURE : 
11ERCURY FILLING PRESSURE: 0.7450 psia 
LAST LO\I PRESSURE POINT: 25 . 4604 psia 
HIGH PRESSURE: 
RUN TYPE: AUTOf!ATIC 
EQUILIBRATED 
10 seconds 
RUN 11ETHOO : 
EQUILIBRATION Tl"E: 
INTRUSION DATA SU"AAAY 
TOTAL INTRUSION VOLUME = 
TOTAL PORE AREA = 
11EOIAN PORE DIA"ETER : voLU/1E) = 
KEDIAN PORE OIA"ETER ~ AREA) = 
AVERAGE PORE OIA"ETER (4V/A) = 
BULK DENSITY = 
APPARENT (SKELETAL) DENSITY .: 
POROSITY = 
STE/'1 YOLU/'1E USED .: 
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0.2815 oL /g 
27. 425 sq-o / g 
0 . 0480 '"' 
0.0330 µ• 
0 .0411 11• 
0. 962.2 g/ oL 
1 . 3198 g/ oL 
27 .09 x 
21 X tttt 
( Nifedip ine pellets, disso lution time: 2.0 hours 
PORES!ZER 9320 V2 .07 PAGE 1 
SAMPLE DIRECTORY/NUMBER: l:fATA1 / 83 
OPERATOR: le.et an Mehta 
SAMPLE ID : 201.n lt~ i pine bead's2~hr~ 
SUBl"IITTER : Ketan Mehta 
LP 00 : 13 : 47 04 / 07 / 97 
HP 00 : 48 : 22 04 / 07 /97 
REP 00 : 48 : 23 04 / 07/ 97 
PENETRottETER NUMBER : 13-o868 
PENETRot'IETER CONSTANT : 10 . 79 µL/pF 
PENETRottETER UE I GHT : 67 . 9982 g 
ADVANCING CONTACT ANGLE: 130 . 0 deg 
RECEDING CONTACT ANGLE : no .a deg 
MERCURY SURFACE TENSION: 485 . 0 dyn / c11 
ST EM VOLUME : 0 . 4120 •L f'\ERCURY DENSITY: 13.5335 g / 11L 
11AX I /1Uf'\ HEAD PRESSURE : 4. 6800 ps i 
PENETRO!'tETER VOLU11E : 3 . 6991 ml 
SA•PLE WEIGHT : 0 .3016 g 
SAP1PLE+PEN+Hg UEIGHT : 113. 3140 g 
L® PRESSURE : 
MERCU RY FI LLING PRESSURE : 0 . 6052 psia 
LAS T LO\I PRESSURE POINT : 25 . 5137 ps i a 
HIGH PRESSURE : 
RUN TYPE: AUTOMATIC 
EQU!LIBRATED 
10 second~ 
RUN ME THOD: 
EOU!LIBRAT!ON Tl •E : 
INTRUSION DA TA SUl1P1ARY 
TOTAL INTRUSION YOLUPiE = 0 . 4650 11L/g 
TOTAL PORE AREA= 27 . 813 sq-• / g 
P1EDUN PORE DUP1ETER ( VOLUP1E ) = 0 .0814 I'• 
P1EDIAN PORE DIAMETER ( AREA ) = 0 . 0318 I'• 
AVERAGE PORE OIAP1ETER ( 4Y / A) = 0 .0669 I'• 
BULK DENSITY = 0 .8086 g/ ol 
APPARENT ( SKELETAL) DENSITY = 1 . 2960 g / •l 
POROSITY= 37 . 61 X 
STEK VOLLKE USED = 34 X 
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Nifedipine pellets. dissolution time: 4.0 hours 
PORESIZER 9320 V2.07 PAGE 1 
SAMPLE DIRECTORY/NUP18ER: DATA1 / 85 
OP ERATOR: Ketan caehta 
SAMPLE ID: 207.nifedipine beads 2M, 4 hours 
SUBfHTTER: Ketan 11ehta 
LP 05 :42 :1 6 04/07/97 
HP 06:18:05 04 / 07/ 97 
REP 06 : 18 : 06 04 / 07/97 
PENETROKETER NU118ER: 13-0868 
PENETR°"ETER CONSTANT : 10 . 79 ,uL/pF 
PENETROf1ETER WEIGHT: 68 . 1666 g 
ADVANCING CONTACT ANGLE : 130.0 deg 
RECEDING CONTACT ANGLE : 130.0 deg 
MERCURY SURFACE TENSION: 485.0 dyn/ca 
STEl't VOLUf1E: 0 . 4120 •L MERCURY DENSITY: 13.5335 g/oL 
11AXIl'1U/1 HEAD PRESSURE : 4.6800 psi 
PENETROf1ETER VOLUME : 3.6991 11L 
SAP'llPLE !JEIGHT: 0 . 3017 g 
SAMPLE+PEll+Hg VEIGHT: 113 .4587 g 
LQIJ PRESSURE: 
MERCURY FILLING PRESSURE: 0.8105 psia 
LAST Lexi PRESSURE POINT: 28 .~694 psia 
HIGH PRESSURE : 
RUN TYPE: AUTOMATIC 
EQUILIBRATED 
10 seconds 
RUN METHOD : 
EQUILIBRATION Til'IE : 
INTRUSION DATA SUP11'tARY 
TOTAL INTRUSION VOLUf1E = 
TOTAL PORE AREA = 
MEDIAN PORE OIAl1ETER (VOLUl'tE ) 
MEDIAN PORE DIAMETER (AREA) = 
AVERAGE PORE DIAMETER ( 4V/Al = 
BULK DENS 1 TY = 
APPARENT ( SKELETAL) DENSITY = 
PO'tOSITY = 
STE" VOLU"E USED = 
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0. 4904 oL/g 
26. 559 sq-•/g 
0. 1530 •• 
0 .0305 u• 
0 .0739 jf• 
0 . 8051 g/oL 
1.3303 g / oL 
39 . 48 x 
36 x 
Nifedipine pellets. dissolution time: 6.0 hours 
PORESlZER 9320 V2.07 PAGE 1 
SAMPLE OIRECTORY/ NUl'IBER : DATA1 / 87 
OPERATOR: Ket an • eh ta 
SAMPLE ID: 20Xnifedipine beads 2u, 6 hrs 
SUBMITTER: Ketan f1chta 
LP 04 : 37:01 04/08/97 
HP 05:12:02 04/08/97 
REP 05:12:02 04/ 08/97 
PENETROf'IETER NUMBER : 13-Q868 
PENETROf'IETER CONSTANT: 10. 79 11Llpf 
PENETROttETER \IEIGHT: 67. 9340 g 
ADVANCING COllTACT ANGLE : 130.0 deg 
RECEDING COllTACT ANGLE: 130.0 deg 
MERCURY SURFACE TENSION: 485 .0 dyn /cM 
STEM VOLUME: 0.4120 ML "ERCURY DENSITY : 13.5335 g /•L 
!1AXll'tUt1 HEAD PRESSURE : 4.6800 ps i 
PENETROf1ETER VOLU"'E: 3 . 6991 •L 
SA"PLE WEIGHT : 0 . 2671 g 
SMPLE+PEN+Hg WEIGHT: 113.6380 g 
LOW PRESSURE: 
MERCURY FILLING PRESSURE: 0.5458 psia 
LAST LOW PRESSURE POINT : 28.4n1 psia 
HIGH PRESSURE: 





INTRUSION DATA SUHMRY 
TOTAL INTRUSION VOLUf1E = 0. 5038 aL/g 
TOTAL PORE AREA = 25. 529 sq-•/g 
!1EDIAN PORE OIA11ETER (VOLUKE) = 0 .4056 JI• 
"EOIAH PORE DIAMETER (AREA) ;: 0.0296 Jl• 
AVERAGE PORE DIA"ETER (4V/A) .=: 0.0789 Jl• 
BULK DENSITY = 0. 7816 g / •L 
APPARENT (SKELETAL) DENSITY = 1 . 2893 g / •L 
POROSITY = 39 . 38 X 
STE" VOLU"E USED = 33 X 
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Nifedipine pellets. dissolution time: 8.0 hours 
PORESIZER 9320 V2.07 PAGE 1 
SA!1PLE OIRECTORY/NU11BER: DATA1 /89 
OPERATOR: l<etan 11ehta 
SMtPLE IO : 20Xnifec:hpine beads, 2.u , Bhours 
SUBIHTTER: Ketan Mehta 
LP 00:04 : 47 04 109197 
HP 00 : 39 : 37 04 / 09197 
REP 00:39:37 04 / 09197 
PENETR011ETER NU118ER: 13-()868 
PENETROPtETER CONSTANT: 10. 79 JJL/pf 
PENETROMETER WEIGHT: 68 . 2047 g 
ADVANCING CONTACT ANGLE: 130.0 deg 
RECEDING CONTACT ANGLE : 130.0 deg 
11ERCUAY SURFACE TENSION : 485.0 dyn/ca 
STEl1 VOLU11E: 0 .4120 •L 11ERCURY DENSITY: 13. 5335 g/ aL 
f'tAXIl1U11 HEAD PRESSURE: 4.6800 psi 
PENETROl1ETER VOLU"E: 3.6991 oL 
SA11PLE WEIGHT: 0.2549 g 
SA"PLE+PEN+Hg OEIGHT : 114 . 1119 g 
LOii PRESSURE: 
MERCURY FILLING PRESSURE: 0.6518 psia 
LAST LOY PRESSURE POINT: 28 . 4637 psia 
HIGH PRESSURE: 
RUN TYPE: A.UTOKATIC 
RUN METHOD : 
EQUILIBRATION TI•E: 
EQO I LIBRA TEO 
1J seconds 
INTRUSION DATA SUl1KARY 
TOTAL lHTRUSIOf- VOLU11E = 0.4950 11L/9 
TOTAL PORE AREA = 26.074 sq-a/g 
MEDIAN PORE DIA11ETER CVOLUl'tE) "" 0.5036 1111 
"EDIAN PORE DIA"ETER (AREA) = 0.0290 11• 
AVERAGE PORE DIA"ETER C4V/A) = 0.0759 11• 
BUU< DENSITY = 0 . 7823 g/ oL 
APPARENT (SKELETAL) DENSITY = 1 . 2768 g/•L 
POROSITY • 38 . 73 X 
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.... ..... · 
Nifedipine:Pluronic® F-68 solid dispersion pellets. disso lution time: 0 hours 
PORESIZER 9320 Y2 .07 PAGE 1 
SAMPLE OIRECTORY / NUP1BER: OATA1 / 82 
OPERATOR: Ketan P1ehta LP 07:42:00 04 / 06 /97 
SAMPLE IO : 1 :1 NFD SD Ohours HP 08 : 52:13 04 / 06 / 97 
SUBMITTER : Ketan l'lehta REP 08 : 52 : 14 04 / 06 /97 
PEHETROf'1ETER NUMBER: 13-Q854 
PEHETROf'IETER CONSTANT: 10. 79 µL/pr 
PEHETROl'IETER WEIGHT: 68 . 3914 g 
ADVANCING CONTACT ANGLE: 130.0 deg 
RECEDING CONTACT ANGLE : 130 . 0 de<J 
MERCURY SURFACE TENSION: 485 .0 dyn/ea 
STEM VOLUME: 0.4120 •L MERCURY DENSITY: 13.5335 g / oL 
0.3004 g HAXIP1UP1 HEAD PRESSURE: 4.6800 ps i 
PENETROPtETER VOLUME : 3. 5541 •l SAltPLE+PEH+Hg WEIGHT : 112 . 9926 g 
LO\I PRESSURE : 
MERCURY FILLING PRESSURE: 0. 7450 psi a 
LAST LOW PRESSURE POINT: 25 . 4604 psia 
HIGH PRESSURE : 





INTRUS IOH DAU SUMMARY 
TOTAL INTRUSION WOLU11E = 
TOTAL PORE AREA = 
11EOIAN PORE DIMETER (VOLUME) = 
11EDIAH PORE OIAMTE11 (AREA) = 
AVERAGE PORE DIAMETER (4V/A) = 
BULK DENS I TY = 
APPARENT (SKELETAL) DENSITY = 
POROSITY = 
STEM VOLUME USED = 
249 
0.1636 •Llg 
18. 159 sq-•/ g 
0.0518 11• 
0.0164 11• 
0 .0360 11• ' 
1.0702 g/oL 
1.2974 g / oL 
17 . 51 x 
12% tttt 
Nifedipine:Pluronic® F-68 solid dispersion pellets. dissolution time : 2.0 hours 
PORES IZER 9320 V2 . 07 PAGE 1 
SAMPLE O!RECTORY / HUP18ER: IMTA1 / 84 
OPERATOR : Ketan P1eht:a 
SAP1PLE IO : 1 :1Hifedipine SO , .2-, 2 hrs 
SUBMITTER : Ketan P1ehta 
LP 00:13 : 47 04/07/97 
HP 02 : 16 : 35 04/07/97 
REP 02 : 16 : 36 04 / 07/ 97 
PEHETROf'1ETER NUP1BER : 13-Q854 
PEHETR°"ETER CONSTANT : 10 . 79 pL/ pF 
PENETROltETER OEIGHT : 68 . 3229 g 
ADVANCING CONTACT ANGLE : 130 . 0 deg 
RECEDING CONTACT ANGLE : 130.0 deg 
MERCURY SURFACE TENSION: 485.0 dyn/c• 
STEl'I VOLUME : 0 .4120 •L NERCURY DENSITY : 13.5335 g / oL 
"A.Xll1Uf1 HEAD PRESSURE : 4 . 680C'I psi 
PENETROl1ETER VOLUNE : 3.5541 oL 
SAP1PLE WEIGHT : 0 . 2612 g 
SANPLE+PEN+H<J OEIGHT : 112. 7089 g 
LOW PRESSURE : 
P1ERCURY FILLING PRESSURE : 0 .6052 psia 
LAST LOU PRESSURE POINT: 25.5137 ps i a 
HIGH PRESSURE : 




EQUILIBRATION TH~E : 
INTRUSION DATA SUP1P1ARY 
TOTAL INTRUSION VOLUME = 
TOTAL PO"C: AREA = 
l'IEO IAN PORE 0 I.METER (VOLUME) = 
NEDIAN PORE DIAMETER ( AREA) = 
AVERAGE PORE DI.METER (4V/A) "' 
BULX ~<NSITY • 
APPARENT (SKELETAL ) DENSITY = 
POROSITY = 
STHI VOUJftE USED = 
250 
0 .3527 •L/g 
12 . 105 sq-•/ g 
11 .4396 JI• 
0.0109 po 
0 . 1166 JI• 
0 . 8894 g / oL 
1 .2960 g/oL 
31 . 37 x 
22 Xtttt 
Nifedipine:Pluronic® F-68 solid dispersion pellets, dissolution time: 4.0 hours 
PORESIZER 9320 V2 .07 PAGE 1 
SAMPLE OIRECTORY/ NU"BER : QATA1 / 86 
OPERATOR : Ketan "eh ta 
SA/"IPLE IO: 1 :1 nifedipine beads , 2•, 4 hours 
SUBMITTER: Ket en eehta 
LP 05:42:16 Ol.107197 
HP 22 :52:28 Ol.107197 
REP 22 : 52 : 29 Ol. 107197 
PENETRO/"IETER NU118ER : 13-0854 
PENETROIOETER CONSTANT: 10. 79 •L/pF 
PENETROPtETER WEIGHT : 68.4334 g 
ADVANCING CONTACT ANGLE : 130.0 deg 
RECEDING CONTACT ANGLE: 130 .0 deg 
/"IERCURY SURFACE TENSION : 485.0 dyn/c• 
STE/"I VOLU/"IE: 0 .4120 •L •ERCURY DENSITY: 13. 5335 g/ ol 
/"IAXIl'IU" HEAD PRESSURE : 4 . 68CX) psi 
PENETR°"ETER VOLU/"IE: 3. 5541 el 
SA•PLE WEIGHT: 0 . 1880 g 
SAltPLE+PEN+Hg WEIGHT: 113.5487 g 
LOii PRESSURE: 
MERCURY FILLING PRESSURE: 0 . 8105 ps i a 
LAST LOU PRESSURE POINT: 28 .5694 psia 
HIGH PRESSURE: 
RUN TYPE: AUTCftATIC 
EQUILIBRATED 
10 seconds 
RUH /"IETHOO : 
EQUILIBRATION TI ME : 
IHTRUS IOH DATA SUl1MRY 
TOTAL INTRUSION VOLU/"IE = 
TOTAL PORE AREA = 
MEDIAN PORE DIAMETER (VOLUME) = 
11EOIAN PORE DIAptEffR CA.REA) 2 
AVERAGE PORE DI.METER C4V/A) ,. 
BULK DENSITY = 
APPARENT (SKELETAL) ~r::NSITY ::1 
POROSITY .. 
STEpt YOlUptE USED • 
25 1 
0 .4689 oL/g 
15. 734 sq-o/g 
12.2373 11• 
0 .0112 •• 
0 . 1192 11• 
0 . 8021 g/ •L 
1 . 2856 g/ oL 
37 . 61 x 
21 Xtttt 
_ .... · 
Nifedipine:Pluronic® F-68 solid dispersion pellets, disso lution time: 6.0 hours 
POAESIZER 9320 V2 . 07 PAGE 1 
SA"PLE 01RECTORY/HU'18ER: DATA1 /88 
OPERATOR: ketan ffhta 
SA'1PLE ID: 1:1nifedipine SO , _2M, 6 h:-s 
SUBIHTIER: Ketan Mehta 
LP 04:37 : 01 04 / 08 / 97 
HP 06 :05:40 04 / 08 / 97 
REP 06 :05:40 04 / 08 / 97 
PENETROftETER NU"BER: 13-()241 
PENETR°"ETER CONSTANT: 10 . 79 µL/ pF 
PENETROllETER WEIGHT : 69 . 0044 g 
ADVANCING COHTACT ANGLE : 130.0 deg 
RECEDING COHTACT ANGLE: 130. 0 deg 
"ERCURY SURFACE TENSION : 485 .0 dyn/c • 
STE" VOLUME: 0 . 4120 •L "ERCURY DENSITY : 13 . 5335 g / •l 
MA.XU~U" HEAD PRESSURE: 4.6800 ps i 
PEHETROllETER VOLU•E: 3. 5443 oL 
SA,.PLE WEIGHT: 0 . 1489 g 
SA!IPLE+PEH+Hg WEIGHT: 114 . 3570 g 
LOW PRESSURE : 
"ERCURY FILLING PRESSURE : 0 . 5458 psia 
LAST L°" PRESSURE POINT : 28.4"/31 ps i a 
HIGH PRESSURE : 




EQUILIBRATION TU~E : 
INTRUSION DATA SUMMARY 
TOTAL INTRUS!OH VOLU•E = 
TOTAL PORE AREA = 
•ED!AN PORE DIA!IETER CVOLU•E> = 
•EDIAN PORE DIA•ETER ( AREA) = 
AVERAGE PORE DIA!IETER (4V/A) = 
BULK DENSITY = 
APPARENT (SKELETAL) DENSITY = 
POROSITY = 
STE• VOLU•E USED = 
252 
0. 5703 ol/g 
18. 161 sq-•/g 
13 . 7318 •• 
0 . 0118 •• 
0 . 1256 •• 
0. 7293 g/oL 
1 . 2487 g / oL 
41 . 59 % 
21 Xtttt 
( 
Nifedipine:Pluronic® F-68 solid dispersion pellets, dissolution time: 8.0 hours 
PORESIZER 9320 V2 . 07 PAGE 1 
SAMPLE OIRECTORY / NUMBER: ~TA.1 /90 
OPERATOR: Ketan ltehta 
SAMPLE 10: 1 : 1 niff:'dipine SO~ 2•, 8 hours 
SUBl1ITTER: Ketan 11ehta 
LP 00 : 04 : 47 04 / 09197 
HP 01:13:41 04/ 09/ 97 
REP 01:13:42 04 / 09197 
PENETR°"ETER NUMBER: 13-Q241 
PENETRO•ETER CONSTANT : 10 . 79 pl/ pf 
PENETR°"ETER WEIGHT: 68 . 3024 g 
ADVANCING CONTACT ANGLE : 130 . 0 deg 
RECEDING CONTACT ANGLE: 130 . 0 deg 
11ERCURY SURFACE TENSION : 485 .0 dyn /c11 
STE/'t VOLU11E: 0 . 4120 11L •ERCU RY DENSITY: 13 . 5335 9 / ol 
11AXU'IUl1 HEAD PRESSURE: 4.6800 psi 
PENETROftETER VOLUl'IE : 3. 5443 11L 
SAl'!PLE WEIGHT: 0.0753 g 
SAP1PLE+PEN+Hg WEIGHT: 114.8735 g 
LOU PRESSURE : 
11ERCURY FILLING PRESSURE: 0 . 6518 psia 
LAST LOU PRESSURE POINT: 28.4637 ps i a 
HIGH PRESSURE : 
RUN TYPE : AUTOftATIC 
EQUILIBRATED 
~O seconds 
RUN 11ETHOO : 
EQ4JILIBRATIOH TI/'tE: 
INTRUSION DATA SUl1'1ARY 
TOTAL INTRUSION VOLUl'IE = 
TOT Al P0 RE AREA = 
"EOIAH PORE DIA"ETER (VOLU"E) = 
"EDIAH PORE DIAMETEf (AREA) = 
AVER.AGE PORE DlAAETER C4V/A) = 
BULK DENS I TY = 
APPARENT (SKELETAL) DENSITY = 
POROSITY = 
STEM VOLUME USED ,. 
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0. 5925 ol/9 




0 . 6928 g / ol 
1. 1752 9 / •l 
41 . 05 x 
,, % **** 
__ ,..· 
Appendix 4 
Determination of nifedipine in plasma after oral administration of nifedipine erosion matrix 
pellet capsule and Adalat® soft gelatin capsule in fasted dogs. 
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!-!PLC METHOD VALIDATION: 
DETERMINATION OF NIFEDIPINE IN PLASMA AFTER ORAL 
ADMINISTRATION OF NIFEDIPINE EROSION MATRIX PELLETS AND 
ADALAT® SOFT GELATIN CAPSULES IN FASTED DOGS. 
l. TEST ARTICLES : 
Nifedipine erosion matrix pellets (30 mg capsules, Lot #KM 280/2) . 
Adalat® soft gelatin capsules (I 0 mg and 20 mg, Lot # 6 EAB and 5 HAX respectively 
manufactured by Bayer Corporation, West Haven, CT, USA). 







Waters 600 E Multi Solvent Delivery System (Waters Corporation, 
Milford, MA, USA). 
Waters 717 Plus Auto Sampler (Waters Corporation, Milford, MA, USA). 
Zorbax ODS, 4-6 microns reverse phase, 25 cm X 4.6 mm (I. D., Dupont 
Inc., Wilmington, DE). 
Column Heator Model Code 600 (Waters Corporation, Milford, MA, 
USA). 
Variable wavelength detecto r, Model Spectra Physics 100, UV/VIS 
(Spectra Physics, USA). 
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Parameters: 
Flow Rate: 0.8 rnUmin 
Injection Vol: 20 µL 
Col Tempt: 55°C 
Col Pressure: 1200 Psi 
Detector: A..,,., 237 nm, 0.001 AUFS 
Run Time: 30 minutes 
Solutions: 
Mobile Phase: 
0.01 M disodium hydrogen phosphate buffer : methanol (45 :55) was mixed for 30 minutes 
Before mixing the buffer was brought to pH 6. I with 50% v/v phosphoric acid . This 
solution was then sonicated for IO minutes and was filtered through a 0.5µ filter. 
Extraction Solvent: 
Chloroform : acetone were mixed in ratio of I : I for 3 0 minutes and was used as the 
extraction solvent for nifedipine from the plasma. 
3. LINEARITY: 
Linearity of nifedipine in methanol and plasma samples spiked with standard methanolic 
solution of nifedipine was determined by simple linear regression method. Figure I 
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depicts the standard curve and linear regression of nifedipine in methanol and plasma. The 



















Correlation coefficient for linearity determinations in methanol was 0. 9998 and in plasma 
was 0.9940. Extraction ratio of drug from plasma to organic phase at all concentrations 
was not less than 95 %. 
4. PRECISION: 
Assay precision was determined by plotting the peak height ratios of triplicate injections of 
nifedipine samples of known concentrations against the standard curves generated in the 
previous section. The mean % difference between the actual concentration of the samples 
and that determined by the standard curve were always below 5% during the entire 
analysis period. 
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5. REPRESENTATIVE CHROMATOGRAMS: 
Figures 2 through 41 are the chromatograms of plasma samples after injection, obtained 
from four dogs each administered with nifedipine erosion matrix pellet capsule (30 
mg/dog/day) at 0, l , 2, 4, 6, 8, 12, 16, 20 and 24 hours. Figures 42 through 73 ar_e the 
chromatograms of plasma samples after injection , obtained from four dogs each 
administered with Adalat® soft gelatin capsule (10 + 20 mg/dog/day) at 0, 0.5, I, 2, 4, 6, 
8 and 12 hours. 
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Calibration graph of nifeipine in methanol and plasma. 
D methanol, Y = 2.7097 X - 0.0127, r2 = 0.9998 
0 plasma, Y = 2.28744 X + 0.0731, r2 = 0.9940 
5 21 ..Q 
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Chromatogram of plasma sample obtained from dog# I administered with nifedipine 
erosion matrix pellet capsule at 0.0 hours. 
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Figure 3 
Chromatogram of plasma sample obtained from dog # I administered with nifedipine 
erosion matrix pellet capsule at I. 0 hours. 
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Figure 4 
Chromatogram of plasma sample obtained from dog # I administered with nifedipine 
erosion matrix pellet capsule at 2.0 hours. 
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Chromatogram of plasma sample obtained from dog # I administered with nifedipine 
erosion matrix pellet capsule at 4.0 hours . 
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Chromatogram of plasma sample obtained from dog # I administered with nifedipine 
erosion matrix pellet capsule at 6.0 hours. 
'"·"',,°'-"'-----.----..,.---.. -.• ~ ..-•. -•. -.--~---~----
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Figure 7 
Chromatogram of plasma sample obtained from dog # 1 administered with nifedipine 
erosion matrix pellet capsule at 8.0 hours. 
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Figure 8 
Chromatogram of plasma sample obtained from dog # I administered with nifedipine 
erosion matrix pellet capsule at 12.0 hours. 
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Figure 9 
Chromatogram of plasma sample obtained from dog# I administered with nifedipine 
erosion matrix pellet capsule at 16.0 hours . 
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Chromatogram of plasma sample obtained from dog # 1 administered with nifedipine 






Chromatogram of plasma sample obtained from dog # I administered with nifedipine 
erosion matrix pellet capsule at 24.0 hours. 
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Figure 12 
Chromatogram of plasma sample obtained from dog # 2 administered with nifedipine 
erosion matrix pellet capsule at 0.0 hours. 
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Chromatogram of plasma sample obtained from dog # 2 administered with nifedipine 
erosion matrix pellet capsule at I. 0 hours. 
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Chromatogram of plasma sample obtained from dog # 2 administered with nifedipine 
erosion matrix pellet capsule at 2.0 hours. 
272 
fulill...12 
Chromatogram of plasma sample obtained from dog # 2 administered with nifedipine 
erosion matrix pellet capsule at 4.0 hours. 
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Chromatogram of plasma sample obtained from dog # 2 administered with nifedipine 
erosion matrix pellet capsule at 6.0 hours. 
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Chromatogram of plasma sample obtained from dog # 2 administered with nifedipine 




Chromatogram of plasma sample obtained from dog # 2 administered with nifedipine 
erosion matrix pellet capsule at 12.0 hours. 
"'·"·.~-~--.----~--"--,~. ---=-".l------­
TI •• C•lnl 
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Chromatogram of plasma sample obtained from dog # 2 administered with nifedipine 





Chromatogram of plasma sample obtained from dog # 2 administered with nifedipine 
erosion matrix pellet capsule at 20.0 hours. 
\ 
\\\ 
"'·"','--'--~---~,..,._-'--.. -.. ~ ..-.. -."-,--~~--~----
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Chromatogram of plasma sample obtained from dog # 2 administered with nifedipine 
erosion matrix pellet capsule at 24. 0 hours. 
Hl.H•,.1---"-L-------l..l.L-,,-•• -.. ,-.,-.-, --,_.'-''----~----
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Chromatogram of plasma sample obtained from dog# 3 administered with nifedipine 
erosion matrix pellet capsule at 0.0 hours. 
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Figure 23 
Chromatogram of plasma sample obtained from dog # 3 administered with nifedipine 
erosion matrix pellet capsule at I. 0 hours. 
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Chromatogram of plasma sample obtained from dog # 3 administered with nifedipine 
erosion matrix pellet capsule at 2.0 hours . 
1.·\~. ' 







Chromatogram of plasma sample obtained from dog # 3 administered with nifedipine 
erosion matrix pellet capsule at 4. 0 hours. 
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Figure 26 
Chromatogram of plasma sample obtained from dog# 3 administered with nifedipine 
erosion matrix pellet capsule at 6.0 hours. 
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Figure 27 
Chromatogram of plasma sample obtained from dog # 3 administered with nifedipine 
erosion matrix pellet capsule at 8.0 hours. 
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Chromatogram of plasma sample obtained from dog # 3 administered with nifedipine 
erosion matrix pellet capsule at 12.0 hours. 
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Chromatogram of plasma sample obtained from dog # 3 administered with nifedipine 
erosion matrix pellet capsule at 16.0 hours. 
cn.u•,~----....---..----.,...---~~--~-­
tl •• 1. 1 .. 1 
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Chromatogram of plasma sample obtained from dog # 3 administered with nifedipine 
erosion matrix pellet capsule at 20.0 hours. 
r · ... 
... 
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Chromatogram of plasma sample obtained from dog# 3 administered with nifedipine 




Chromatogram of plasma sample obtained from dog # 4 administered with nifedipine 
erosion matrix pellet capsule at 0.0 hours. 
,. .... · 
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Chromatogram of plasma sample obtained from dog # 4 administered with nifedipine 
erosion matrix pellet capsule at I. 0 hours. 
--· 
29 1 
Chromatogram of plasma sample obtained from dog # 4 administered with nifedipine 







Chromatogram of plasma sample obtained from dog # 4 administered with nifedipine 
erosion matrix pellet capsule at 4.0 hours . 
nt.11•,p>----J=--.---,.-----,,,, ::::::?"""'et:::-:;;:_:__L,,.- --
fl•• l • l"I 
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Chromatogram of plasma sample obtained from dog # 4 administered with nifedipine 





Chromatogram of plasma sample obtained from dog # 4 administered with nifedipine 
erosion matrix pellet capsule at 8.0 hours. 
/ 
'7t.H11, ........ ~-----.,.-------;;;----,-• • "";•;--,•-,•-,--~---~-=::,..,,,,,._L_ 
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Chromatogram of plasma sample obtained from dog# 4 administered with nifedipine 
erosion matrix pellet capsule at 12.0 hours . 
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Chromatogram of plasma sample obtained from dog # 4 administered with nifedipine 
erosion matrix pellet capsule at 16. 0 hours. 
297 
Chromatogram of plasma sample obtained from dog # 4 administered with nifedipine 
erosion matrix pellet capsule at 20.0 hours. 
· ....... . 
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Chromatogram of plasma sample obtained from dog # 4 administered with nifedipine 
erosion matrix pellet capsule at 24.0 hours. 
:.----------· 
" Tl •• l • \ nJ 
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Figure 42 
Chromatogram of plasma sample obtained from dog # I administered with Adalat soft 
gelatin capsules at 0.0 hours. 
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Figure 43 
Chromatogram of plasma sample obtained from dog # I administered with Adalat soft 
gelatin capsules at 0.5 hours. 
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Figure 44 
Chromatogram of plasma sample obtained from dog # l administered with Adalat soft 
gelatin capsules at I. 0 hours. 
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Figure 45 
Chromatogram of plasma sample obtained from dog# I administered with Adalat soft 
gelatin capsules at 2. 0 hours. 
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Chromatogram of plasma sample obtained from dog# 1 administered with Adalat soft 
gelatin capsules at 4. 0 hours. 
ut .11•,.L--~---~---u-.. ~' -,. -,.-, --...------...----
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Chromatogram of plasma sample obtained from dog # I administered with Adalat soft 
gelatin capsules at 6.0 hours. 
C7,.ttl1)---~---~---.. ~.;~',-.,-.,--~--~~---
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Chromatogram of plasma sample obtained from dog # I administered with Adalat soft 





Chromatogram of plasma sample obtained from dog # I administered with Adalat soft 




Chromatogram of plasma sample obtained from dog # 2 administered with Adalat soft 
gelatin capsules at 0. 0 hours. 
157'.H•1 -----------H-•;-·,-.,-",----------
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Chromatogram of plasma sample obtained from dog # 2 administered with Adalat soft 
gelatin capsules at 0. 5 hours. 
'"'·"',~--~--~~--,..~;~ ..-.. "-.-~~--~---
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Chromatogram of plasma sample obtained from dog# 2 administered with Adalat soft 
gelatin capsules at I. 0 hours . 
....... 1 
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Chromatogram of plasma sample obtained from dog # 2 administered with Adalat soft 
gelatin capsules at 2. 0 hours. 
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Chromatogram of plasma sample obtained from dog # 2 administered with Adalat soft 
gelatin capsules at 4.0 hours. 
\ 
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Chromatogram of plasma sample obtained from dog # 2 administered with Adalat soft 
gelatin capsules at 6.0 hours. 
\ 
·----
'"··",'-----.----..---,-.. ·:·.-.. -.. --...----..~---
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Chromatogram of plasma sample obtained from dog # 2 administered with Adalat soft 
gelatin capsules at 8.0 hours. 
" fl •• l • lnl 
3 14 
Chromatogram of plasma sample obtained from dog # 2 administered with Adalat soft 
gelatin capsules at 12.0 hours. 
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Chromatogram of plasma sample obtained from dog# 3 administered with Adalat soft 





Chromatogram of plasma sample obtained from dog# 3 administered with Adalat soft 
gelatin capsules at 0.5 hours. 
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Chromatogram of plasma sample obtained from dog # 3 administered with Adalat soft 
gelatin capsules at I. 0 hours. 
H ....... L---,.---....----,.,_;"',-.. -.. --..-----,,.----
3 18 
Chromatogram of plasma sample obtained from dog # 3 administered with Adalat soft 
gelatin capsules at 2.0 hours. 




Chromatogram of plasma sample obtained from dog # 3 administered with Adalat soft 
gelatin capsules at 4. 0 hours. 
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Chromatogram of plasma sample obtained from dog # 3 administered with Adalat soft 
gelatin capsules ~t 8. 0 hours. 
• 
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( Figure 65 
Chromatogram of plasma sample obtained from dog# 3 administered with Adalat soft 
gelatin capsules at 12.0 hours. 
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gelatin capsules at 0.0 hours . 
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Figure 67 
Chromatogram of plasma sample obtained from dog # 4 administered with Adalat soft 
gelatin capsules at 0.5 hours. 
325 
Chromatogram of plasma sample obtained from dog # 4 administered with Ad al at soft . 
gelatin capsules at 1.0 hours. 
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Figure 69 
Chromatogram of plasma sample obtained from dog # 4 administered with Adalat soft 
gelatin capsules at 2.0 hours. 
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Chromatogram of plasma sample obtained from dog # 4 administered with Adalat soft 
gelatin capsules at 4. 0 hours. 
, ...... ,,____~-~------~.----~~~~~-~ 
Tl • • l •l"I 
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Figure 71 
Chromatogram of plasma sample obtained from dog # 4 administered with Adalat soft 
gelatin capsules at 6.0 hours. 
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Figure 72 
Chromatogram of plasma sample obtained from dog # 4 administered with Adalat soft 
gelatin capsules at 8.0 hours. 
330 
Chromatogram of plasma sample obtained from dog # 4 administered with Adalat soft 
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